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Abstract 
Health supplement products contain ingredients of more than thousand chemicals. 
Several of these chemicals may adversely affect human health. Previous studies have 
found that consumers are generally unaware regarding the risks of health supplements 
and their associated adverse events. In addition, they are unaware of the appropriate 
reporting process to relevant authorities should adverse events occur. Moreover, many 
healthcare professionals have inadequate knowledge, attitude and practice in health 
supplement consumption-related adverse events and their reporting. The purpose of 
this research was to measure the health supplement consumption in the population of 
Dubai, the adverse events thereof, and the level of knowledge, attitude, and practice 
among healthcare professionals about the issue. 
This research project comprised two cross-sectional studies. The first was a telephone 
survey using computer-assisted personal interviewing carried out among the general 
population. The second study was an on-line survey among healthcare professionals 
from various private and government healthcare settings in Dubai that sought to assess 
their knowledge, attitude, and practice (KAP) toward health supplements. Descriptive 
statistics were used to describe the demographic characteristics of the sample using 
frequencies and percentages as appropriate. Chi-square, or ANOVA, was used as 
appropriate to test for statistical differences. Analyses were conducted using STATA 
version 14.2. 
In the first survey, among 1,203 participants, 455 (37.8%) reported either current or 
previous use of health supplements. Of the 455 users, 389 (85.54%) were 
knowledgeable about health supplements and 442 (97.14%) had encountered no 
adverse events. Of the 13 (2.86%) who had encountered adverse events, the degree of 
severity was either moderate or mild. Most (10, 76.92%) did not know how to report 
the adverse event to healthcare professionals. Only 3 (23.08%) had ever reported an 
event.  
In the second study, 427 healthcare professionals participated to the online survey. Of 
these, 78 (18.3%) had a good level of KAP towards health supplements, 166 (38.9%) 
had a fair level of KAP, while 183 (42.9%) had a poor level. Job experience of over 6 
years resulted in a significant difference (P=0.017) in mean KAP scores. No 
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statistically significant differences in scores were found with gender or educational 
levels. Significant differences, however, (P=0.001) were found with nationality where 
non-UAE national participants had a higher level of KAP than UAE nationals. There 
were also significant differences in mean KAP scores between occupational groups, 
physicians and pharmacists having higher scores than other healthcare providers. 
The findings of this research provide important new knowledge about health 
supplement use in Dubai. The findings may be used to develop policies and programs 
on health supplements that will help to minimise the risk of adverse events arising 
from their use. The results also point out that it is important to institute educational 
initiatives to assess any risks related to the use of health supplements. Such initiatives 
will help to raise both awareness and knowledge in both the population and healthcare 
professionals regarding the use and adverse events of health supplements. 
Keywords: Health supplements, Dubai, adverse event, knowledge, attitude, practice. 
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 )cibarA ni( tcartsbA dna eltiT
الإمارات العربية  –استهلاك المكملات الصحية والآثار الصحية المرتبة في إمارة دبي 
 المتحدة: دراسة استقصائية
 الملخص
كل منتج مكمل صحي في إمارة دبي يحتوي على العديد من المكونات التي تصل إلى 
ثر من ألف مادة كيميائية في المجموع. العديد من هذه المواد الكيميائية قد يكون لها بعض الآثار أك
مما سيؤثر على صحة الإنسان. كثير من الدراسات أثبتت أن المستهلكين بشكل عام لا  السلبية 
ض عيدركون عن المخاطر المصاحبة للمكملات الصحية والآثار السلبية المرتبطة بها. كذلك، ب
المستهلكين لا يدركون كيفية تزويد السلطات المعنية في حال وجودها بأي من الأعراض الجانبية 
التي يتعرضون إليها. وبالإضافة إلى ذلك، فإن العديد من المتخصصين في مجال الرعاية الصحية 
كملات مليس لديهم المعرفة الكافية، أو التصور على الأعراض السلبية والمصاحبة مع استهلاك ال
 .الصحية
يهدف هذا البحث إلى إجراء مسح سكاني في إمارة دبي لتحديد نسبة استهلاك المكملات 
الصحية من قبل سكان دبي، والآثار السلبية والمصاحبة مع استهلاك المكملات الصحية (إذا تم 
تحديدها) ومستوى المعرفة والممارسة بين المتخصصين في مجال الرعاية الصحية حول هذه 
القضية. لاحقا تم استخدام نتائج البحث لتقييم الأثر الصحي لإنشاء نظام اليقظة للمكملات الصحية 
 .في دبي
أجريت دراسات من خلال توزيع استبيانات للمستهدفين من السكان والمختصين وتم 
حث باستخدام المعلومات التي تم جمعها في تقييم الأثر الصحي للنظام المراد إنشائه. قام هذا ال
بملء الفجوة المعرفية الحالية في هذا المجال البحثي في دبي كما لا تتوفر أي معلومات سابقة 
 .بشأن هذا الموضوع في دولة الإمارات العربية المتحدة
: المكملات الصحية، دبي، الإمارات العربية المتحدة، الأعراض الضارة، مفاهيم البحث الرئيسية
 .المعرفة، الممارسة، التصور
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Chapter 1: Introduction 
1.1 Overview 
Within the last two decades, consumption of dietary supplements has increased 
worldwide, especially in the United States of America (Millen et al., 2004; Slesinski 
et al., 1995; Wu et al., 2011). This has raised the awareness and interest of regulatory 
organizations, healthcare professionals and researchers (Al-Ahmad et al., 2012). 
The World Health Organization (WHO) and the United States (US) Dietary 
Supplements Health and Education Act (DSHEA) of 1994 both define dietary 
supplements as a product (other than tobacco) that is meant to supplement the diet. 
Both organizations include vitamins, minerals, herbs, botanical products, amino acids, 
or dietary substances in their definitions. The use of dietary supplements including 
herbal supplements is gaining popularity in many developed countries (Aina & 
Ojedokun, 2014). 
In the Local Order No. (11) of 2003 concerning Public Health and Safety of 
the Society in the Emirate of Dubai and its Administrative Resolution No. (30) of 2007, 
dietary supplements are referred to as health supplements (HS). These supplements are 
strongly related to human health as about 1,000 different chemicals may be included 
in the ingredients. These constituents may cause disease or other adverse events by 
their chemical reactions with the human body. HS products such as minerals and 
vitamins are widely available over-the-counter and are often purchased by consumers 
without advice from a healthcare provider. HS products are widely consumed for the 
purposes of weight reduction and energy enhancement, among several other reasons 
(CPSS, 2015). 
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Herbs were the predominant form of healthcare for the world’s population 
before the advent of modern medicine and are still common among many underserved 
populations (Su & Li, 2011; Rossler et al., 2007). HS products, including herbal 
supplements, also have the potential for drug interaction (Izzo & Ernst, 2009; Moyad, 
2010; Tsai et al., 2013; Van & Bogers, 2012), which necessitates consumer awareness 
and diligence among healthcare professionals in their daily practice (Kemper et al., 
2006; Piening et al., 2012). 
HS products play an important role in the general healthcare system of many 
developing countries and are rapidly gaining popularity in many developed countries 
(Chitturi & Farrell, 2008). WHO estimates that 80% of Asian and African populations 
rely on traditional medicine as the primary method to meet their healthcare needs 
(WHO, 2008). The scenario in developed countries is very similar with 70% to 80% 
of the population using some form of complementary or alternative medicine. Most of 
these can be used safely if the public is given the right education and advice (Barnes 
et al., 2004). Physicians need to be ready to discuss their use with patients or advise 
patients accordingly (Neergheen-Bhujun, 2013). 
As HS products have a wide range of possible actions, their effectiveness and 
safety for human consumption is of concern. Harmful side effects have been reported 
following the use of some types of HS products (Tsai et al., 2013). For example, 
Ginkgo Biloba has been implicated in the occurrence of epileptic seizure, and chronic 
use of zinc may result in anaemia (Al-Ahmad et al., 2012; Izzo & Ernst, 2009; Shaw 
& Palmer, 2003). 
Adverse events, such as allergy, drug interactions, heavy metal poisoning, 
reactions to adulterants or contaminants and other toxicities, can arise from the product 
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itself (Tachjian et al., 2011). When these problems occur, a rational approach to 
management with resuscitation, symptomatic, and supportive care is essential. Clinical 
features may give clues about the offending agents. HS products that possess 
pronounced pharmacological effects or toxic constituents can be inherently poisonous, 
and physicians should anticipate problems with such toxicities if they encounter 
patients using these products (MOH, 2011). 
Also, potentially hazardous interactions between HS products and some 
medicines have been reported in the literature including synergistic effects, poisoning, 
or inactivation of at least one of the substances (Tsai et al., 2013). For example, St. 
John’s Wort is a substance that is used as a HS product to treat mild and moderate 
depression. St. John’s Wort can induce liver enzymes and so has the potential to 
interact with many narrow therapeutic range medicines that are metabolised through 
the liver such as anti-depressants (Van & Bogers, 2012). Some other substances such 
as garlic, ginger, and Ginkgo Biloba can induce the risk of bleeding when administered 
with anticoagulants (Moyad, 2010). 
Many HS products, used singly or in combination, have unknown effects. 
Under the DSHEA, the U.S. Food and Drug Administration (FDA) does not mandate 
any efficacy and safety assessments of HS products. This is unlike novel medicines 
and over-the-counter drugs (USFDA, 2016). 
HS products are generally regarded as safe by the USFDA unless proven 
otherwise through its Adverse Event Reporting System (AERS). Since 2006, all 
manufacturers, packers, distributors and retailers are responsible for reporting serious 
adverse events associated with their products, including HS products, to the FDA’s 
MedWatch system (Kailin, 2008). 
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A study by Frankos et al. (2010) showed that many healthcare professionals 
fail to report adverse events related to the use of HS products to the appropriate 
authority, as many of them are unaware of the risks and benefits of HS products. Some 
researchers have investigated the knowledge, attitudes and practices of physicians in 
terms of complementary and alternative medicine, but there has been little focus on 
herbal supplements (Clement et al., 2005). 
1.2 Statement of Problem 
In the United Arab Emirates (UAE) and particularly in Dubai, dietary 
supplement products and herbal supplements are combined under a definition called 
health supplement products (HS). Currently, there are limited data and information on 
HS products and any related adverse events. In addition, unlike the situation in other 
developed and some developing countries, in Dubai there is no surveillance or 
reporting system for adverse events resulting from HS product use. It is probable that 
there are adverse events associated with the consumption of HS products in Dubai. 
There is a need, therefore, to investigate the current situation and explore the 
possibilities of establishing a reporting system. 
In many countries, spontaneous reporting or vigilance systems are the main 
means of detecting safety issues associated with HS products. If suspected adverse 
events associated with HS products do not reach the system, either through direct 
patient reporting or through reporting from healthcare professionals, the detection of 
safety issues may be missed or delayed (Gavaza et al., 2011; Piening et al., 2012). This 
has important implications for public health protection. It is, therefore, important to 
identify the extent of the problem and the underlying causes to inform public health 
policy. 
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1.3 Research Questions 
The following research questions were proposed to achieve the objectives of the 
research: 
1. What are the prevalence and characteristics of HS product consumption in the 
general population of Dubai? 
2. Are the consumers of HS products aware of and able to identify HS product 
related adverse events? 
3. How extensive is consumer knowledge about HS products? 
4. Do HS products present any potential risks to human health, and, if so, what 
is the level of this risk? 
5. What are the knowledge, attitude and practice of healthcare professionals in 
Dubai towards HS product related adverse events and the reporting or 
notification of such events? 
6. What is the level of reporting of suspected HS product related adverse events 
in Dubai? 
1.4 Research Aim 
Previous studies have found that consumers are generally unaware of the risks 
of HS products and associated adverse events. In addition, they are unaware of the 
appropriate reporting process to the specific authorities in the event of adverse events. 
Also, many healthcare professionals do not have adequate knowledge, attitude or 
practice in relation to adverse events related to HS product consumption (Qassim et 
al., 2014; Ting et al., 2010). In a study among community pharmacists working in the 
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cities of Ajman and Sharjah, United Arab Emirates, only 4.9% were found to have 
good knowledge of ADRs (Qassim et al., 2014). In a cross-sectional prospective study 
conducted among US military physicians, 60% of the physicians observed adverse 
events associated with HS and only 18% reported these events. Around 70% 
physicians did not know how or where to report the adverse events associated with HS 
(Cellini et al., 2013). The prevalence of HS product consumption ranges from 10% to 
30% according to Kemper et al. (2006) and around 19% according to Hara et al. 
(2011). In the case of Dubai, however, there is no information about the prevalence of 
HS product consumption or any related risks. The main aim of this research, therefore, 
is to evaluate the public health importance of HS product consumption related adverse 
events in the Emirate of Dubai. 
1.5 Research Objectives  
The research objectives of this research are as follows: 
a- To assess the knowledge of HS products, levels of consumption and 
occurrence of adverse events in the population of Dubai. 
b- To assess the knowledge, attitude and practice (KAP) of healthcare 
professionals in Dubai regarding HS products and HS product related adverse 
events. 
c- To assess the reporting level of HS product related adverse events among 
healthcare professionals in Dubai regarding HS products and HS product 
related adverse events. 
d- To understand the views on the setting up of a surveillance system. 
7 
 
1.6 Research Significance 
HS products are imported and distributed in many countries where pre-
marketing safety and efficacy assessment is not usually a mandatory requirement 
(Kailin, 2008). Despite high levels of HS product consumption in many countries, 
there are low levels of reporting of related adverse events by consumers, manufacturers 
and healthcare professionals (Al-Ahmad et al., 2012). In a free trading country like the 
UAE, and especially in Dubai, the availability and consumption of HS products with 
established harmful effects is an issue of significant public health importance (CPSS, 
2016). 
Healthcare professionals have a key role in identifying HS product related risks 
and adverse events, but this role may be underdeveloped because of low levels of 
knowledge and lack of awareness (Walji et al., 2009). For the first time in the UAE, 
this research will provide an assessment of HS product awareness and practice among 
both consumers (the general population) and healthcare professionals alike. It will 
inform and help policymakers, where necessary, to develop programs for public and 
professional education, establish new policies and regulations on HS products and an 
adverse event reporting system (CPSS, 2016). 
1.7 Organization of the Remainder of Dissertation 
The remainder of this dissertation is structured as follows: chapter two reviews 
the literature in eleven sections; section one presents introductory statements of the 
chapter. Section two presents the diverse definitions of HS products. Section three 
provides a review of the literature on the use and demand of HS products in the world 
population and discusses the gap in knowledge in the UAE context. Section four 
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describes the global regulations for HS products including the current codex aimed at 
harmonising food and food supplement rules among all nations of the world. This 
section gives an overview of the HS product regulations in the following countries: 
USA, Canada, Australia, and UAE (Dubai). Section five considers the safety and 
efficacy of HS products including HS product interactions with other food and/or 
drugs, or other HS products. This section also discusses the various types of HS 
product related adverse events. Section six presents the literature on global adverse 
event monitoring systems for HS products including adverse event reporting systems 
and post-market surveillance. In addition, it discusses the adverse event monitoring 
system of HS products in some leading countries.  
Section seven discusses patient disclosure of HS product use information to 
healthcare professionals. Section eight identifies the literature on healthcare 
professionals’ knowledge, attitude and practice of HS product related adverse events. 
Section nine reviews the current literature on the challenges in adverse event data 
collection and analysis including the under-reporting of adverse events and the quality 
of data collection. Section ten discusses the benefits of having an adverse event 
reporting and monitoring system. The last section of this chapter discusses in summary 
all related HS concepts in relation to the current research. 
Chapter three covers the methods used in this research, namely two cross-
sectional studies using questionnaires in four sections. The first section presents 
introductory statements on the research methods. The second section presents details 
of the survey of HS product consumption in the population of Dubai including study 
design, study setting, study participants, sampling, sample size, survey instrument, the 
actual questionnaire including variables, data management including re-coding and 
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interpretation of the variables, statistical analysis, data limitation, and ethical approval 
and safeguarding participants. Section three presents similarly on the knowledge, 
attitude and practice of HS product related adverse events among healthcare 
professionals. The last section provides a summary of all related information regarding 
research methods. 
Chapter four presents the results from the analysis of the two cross-sectional 
studies. Chapter five discusses these findings. It presents a summary for each of the 
study objectives that have emerged from the findings and review of the literature. This 
chapter also presents the strengths of the study and reviews the limitations of the 
research. 
Chapter six presents a summary of the previous chapters and the conclusion of 
the findings. This chapter also presents the lessons and contribution of the study for 
academics and practitioners and makes recommendations for further research. 
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Chapter 2: Literature Review 
2.1 Introduction 
Dietary or health supplements (HS) are widely consumed by people across the 
world and their availability in the global market has been increasing in recent years. 
They are readily available without prescription and their regulation is not as stringent 
as medicines/drugs. Though many HS have a clean safety history, various 
reports/studies imply potential safety concerns regarding the quality and use of these 
products. Apart from regulating the manufacture and introduction of HS into the 
market, it is also important to monitor, collect and analyse the adverse events that may 
be caused by HS to improve the safety of HS use. 
These products are becoming an integral part of diet plans, mostly in developed 
countries. Increasing awareness of essential nutrients and their importance in 
maintaining a healthy lifestyle has led to a higher consumption of these supplements 
to offset a perceived lack of essential nutrients from normal diets. Over the years, 
increasing numbers of products have entered the markets under the label of HS. Today, 
HS is an umbrella term used to denote a vast variety of supplements that may include 
vitamins, minerals, herbs or other plants, amino acids, enzymes, and fibres among 
other products. They are available in various dosage forms and are meant to be 
exclusively taken by oral route. 
Unlike drugs, for which safety profile is well documented and closely monitored 
with established mechanisms, HS are thought to be harmless and safe for consumption 
without undergoing vigorous clinical testing. Even though established regulatory and 
monitoring policies are in place in many countries, adverse events caused by the 
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consumption of HS may not be adequately reported. This results in a potential health 
hazard which may go undetected. Lack of awareness about the potential harmful 
effects of HS among both consumers and healthcare professionals emphasizes the need 
for more effective regulatory and monitoring systems. 
The prevailing policies in regulating the consumption of HS in various countries 
together with the mechanisms established to identify the potential health risks caused 
by HS are discussed here. The limitations of current policies and monitoring systems 
and the specific areas which could make health supplement surveillance more 
inclusive are also discussed. Dubai, United Arab Emirates (UAE), has an HS market 
that is expanding year by year. As a result, there is a need to have proper monitoring 
and reporting systems. In this thesis, extensive research has been carried out to review 
the regulation and monitoring of HS, the reporting of adverse events in various 
countries, the various factors preventing the effectiveness of these systems and the 
need to improve existing systems with specific focus on Dubai. 
In this chapter, a detailed review of available literature on the following essential 
topics was carried out including HS definitions, use of HS in the world population, 
global regulations of HS, efficacy, safety and adverse events of HS, global adverse 
event monitoring systems for HS, disclosure of HS use to healthcare professionals, 
healthcare professionals’ knowledge, attitude and practice on HS related adverse 
events, challenges in adverse event data collection process and analysis, and the 
benefits of having an adverse drug reaction reporting and monitoring system. 
The research questions played a vital role in the selection of the topics for the 
literature review. 
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After finalising the topics, the literature review was written from access to the 
library of the UAE University and Hamadan Bin Mohammed Smart University. Some 
of the literature was accessed from the Pubmed on-line library. The literature search 
was conducted using a set of key words and phrases suitable for the framework, like 
health supplements, dietary supplements, risks of health supplement, use of health 
supplement, adverse events of health supplements, global regulation of health 
supplements, food supplements, etc. The literature and related topics were reviewed. 
Around 87 publications were shortlisted from a total number of 216 as references for 
the literature review chapter. This filtration process excluded articles after abstract 
review, after full article review and after data abstraction due to weak evidence. 
2.2 Health Supplement - Definitions 
The definition of HS differs from country to country and the products considered 
as HS also differ. The World Health Organization (WHO) and the United States 
Dietary Supplements Health and Education Act (DSHEA) of 1994 both define dietary 
supplements as products (other than tobacco) that are meant to supplement the diet. 
Both include vitamins, minerals, herbs, botanical products, amino acids, and dietary 
substances in their definitions (Phua et al., 2009). 
The Consumer Products Safety Section (CPSS) of Dubai Municipality defined 
HS as products (other than tobacco) complementary to the diet that include one or 
more of any dietary ingredient like vitamin, mineral, herb or other botanical, and/or 
amino acid ingredients. Additionally, dietary substance is defined as any preparation 
that is planned for use by any individual to enhance the diet’s nutritional value by 
amplifying the overall dietary intake and in a concentrated dosage form, a metabolite 
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preparation, element, extract, or a blend of any of the ingredients mentioned earlier 
(CPSS, 2015). 
Under Canadian federal regulations, natural health products (NHPs) are 
technically a sub-category of drugs. Any substance naturally found in plants, animals, 
fungi, algae or microorganisms (regardless of the source used for the supplement) that 
is used to diagnose, treat or prevent disease and is suitable for self-care use is 
categorized as an NHP in Canada. This category includes vitamins (regardless of 
source), minerals, traditional Chinese medicines, Ayurvedic medicines, Native North 
American medicines, traditional herbal remedies and homeopathic medicines. 
Biologics such as insulin, tobacco and marijuana are specifically excluded from the 
NHP definition (Walji et al., 2010). 
2.3 Use of Health Supplement in the World Population 
The use of HS is increasing worldwide. People around the world consider 
supplements to be safer and more effective than conventional medicines. Ready 
availability of HS without prescription and extensive advertisements make them the 
people’s medicine of choice for many ailments. Supplements are preferred over 
conventional medicines for the treatment of digestive conditions, common respiratory 
ailments and for weight management (NBJ’s Supplement Business Report, 2012). In 
the United States (US) the use of HS is increasing year by year. Statistics show that 
65% of the population in 2009, 66% in 2010 and 69% in 2011 were using HS (Gahche 
et al., 2011; Council for Responsible Nutrition, 2003). 
The demand for HS is also increasing globally. The global HS market was worth 
$243 billion in 2014 (Jose, 2015). The number of visits to providers of complementary 
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and alternative medicine (CAM) exceeds those to primary care physicians, for annual 
out-of-pocket costs of $30 billion. Herbal products constitute the major proportion of 
these treatments (Tachjian et al., 2010). In the US, sales of HS reached $28.1 billion 
in 2010, a 4.4% growth over 2009 sales. Top supplement categories included: 
multivitamins ($4.9 billion), sports nutrition powders and formulae ($2.8 billion), B 
vitamins ($1.3 billion), calcium ($1.3 billion), and fish/animal oil ($1.1 billion) (NBJ’s 
Supplement Business Report, 2012). 
According to recent studies, the use of HS and herbal preparations has also 
increased in the Middle East (Mamtani et al., 2015). In Dubai, the demand for and sale 
of HS are increasing year by year. The increasing number of HS premises in Dubai 
indicates the growing HS market: 690 premises in 2014, 740 premises in 2015, and 
800 premises in 2016 (CPSS, 2016). In addition, the increasing number of on-line 
applications for importing HS to Dubai, as shown in Table 2.1, supports evidence of 
the growth in the market. The HS consignment statistics in Dubai for the years 2012 
to 2015 indicate that the number of consignments containing HS imported to Dubai 
through Dubai ports increased by 86% from 2012 to 2015 (see Table 2.1 for more 
details). This probably relates to increased consumption of HS in Dubai as the 
percentage of non-complied HS in Dubai increased from 55% in 2013 to 63% in 2015. 
This indicates that a growing number of various, new and non-registered types of HS 
are being imported and marketed in Dubai (CPSS, 2016). 
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Table 2.1: Health supplement consignments (number, weight) Dubai 2012–2015 
Year Quantity Gross Weight (Kg) 
2012 2019 2,940,877.89 
2013 2448 3,790,542.40 
2014 3224 4,702,010.22 
2015 3752 4,790,351.00 
Table compiled by the author from data from Consumer Products Safety Section 
Annual Reports 2012-2015. 
2.4 Global Regulations of Health Supplements 
Despite the belief that HS are safe, these products are pharmacologically active 
and therefore have inherent risk. Most countries are aware of the need for regulation 
of HS and have regulatory systems for HS. HS are regulated by different authorities 
around the world. The policies and procedures of established authorities 
internationally and in various countries in terms of HS regulation are discussed in the 
following sections. 
2.4.1 Codex: harmonising food and food supplement rules 
In 1962, the Codex Alimentarius (food code) Commission (Codex) was created 
to harmonise health food standards internationally by two United Nation (UN) 
Organizations, the Food and Agriculture Organization (FAO) and the World Health 
Organization (WHO). Codex comprises more than 150 member countries and 
international organizations that meet to exchange information and ideas related to food 
safety and trade issues. The members of Codex are also members of WHO and FAO. 
Codex Alimentarius is a collection of standards, codes of practice, guidelines, and 
other recommendations. It has become the global reference point for consumers, food 
producers and processors, national food control agencies, and the international food 
trade. Currently, Codex Alimentarius lists more than 200 standards, encompassing 
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issues like labelling, additives, methods of analysis and sampling, food import and 
export inspection and certification, pesticides in foods, and contaminants. The code 
also deals with nutrition and foods for special dietary uses, which includes dietary 
supplements. The Codex Committee on Nutrition and Foods for Special Dietary Uses 
(CCNFSDU), hosted by Germany, meets every year to study the nutritional problems 
referred by the Codex Alimentarius Commission. The committee also considers draft 
provisions on nutritional aspects for all foods and develops guidelines, general 
principles, and standards for foods for special dietary uses (Das & Sen, 2014). 
The CCNFSDU began discussions on the guidelines for vitamin and mineral 
food supplements in the 1990s and these were adopted in 2005. The guidelines were 
limited only to food supplements that contain vitamins and/or minerals, where these 
products are regulated as foods. Although guidelines address the composition of 
vitamin and mineral supplements, including sources, safety, purity, and 
bioavailability, they only provide criteria for establishing maximum amounts of 
vitamins and minerals per daily portion of supplement consumed rather than setting 
upper limits for vitamins and minerals in supplements. The packaging and labelling 
requirements of vitamin and mineral supplements are also addressed in the guidelines 
(Das & Sen, 2014). 
These guidelines unfortunately do not address the broad category of dietary 
supplements, which includes herbals, amino acids, metabolites, concentrates, and 
many other non-essential nutrients. The codex in its current form has limited global 
implementation and individual countries have established more effective regulations 
on a wider range of food supplements (Das & Sen, 2014). 
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2.4.2 United States food and drug administration regulations 
In the US, products falling under the definition of HS include vitamins, minerals, 
and herbs addressed as dietary supplements and regulated by the Food and Drug 
Administration (FDA) within the context of the US Federal Food, Drug, and Cosmetic 
Act (FFD&C Act). Dietary supplements are considered food, and there are no 
regulatory categories or regulatory definitions to accommodate them separately from 
other food ingredients. In respect of dietary supplements, the FDA mainly regulates 
the labelling (including the label on the product container and accompanying material) 
of the product. The FFD&C Act was amended by US congress many times in the 
1990s. These amendments include the1990 Nutrition Labelling and Education Act 
(NLEA), the 1994 Dietary Supplement Health and Education Act (DSHEA), and the 
1997 Food and Drug Administration Modernisation Act (FDAMA). 
The 1994 Dietary Supplement Health and Education Act (DSHEA) regulates 
various types of health claims and structural/functional claims that may be made about 
dietary supplements. 
Health claims in dietary supplements should characterise a relationship between 
a food, a food component, or dietary ingredient and the risk of a disease (e.g. adequate 
calcium throughout life may reduce the risk of osteoporosis). The FDA authorises 
these types of health claims based on an extensive review of scientific literature. Only 
NLEA authorised health claims or health claims based on authoritative statements may 
be used in the labelling of dietary supplements. 
Structural/functional claims describe the role of a nutrient or dietary ingredient 
intended to affect the normal structure or function of the human body, (e.g. calcium 
builds strong bones). In addition, they may characterise how a nutrient or dietary 
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ingredient acts to maintain such structure or function, (e.g. fibre maintains bowel 
regularity, or antioxidants maintain cell integrity). Such claims do not need approval 
from the FDA, but the manufacturer must have substantiated that the claim is truthful 
and not misleading and must submit a notification with the text of the claim to the 
FDA no later than 30 days after marketing the dietary supplement with the claim. If a 
dietary supplement label includes such a claim, it must state in a disclaimer that the 
FDA has not evaluated the claim. The disclaimer must also state that the dietary 
supplement product is not intended to diagnose, treat, cure or prevent any disease. 
Only a drug can legally make such a claim (Hoadley & Rowlands, 2014). 
The FDA established current good manufacturing practice (cGMPs) 
requirements for dietary supplements in 2003 which specify detailed conditions for the 
preparation, packing, and storing of dietary supplements, and required that dietary 
supplements be unadulterated and accurately labelled to meet full safety and sanitation 
standards. Furthermore, the Dietary Supplement and Non-prescription Drug Consumer 
Protection Act (Public Law 109-462, effective December 2007) was issued and 
requires that serious adverse events related to dietary supplements and non-
prescription drugs be reported (Fu & Xia, 2014). 
2.4.3 Canada regulations 
In Canada, dietary supplements are referred to as Natural Health Products 
(NHPs) and comprise a group of health products that include vitamin and mineral 
supplements, herbal and other plant-based health products, traditional Chinese and 
Homeopathic medicines, probiotics and enzymes, and certain personal care products 
like toothpastes that contain natural ingredients (Health Canada, 2012a). The Natural 
Health Products Regulations (NHPR) under the Canadian Food and Drugs Act 
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regulates NHPs. NHPR is implemented by the Natural and Non-prescription Health 
Products Directorate (NNHPD) (Health Canada, 2012b). NNHPD requires all NHPs 
sold in Canada to have product licenses and the Canadian sites that manufacture, 
package, label and import NHPs must have site licenses. 
Producers of NNHPs are required to register the product with the NNHPD before 
launching the product in the market. The NNHPD may issue a license after evaluating 
the submitted documents including a consideration of the safety of the product. 
NNHPD follows a three-class system for licensing the product where the review time 
for the products are dependent on how much is already known about the benefits and 
risks of the products. This system enables quick reviewing and licensing of products 
about which there is most knowledge and certainty regarding safety, while complex 
applications require more detailed evaluation efforts. 
Class 1: This class has the highest level of certainty about the product (how much 
is known about the product) and the lowest potential risk. Seventy five percent of 
NHPs are in this category. These products are supported by pre-cleared information 
(PCI) based on previous NHPD decisions and can receive a license within 10 days of 
submission of the application. 
Class 2: This class covers moderate certainty of product and moderate risk. 
Around 20% to 24% of NHPs are in this class, typically those with at least one claim 
or ingredient supported by a PCI.  For example, a Class 2 product may be an existing 
authorised product with a new claim related to product use. Products falling into this 
category will undergo an expedited risk-based review with a target of 30 days. 
Class 3: This class covers NHPs with the lowest certainty and highest risk and 
comprises about one to five percent of NHPs. In this class, there are no ingredients or 
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claims supported by PCI. For example, if a new product is claimed to prevent 
rheumatoid arthritis, clinical trial evidence with a full pre-market assessment is the 
level of review needed. The current review period for this class is 180 days, but 
companies could reduce this time by revising their claims for the NHP to meet the PCI 
(Harrison & Nestmann, 2014). 
2.4.4 United Arab Emirates - Dubai regulations 
HS in Dubai Emirate are controlled by Dubai Municipality through Local 
Circular No. (11/2003) for the year 2003 and the Health Supplement Circular dated 24 
February 2010. The trading companies who are licensed inside the UAE and have 
business related to HS product trading can do HS business in Dubai, but need to 
register their product(s) with Dubai Municipality prior to importation or any other 
business related practice. 
The Consumer Products Safety Section (CPSS) of the Health and Safety 
Department is the responsible regulatory authority at Dubai Municipality for HS 
products. The CPSS controls HS products in three different areas: HS products 
registration, HS product consignment release, and HS product monitoring in Dubai 
Emirate through field inspection. 
2.4.4.1 Health supplement registration 
Companies may register HS products with the CPSS using an on-line system 
prior to importation of the product into Dubai. Companies submit documentation for 
the products including artwork of the product, free-sale certificate, which is a 
certificate that is issued by a related authority in the country of origin of the product 
certifying that goods such as food items, cosmetics, biologics, or medical devices are 
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legally sold or distributed in the open market, freely without restriction, and approved 
by the regulatory authorities in the country of origin (Web Finance Inc., 2016). 
Additional documentation includes an ingredient report and an analysis report from 
the manufacturer, a related test report from an accredited laboratory and other 
supporting documents. The CPSS team then assesses the product documents and its 
application. If the product does not raise any concern then the CPSS team will register 
the product. If there are concerns then these must be rectified by the company before 
re-applying for registration. The validity of registration is 5 years. The company must 
renew the registration before the expiry date (CPSS, 2015). 
2.4.4.2 Health supplement consignment release 
The CPSS team at Dubai ports controls the entry of HS products into Dubai 
Emirate. Companies apply through an on-line system for the shipment release with 
shipment details and registration details. Inspectors from CPSS consignment release 
teams to inspect the shipment and the shipment is released if it meets the required 
standards which include the quality of the product, the storage condition during the 
shipment and the registration status of the product (CPSS, 2015). 
2.4.4.3 Health supplement field inspection 
The field inspection team of CPSS monitors the Dubai market through routine 
inspections of premises where HS are on sale. Field inspectors inspect the shops and 
ensure compliance with regulations including label modifications, use of unapproved 
claims and storage conditions. Random sampling and laboratory testing of the 
registered products further ensure the quality of the HS products in Dubai (CPSS, 
2016). 
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2.5 Efficacy, Safety and Adverse Events of Health Supplements 
2.5.1 Efficacy of health supplements 
The efficacy of HS has been established through years of practice and is now 
one of the essential parts of day to day life. Some HS have proven their efficacy 
through clinical studies. For example, vitamin D and calcium supplements have been 
shown to be beneficial in the prevention and treatment of bone loss and osteoporosis 
(Lanham-New, 2008). Similarly, folic acid has been shown to be effective in 
preventing certain birth defects such as neural tube defects (Wolff et al., 2009). 
Glucosamine containing supplement use has a proven effect in improving locomotor 
function and reducing knee pain in osteoarthritis (Kanzaki et al., 2015). Vitamin B12 
along with Omega 3 fatty acid were shown to be beneficial in Alzheimer’s disease by 
slowing the rate of brain shrinkage in patients with Mild cognitive impairment (Oulhaj 
et al., 2016). 
2.5.2 Safety of health supplements 
As the definition implies, HS are mainly intended to supplement the diet with 
one or more dietary ingredients like vitamins, minerals, herbs or other botanical, and/or 
amino acid ingredients. The use of HS and herbs was thought to be safe in the past, 
but an excessive intake of any nutrient could result in adverse events. There exists a 
wide variability in the nature and concentration of the ingredient and the source and 
purity of raw material, especially in herbal supplements. This, along with variations in 
methods of preparation and a lack of related safety data for human consumption, 
highlights the potential safety risks involved in HS consumption. The factors affecting 
the safety and the risk of consuming the supplement may vary by product and category. 
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For vitamins and minerals, even if they have been established as safe over years of 
practice and clinical trials, over-dosage may lead to severe direct toxicity to the 
consumers. 
The risk of consuming vitamins and minerals increases as the consumed dose 
increases. At low dosage, the risk of compromised health due to deficiency is high. At 
high dosage, the risk of compromised health due to toxicity is high. As the margins 
between the essential amounts and toxicity are narrow, a conventional method of risk 
assessment has been established in an Acceptable Daily Intake (ADI) for vitamins and 
minerals which is a recommended safe level. This level is established following a 
consideration of two risk assessment values, the NOAEL and the LOAEL. NOAEL is 
the non-observed adverse event level, which is the maximum dose in acceptable daily 
intake. LOAEL is the lowest observed adverse event level. If there are no adequate 
data demonstrating a NOAEL, then a LOAEL may be used. Where various adverse 
events (or endpoints) occur for a nutrient, the NOAELs (or LOAELs) for these 
endpoints will differ. The critical endpoint is the adverse event exhibiting the lowest 
NOAEL (i.e. the most sensitive indicator of a nutrient’s adverse events) which ensures 
protection against all other possible adverse events (COT, 2003; EFSA, 2006).  
NOAEL and LOAEL play a vital role to establish an acceptable daily intake of 
vitamins and minerals. NOAEL can be calculated by extrapolating LOAEL from the 
dose response curve (one of the most important concepts in pharmacology which 
describes the relationship between an effect of a drug and the amount of drug given). 
The factor of 3 is commonly used when extrapolating from a LOAEL to a NOAEL for 
data derived from studies in experimental animals. This is because the dose levels used 
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in such studies are commonly at 3-fold intervals. ADI can be calculated from the below 
formula. 
 
ADI =
No Observed Adverse Effect Level
10 (inter species variation) ×  10 (inter individual variation)
 
 
For example, the LOAEL of Vitamin B6 (pyridoxine) is identified as 50 mg/kg 
bw/day based on studies. Uncertainty factor for LOAEL to NOAEL extrapolation was 
3. The NOAEL calculated as 16.66 (LOAEL/3). The ADI calculated for Vitamin B6 
(pyridoxine) is 16.7 mg/kg bw/day which is equivalent to 10 mg/day for a 60 kg adult. 
(COT, 2003). 
The referral intake of vitamin C by an adult is in a range of 45-90 mg/d, an 
amount needed to prevent scurvy. The maximum level of safe intake (NOAEL) is 1 
gram (g). The margin of ADI is larger and it is more than 10 times greater than the 
referral intake. A much larger quantity of vitamin C can cause gastrointestinal events 
such as osmotic diarrhoea, which occurs at intakes of several grams. In the case of 
vitamin A, the referral intake is 600-900 microgram (µg), and evidence exists of 
adverse events on bone health at an intake of 1500 µg. Safety and risk assessment 
values vary for different vitamins and minerals. A close monitoring of international 
safety standards and studies is essential in the safe control of vitamins and minerals 
(Mulholland & Benford, 2007). 
The established safe range or ADI may not be applicable to all groups. The ADI 
may differ with life stage or increased or decreased susceptibility to adverse events. 
Nutritional requirements vary because of growth and existing conditions like altered 
renal function. A dose that is beneficial for some sub-groups in the population may 
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possess potential harmful effects for others. Folate supplementation reduces the 
incidence of neural tube defects in the foetus, but may mask the anaemia associated 
with vitamin B12 deficiency in older persons, allowing neuropathy, also associated 
with the deficiency, to progress undiagnosed. 
In terms of herbal supplements, one of the safety issues is heavy metal 
contamination. Herbal supplements may be contaminated by heavy metals such as lead 
(Pb), cadmium (Cd) and mercury (Hg). This heavy metal contamination increases the 
risk for the safe use of herbal supplements. The heavy metal contamination is 
influenced by several factors such as occupational contamination, bioaccumulation of 
heavy metals in herbs/plants from atmospheric depositions determined by climatic 
factors, heavy metal pollutions in soil, contaminated wastewater used for irrigation of 
soil on which the herbs are grown, and the degree of maturity of the plant at the time 
of harvest (Bentum et al., 2011; Khan et al., 2008). High doses of heavy metal 
consumption can cause several diseases. They may be carcinogenic or have adverse 
reproductive effects, and they may unfavourably impact on nutrition by displacing 
biologically useful metals such as calcium and zinc (Ejeatuluchukwu et al., 2011; 
Fasinu & Orisakwe, 2013). 
Another safety concern relating to herbal supplements is pesticide residues. 
These may contaminate the herbal supplement due to excessive use of pesticides 
during the cultivation of the herb and from lack of good agriculture practices (GAP). 
Organochlorine pesticide residues have been found in several Chinese herbal plants 
cultivated in China and sold in Hong Kong (Leung et al., 2005). Even though safety is 
a concern, the use of HS in daily life is increasing and it demands more attention and 
control. 
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Other serious concerns in the consumption of HS are adulteration and 
contamination by various methods. The adulteration of herbal products with 
undeclared pharmaceuticals, substitution with exhausted drug and substitution with 
artificially manufactured substances along with contamination from different sources 
like pollens, dust, moulds and fungi can cause serious adverse events. A study in Hong 
Kong published in 2011 shows the severity of the under-recognised problem of 
adulteration of Chinese herbal anti-diabetic and diabetic products with undeclared 
pharmaceuticals, including both registered and banned drugs (Ching et al., 2011). 
When evaluating the safety of the HS, it is important to consider their use by 
vulnerable groups. Some groups of the population may be particularly susceptible to 
adverse events from the ingredient of a HS. Vulnerable groups are defined as a sub-
population who are more likely to have adverse events or individuals in whom the 
specific adverse events identified are more likely serious in comparison with the 
general population. Characteristics that contribute to this vulnerability may be 
physiological, disease related, or related to other aspects such as lifestyle or therapeutic 
interventions. Physiological characteristics include age, genetic predisposition and 
specific physiological conditions. Some age groups may be more susceptible to 
adverse events from some HS than others. The capacity of the human body to 
metabolise the ingredients of HS varies through the life span. HS ingredients that are 
normally excreted or altered by kidney or liver function may potentially pose greater 
risk to the elderly than to the younger population. This must be considered in the HS 
specifically intended for use by the elderly such as HS used for osteoarthritis. Children 
have a lower metabolic capacity than adults, which for certain supplements may make 
them more susceptible to adverse events. Physiological conditions like pregnancy also 
increase the chance of adverse events from HS ingredients. Special concern should be 
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given to the teratogenic effects of HS ingredients intended for use in pregnancy (Phua 
et al., 2009). A well-known example is the teratogenic effect of high doses of vitamin 
A if used in the pre-conception period (Rothman et al., 1996). 
In addition to the life stages, disease conditions also alter susceptibility to 
adverse events. Disease, or pre-existing conditions including hypertension, 
cardiovascular disease, hepatitis, renal disease and diabetes all require special attention 
if present in a person contemplating HS use. Hepatitis or renal dysfunction may delay 
the metabolism and excretion of the ingredient leading to toxic levels which may lead 
to severe adverse events. In diabetic patients, HS may affect insulin and glucose which 
could lead to severe metabolic adverse events. All these factors should be taken in to 
account to ensure the safe use HS (Phua et al., 2009). 
One of the major concerns about the safety of HS is the potential for interaction 
between a supplement and other ingested substances like drugs, other dietary 
supplements or food. This may result in adverse clinical outcomes due to an increase 
or decrease in the level of drugs, dietary supplements or food in the body. Some 
examples of these interactions are discussed below. 
Calcium carbonate taken as HS may interact with the antibiotic, tetracycline. 
This is a direct chemical-to-chemical interaction. The calcium carbonate may bind 
with the tetracycline and form an insoluble product. This will reduce or even eliminate 
the effect of tetracycline (NAS, 2005). 
The use of herbal products forms the bulk of treatments (particularly by elderly 
persons who also consume multiple prescription medications for comorbid conditions) 
which increase the risk of adverse herb-drug-disease interactions (Tachjian et al., 
2010). The concomitant use of yohimbine bark with guanabenz acetate, a drug used 
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for hypertension, may diminish the antihypertensive activity of guanabenz through its 
opposing pharmacodynamic effect (Grossman et al., 1993). Ginkgo biloba leaf, used 
as an HS for mental alertness, may have an antagonistic effect on platelet activating 
factor. If it is ingested with an anti-coagulant like warfarin, it will have an additive 
action and may lead to bleeding (Spencer, 2004). St. John’s Wort, used as an HS for 
depression, has some proven drug interactions. It may interact with cyclosporine, an 
immune suppressant drug and thereby reduce the effect of cyclosporine. The level of 
cyclosporine in the blood is controlled by the MDR1-encoded transporter and the 
enzyme CYP3A4CYP both of which are affected by St. John’s Wort. This will reduce 
the level of the cyclosporine in the blood and may lead to transplanted organ rejection 
(Ruschitzka et al., 2000; Borrelli & Izzo, 2009). St. John’s Wort may also interact with 
oral contraceptives. Circulating oestrogen levels following oral contraceptive intake 
are also regulated in part by the activity of MDR1-encoded transporters so that St. 
John’s Wort may lead to reduced levels of oestrogen in the blood level and a reduced 
contraceptive effect (Borrelli & Izzo, 2009). 
Herbal supplements like cranberry, which is used in blood and digestive 
disorders, in co-administration with warfarin may affect CYP2C9 and CYP3A4. This 
may lead to an additive action and bleeding may occur (Ge et al., 2014; Mohammed 
Abdul et al., 2008). The concomitant use of Echinacea, an HS used as an immune 
stimulant to prevent infections like the common cold and flu, with etoposide, a 
cytotoxic drug used in the treatment of lung cancer, may produce an interaction and 
lead to an increased platelet count. The use of Echinacea is not desirable in patients 
taking etoposide or any other chemotherapeutic drug (Bossaer & Odle, 2012). 
29 
 
All the above mentioned potential HS interactions with drugs shows a clear need 
for the consumer to discuss any planned use of HS with their healthcare professionals 
to avoid possible adverse events. 
2.5.3 Adverse events of health supplements 
The World Health Organization (WHO) has defined an adverse reaction as a 
response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the 
modification of physiological function (WHO, 2002). 
All HS carry risks and benefits. Many of these risks are identified in pre-market 
testing and can be managed as expected or with tolerable side effects that are 
outweighed by the product's benefits. Adverse events may occur even when a product 
is being used as directed. An event may occur within minutes after exposure or it can 
take years to develop. Adverse events can range from minor irritations, like a skin rash, 
to serious and life threatening events, such as a heart attack or liver damage. Most 
often, adverse events are unexpected and are not necessarily indicated on the product 
label or on any other information provided with the product (Health Canada, 2011a). 
Adverse events associated with vitamins and minerals are usually due to over 
consumption compared to the acceptable daily intake (ADI). In this respect, an 
important consideration is the dietary pattern of the individual taking the vitamin and 
mineral supplementation as diet also contributes towards daily intake. As stated above, 
the safe upper level of vitamin C is 1g per day and this can be provided by a single 
tablet, 1.69 kilograms (kg) of kiwi fruit or 2.5 litre (L) orange juice. For a person taking 
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these levels of vitamin C in their diet, even a vitamin C supplement  with a dose less 
than 1g may cause adverse events (EFSA, 2006). 
The WHO’s Uppsala Monitoring Centre, which pools reports from over 100 
countries worldwide, has a database of over four million reports, of which 21,000 
involve adverse events caused by herbal and natural products. The complexity of 
herbal products starts with the method of cultivation and collection of the herbs. Major 
causes of adverse events are the adulteration of herbal products with undeclared 
chemicals including potent pharmaceutical substances such as corticosteroids and non-
steroidal anti-inflammatory agents. Major causes and sources of adverse events 
associated with herbal products include mistaken or deliberate use of the wrong species 
of medicinal plants, incorrect dosing, deliberate over-dosing for a more rapid effect, 
heavy metal contamination (during cultivation or manufacturing),the presence of 
agrochemical and pesticide residues, the presence of pathogenic microorganisms, 
errors in the use of herbal supplements both by healthcare providers and consumers, 
and interactions with other medicines (WHO, 2004; Phua et al., 2009). 
In 2009, a division of the US Food and Drug Administration (FDA), the Internet 
and Health Fraud Team, conducted an internet survey of HS products intended for 
sexual enhancement. They found that one third of such supplements that are marketed 
as dietary supplements to promote sexual performance and treat erectile dysfunction, 
despite having no disclosure of any medicinal content on the label, nevertheless 
contained the medicinal ingredient sildenafil, the active ingredient in Viagra (USFDA, 
2009). 
In Germany, the Deutsches Aerzteblatt International, which is responsible for 
the approval of HS products, carried out research in March 2009 which found that 
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certain Chinese slimming products, such as slimming tea and slimming herbal 
capsules, had been associated with 17 incidents in which the consumer became ill with 
symptoms and signs that included vomiting, arterial hypertension, headache, malaise, 
nausea, chest pressure, dyspnea, tachycardia, insomnia and high fever. The herbal 
products subsequently underwent chemical analysis in which sibutramine, a medicinal 
slimming ingredient, was found. Every capsule of the herbal product contained twice 
the recommended daily dose of sibutramine. Sibutramine is now a banned ingredient 
even in medicinal products due to its potential to cause serious side effects (Müller et 
al., 2009). 
In 2001, the FDA issued warnings and an import alert that herbal products are 
unsafe if they contain or are suspected to contain aristolochic acid (USFDA, 2001). A 
cohort study of 105 patientsat a Belgian clinic found that rapidly progressive 
nephropathy developed after they had been administered an herbal weight-loss product 
containing aristolochic acid (Nortier et al., 2000). Because of a suspected association 
between aristolochic acid and urothelial carcinoma, 39 patients with end-stage renal 
disease underwent prophylactic removal of the kidneys and ureters. Urothelial 
carcinoma was diagnosed in 18 of them. Aristolochic acid nephropathy has been 
reported in eight other countries, and associated urinary tract cancer has been reported 
in two (Arlt et al., 2002). The International Agency for Research on Cancer classifies 
products containing the aristolochia species as human carcinogens (Heinrich, 2003). 
The toxicological evidence of the risks associated with aristolochic acid is strong. In 
1982, tumours were rapidly induced in rats at low doses (Wang et al., 2011). 
Aristolochic acid is among the most potent two percent of the carcinogens in the 
Carcinogenic Potency Database (Gold et al., 2005). It is mutagenic, forms DNA 
adducts in humans, and is carcinogenic in mice. In rabbits, aristolochic acid induces 
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nephrotoxic effects, the same DNA adducts in kidney as in humans, and urothelial 
tumours (Arlt et al., 2002). 
Patients are increasingly using herbal products for purportedly preventative and 
therapeutic purposes. Some products have direct effects on the cardiovascular or 
homeostatic system, whereas others have indirect effects through interactions with 
medications that could lead to serious consequences. Common herbal remedies that 
produce adverse events on the cardiovascular system include St. John’s Wort, 
motherwort, ginseng, gingko biloba, garlic, grapefruit juice, hawthorn, saw palmetto, 
danshen, echinacea, tetrandrine, aconite, yohimbine, gynura, liquorice, and black 
cohosh (Tachjian et al., 2010). 
In a study conducted in 2012 which evaluated the use of supplements containing 
ephedra, which has been temporally associated with sudden death, 48 cases of those 
with known supplement use were compared to 144 age, gender, and socioeconomic-
matched controls in a 1:3 case control design. Of the 48 sudden deaths temporally 
associated with supplement use, the underlying cause of death was fatal atherosclerotic 
coronary disease in 18 (37.5%), sudden unexplained death in 16 (33.3%), and 
hypertrophic cardiomyopathy in 6 (12.5%). In subjects ≥35 years of age, and known 
to be taking supplements, there was a significant increase in mortality due to sudden 
unexplained death (relative risk = 5.1 [95% confidence interval, 1.4–18.7]). This study 
concluded that atherosclerotic coronary disease and idiopathic sudden death are 
common etiologies of death when taking supplements (Appel et al., 2012). 
HS products are gaining popularity throughout the world and the expanding HS 
market in Dubai mirrors this consumption. As previously discussed, the consumption 
of any pharmacologically active substance may have potentially harmful effects. There 
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are also the additional dangers of adulteration, contamination, drug-HS or HS-HS 
interactions to consider as these raise significant health issues. As the consumption of 
HS products may have potentially deleterious effects on human health, there arises a 
need for this issue to be duly addressed. 
2.6 Global Adverse Event Monitoring Systems for Health Supplements 
The following sections present details of various worldwide monitoring systems 
in use regarding HS product related adverse events. 
2.6.1 Adverse event reporting systems and post market surveillance 
Some countries have established adverse event monitoring systems for HS. 
Regardless of the pre-market requirements like notification, registration and pre-
market approval, the most effective safety assessment measure is post-market 
surveillance. Monitoring product performance in the market place through collection 
and investigations of consumer inquiries, complaints, and adverse reactions is the most 
effective means of assuring quality and safety. 
Adverse event reporting is a system that requires the reporting of adverse events 
associated with a product to the appropriate authority. This is a regulatory requirement 
in some countries. Post-market surveillance goes beyond this requirement to ensure 
the overall quality and consistency of products in addition to managing company 
liability by monitoring the performance and safety experience for a given product in 
the market place. Post-market surveillance is a broader field, incorporating the 
collection and analysis of consumer inquiries and complaints, in addition to adverse 
events, and using this information to resolve issues and ensure continuous 
improvement. Some leading companies which carry out post-market surveillance for 
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their products may be in a better position to provide quality and safety assessments 
than the regulators (Shao, 2014; Frankos et al., 2010). 
Many countries have an established pharmacovigilance system for the 
identification of the hazards associated with drugs. Spontaneous reporting systems for 
suspected adverse drug reactions (ADRs) continue to be an essential part of 
pharmacovigilance. Any information on a new or known adverse event that might be 
potentially caused by a medicine and that necessitates further investigation is 
considered as signal. Signals are generated from several sources such as spontaneous 
reports, clinical studies, and the scientific literature.  Signal detection is the process 
that aims to find, as soon as possible, any indication of an unexpected drug safety 
problem which may be either new ADRs or a change of the frequency of ADRs that 
are already known to be associated with the drugs involved. The results of this 
surveillance exercise tend to arouse suspicions and should always be followed up by 
thorough investigations. 
Causality or relatedness assessment evaluates whether the detected adverse 
event is probably caused by the specific product. Causality assessment tools can be 
broadly classified as expert judgment/global introspection, algorithms and 
probabilistic methods (Bayesian approaches) and comprises, among others, the 
evaluation of temporal relationships, dechallenge/rechallenge information, association 
with or lack of association with underlying disease, presence or absence of a more 
likely cause, and biologic plausibility (DSRU, 2017; EMA, 2014; Agbabiaka et al., 
2008). In adverse event reporting systems, the agencies receive reports of adverse 
events from customers, healthcare professionals or companies. Respective regulatory 
agencies utilise the information for signal detection, not causality analysis. Regulators 
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do not individually rate or score individual reported adverse events. Rather, they 
consider all incidents in totality, in context, to identify signals. Agricultural or 
manufacturing errors, product contamination, and tampering are examples of issues 
that can be identified through the collection of adverse events (Shao, 2014). 
A robust post-market surveillance system involves comprehensive investigation 
of quality and adverse reaction incidents. This includes collection, documentation, and 
categorising of incidents followed by causality analysis and corrective action or risk 
mitigation efforts, where applicable. This process falls outside the scope of most 
mandatory adverse event reporting requirements. For the handling and mitigating of 
consumer complaints related to product quality, some regulatory agencies have 
incorporated requirements into Good Manufacturing Practice (GMP) regulations. For 
example, in the United States, the FDA has promulgated requirements for complaint 
handling in the current GMP regulation published in 2007 (USFDA, 2016). 
2.6.2 Adverse event monitoring systems in leading countries 
Adverse event monitoring systems for HS vary greatly around the world. In some 
countries, reporting is practiced voluntarily by some companies and provided by 
healthcare professionals. Some countries have established specific requirements for 
adverse event reporting. Adverse event monitoring systems in selected countries are 
described in the following section. 
2.6.2.1 USA monitoring system 
In December 2006, the US Congress passed the Dietary Supplement and Non-
prescription Drug Consumer Protection Act, requiring manufacturers of dietary 
supplements and OTC drugs to report to the FDA all serious adverse events they 
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receive within 15 business days and to maintain records of all adverse events they 
receive for up to six years. The law defines a serious adverse event as death, a life-
threatening experience, an inpatient hospitalisation, a persistent or significant 
disability or incapacity, a congenital anomaly or birth defect, or an event that requires 
appropriate medical judgment that may jeopardise the patient or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this 
definition. In addition, this law mandates that the name and address of a party (e.g., a 
manufacturer, packer, distributor, or retailer) responsible for collecting information 
about adverse events should appear on the label of a non-prescription drug (also known 
as an OTC drug) or a dietary supplement (USFDA, 2016). 
An adverse event reporting system has been established called MedWatch. By 
law, companies must report serious adverse events to the FDA within 15 days through 
the MedWatch system using form FDA 3500A. The label of the product should be 
attached with the form. Moreover, if the party learns of any new medical information 
related to a serious adverse event report submitted in the previous 12 months, it must 
be passed on to the FDA within 15 business days of receiving that information. 
Consumers and healthcare professionals can also report adverse events 
associated with HS voluntarily through the MedWatch system using the same form. 
The receipt by the FDA of reports of minor adverse events in this way from consumers 
may lead to signal generation. In addition, clinicians who may find some interaction 
of HS with drugs during patient treatment should also report these interactions through 
Medwatch form 3500A. Reports are assigned with a unique identification number and 
forwarded to a Centre for Food Safety and Applied Nutrition (CFSAN) reviewer who 
evaluates the report and characterises the relationship of the dietary supplement to the 
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reported adverse event. Sometimes even reports of minor adverse events can be a 
signal that a serious adverse event could arise from using a dietary supplement. The 
reviewer may contact the person who filed the adverse events to obtain more 
information and may do a scientific background review of the adverse events, whether 
it is associated with the HS or not. If the signals of adverse events indicate a relation 
with the intake of the HS, the FDA will act, including product withdrawal from the 
market (Frankos et al., 2010). 
2.6.2.2 Canada monitoring system 
Health Canada requires NHP licensees to report all serious worldwide adverse 
events (AE) arising from the product within 15 working days (Shao, 2014). 
Health Canada assesses NHP for safety, effectiveness and quality before they 
can be licensed for sale in Canada. Health Canada monitors the safety profile of all 
health products sold in Canada to ensure that the benefits of using them continue to 
outweigh the risks that may be associated with their use (Health Canada, 2011b). 
NHPD controls NHPs after product approval through post-market activities 
including the Adverse Reaction (AR) reporting system. Along with other medical 
device problem reporting reports, the MedEffect Canada website supports the 
reporting of AR associated with NHPs. Canada has an established post-market 
surveillance system run jointly by NHPD and the Marketed Health Products 
Directorate (MHPD) (Harrison & Nestmann, 2014). 
Consumers and healthcare professionals may report adverse events of NHP 
products to the Canadian Vigilance System through MedEffect Canada by telephone, 
on-line or by mail using a consumer side effect reporting form. HC evaluates the 
38 
 
signals associated with the adverse events and the safety profile of the product and, if 
needed, may recall the product from the market. The MedEffect Canada system allows 
consumers, patients and healthcare professionals to report an adverse event or side 
effect thereby generating new safety information of NHP products. Consumers and 
healthcare professionals may search for advisories, warnings and recalls in the Recalls 
and Safety Alerts Database of MedEffect Canada (Health Canada, 2011a). 
2.6.2.3 Australia monitoring system 
In Australia, HS are categorized as Complementary Medicines (CM) and 
controlled by the Therapeutic Goods Administration (TGA). Australia has a 
pharmacovigilance system, Therapeutic Product Vigilance, that requires the reporting 
of adverse events of CMs in the absence of specific requirements for CMs. TGA 
mandates by law that the sponsor or manufacturer of the product should report AEs 
within 15 working days. If it is a critical, significant safety issue, the sponsor should 
report within 72 hours from the time of awareness of the issue by any personnel of the 
sponsor. Consumers and healthcare professionals may also report adverse events of 
CM through an on-line form on the TGA website. Each adverse events report received 
by the TGA is entered into a database and continually evaluated by TGA staff to 
identify potential emerging problems for detailed investigation. TGA staff carry out 
detailed investigation and if they identify a safety concern associated with the product, 
TGA may take regulatory action including recalling or suspending of the product from 
the market (TGA, 2016). 
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2.7 Disclosure of Health Supplement Use to Healthcare Professionals 
Patients’ disclosure of HS consumption to healthcare professionals is one of the 
factors contributing to the safe use of HS. Drug/HS interaction may lead to major 
adverse events and demands the attention of healthcare professionals to avoid this. The 
disclosure rate of complementary and alternative medicine (CAM), which also 
includes HS, varies from 23-70% and one of the reasons for this is that practitioners 
did not need to know about their patients’ CAM use, and the fact that the practitioners 
did not ask (Robinson & McGrail, 2004). One study shows that 69% patients did not 
inform the physician about their dietary supplement use excluding vitamins (Gardiner 
et al., 2006). Without specific prompting or questioning, consumers of natural products 
may not disclose their use of such product to primary healthcare professionals. It is 
helpful if the healthcare professional adopts a pro-active approach and routinely 
includes questions about health supplement use, but this does not usually happen 
(Busse et al., 2005). There is concern about a negative response from healthcare 
professionals: they do not ask, and the perception is that because healthcare 
professionals work within a biomedical framework, they have less knowledge of CAM 
(Robinson & McGrail, 2004). Nutritional supplements are often considered safe and 
natural, and consumers are not aware of the possibility of HS/drug interactions (Bebeci 
et al., 2015). The regulatory authorities should pay more attention to educating 
consumers about the complications of the concomitant use of HS and drugs and the 
need for disclosure of HS use to healthcare professionals. This could be done through 
public information campaigns and continuing professional education for healthcare 
professionals to ensure that both consumer and professional are aware of HS, 
especially herbal supplements (Samojlik et al., 2013). 
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2.8 Healthcare Professionals’ Knowledge, Attitude and Practice on Health 
Supplement Related Adverse Event 
Herbs and other dietary supplements are among the most commonly used 
complementary medical therapies. Clinicians, however, generally have limited 
knowledge and confidence to communicate regarding herbs and dietary supplements. 
Educational interventions and institutional policies are needed for healthcare 
professionals in relation to herbs and dietary supplements to improve the quality of 
patient care (Kemper et al., 2006). 
The unprecedented global increase in the use of herbal remedies is set to continue 
apace well into the foreseeable future. This raises important public health concerns, 
especially as it relates to safety issues including adverse events and herb/drug 
interactions. Most Western-trained physicians have very limited knowledge of the 
risks and benefits of this healthcare modality. Therefore, evaluation of healthcare 
professional knowledge would identify appropriate intervention strategies to improve 
physician-patient communication in this area (Clement et al., 2005). 
A survey conducted in Maharashtra, India, found that a lack of knowledge 
prevented healthcare professionals from advising their patients on herbs and herbal 
preparation in a positive way. The authors recommended that the medical curriculum 
should include training in the use of scientific and evidence-based research on herbal 
medicines. Physicians must become more educated about the safe and effective use of 
herbs. Asking patients about supplement use during an initial medical history should 
be made a central component of patient care and medication use monitoring (Ghia & 
Jha, 2013). 
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In a cross-sectional prospective study of US military physicians, 60% of the 
physicians observed adverse events associated with HS, but only 18% reported these 
events. Approximately 70% of physicians did not know how or where to report adverse 
events associated with health supplements. A gap in information of HS and adverse 
events reporting is identified in the study. A centralised adverse event reporting system 
could serve to identify potentially harmful HS for further evaluation. Health 
professionals need to remain vigilant for adverse events associated with HS use and 
should be better informed on how to report them (Cellini et al., 2013). 
A study carried out among doctors working in a teaching hospital in Lagos, 
Nigeria underlined the fact that there are gaps between knowledge and ADR reporting. 
For the long-term improvement of ADR reporting, it is very important that these gaps 
be filled by improved training in pharmacovigilance and risk perceptions of drugs. 
Healthcare professionals should be made aware that ADR reporting is considered an 
integral part of the clinical activities of doctors (Oshikoya & Awobusuyi, 2009). 
Another descriptive cross-sectional study conducted among oncology 
practitioners, including medical and allied medical personnel, in Doha, Qatar drew 
attention to the need to integrate an educational and training program regarding CAM 
practices and usage to enhance cancer patient management and ensure a more holistic 
and efficient cancer treatment for patients (Hassan, 2015). 
A survey of attitudes and knowledge of HS among US and Canadian pharmacists 
recommended that pharmacists need to have additional training in HS, that there 
should be increased regulation of HS, and that there should be an improvement in the 
quality of information on HS. In addition, the survey data indicated that pharmacists 
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do not perceive their knowledge of HS to be adequate and that they do not routinely 
document, monitor, or inquire about patient use of HS (Kwan et al., 2006). 
A study in Gujarat, India, found that community pharmacists’ knowledge of the 
terminology of ADR and awareness of the national pharmacovigilance centre was 65% 
and 63%, respectively. In addition, 60% of community pharmacists assumed that all 
herbal products were free from ADRs (Rathod & Panchal, 2014). 
In a study among community pharmacists working in the emirates of Ajman and 
Sharjah, United Arab Emirates, only 4.9% were found to have good knowledge of 
ADRs. Moreover, the study concluded that knowledge of ADRs and their reporting 
were also found to be inadequate. Community pharmacists, however, showed a 
positive attitude towards ADR reporting and felt that they had an important role to play 
in ADR reporting. Notwithstanding, community pharmacists were unenthusiastic 
about reporting ADRs that might be caused by over-the-counter drugs (OTC) (Qassim 
et al., 2014). In a study of the knowledge, attitude and the practice of 
pharmacovigilance among healthcare professionals in a teaching hospital in north 
India, fewer than 40% of healthcare professionals knew how to report ADRs (Bajaj & 
Kumar, 2013). 
A cross-sectional survey of community pharmacists in Riyadh, Saudi Arabia 
discussed the most common hurdles that prevent community pharmacists from 
discussing the use of HS. These included a lack of time due to other obligations 
assigned to the community pharmacist (46%), a lack of reliable resources (30.3%), a 
lack of scientific evidence that supports herbal medicine use (15.2%), and a lack of 
knowledge of herbal medicines (13.4%). The study also pointed out that further steps 
must be taken to increase awareness in pharmacists of adverse drug reaction reporting 
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systems and to improve the curricula and continuous education programs to address 
herbal products and related issues (Al-Arifi, 2013). 
A further survey among pharmacists in Virginia and North Carolina in 1998 
concluded that pharmacists with previous continuing education in herbal medications 
were more knowledgeable of these products (Chang et al., 2007). 
In most developing countries, healthcare professionals and, especially, doctors 
are the principal contributors of adverse event reports (Heinrich, 2003). Usually, a high 
number of doctors have the correct understanding regarding adverse events and know 
what should be reported. Nurses, however, know better about where to report adverse 
events (Rehan et al., 2012). Under-reporting of adverse drug events by prescribers is a 
common problem. The underreporting of ADRs among health professionals is 
attributed to various factors including the knowledge and practice of health 
professionals regarding reporting (Kamtane & Jayawardhani, 2012). 
The under-reporting of ADRs, caused by both prescription and OTC drugs, is 
widespread in both developed and developing countries. The lack of awareness of the 
available pharmacovigilance systems and insufficient knowledge of ADRs are major 
reasons. Studies show that increased knowledge correlates to higher ADR reporting 
(Qassim et al., 2014). Despite health care professionals having the right attitude and 
willingness to report ADRs, it is mostly the lack of knowledge or unawareness that 
results in under-reporting. Healthcare professionals need education and formal training 
in herbal medicines, where to source herbal information and how to evaluate it to 
makeinformed decisions prior to making recommendations and providing patient 
information. Continuing education programs, conferences and seminars would assist 
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healthcare professionals in increasing and updating their knowledge base in herbal 
medicines (Al-Arifi, 2013). 
2.9 Challenges in Adverse Event Data Collection Process and Analysis 
The reporting process of adverse events is based on a voluntary system that helps 
in distinguishing vulnerable groups and generating safety indications. Such a system, 
however, also has major disadvantages like under-reporting and sub-optimal data 
quality which limits efforts to establish an effective adverse event monitoring system 
for HS. Under-reporting may negatively affect signal detection and may result in 
under-estimation of the size of a problem. The quantity along with the relevance of 
case reports and the quality of data are important in signal detection (WHO, 2012). 
The following section briefly discusses the challenges of adverse event data collection. 
2.9.1 Under-reporting of adverse event 
A study was conducted to evaluate how well the FDA’s adverse event reporting 
system for dietary supplements functions as a consumer protection tool. It estimated 
that the FDA receives under 1% of reports of all adverse events associated with dietary 
supplements. The study further suggested that factors that may contribute to under-
reporting are many consumers presume supplements to be safe, use these products 
without the supervision of a healthcare professional, and may be unaware that the FDA 
regulates them (DHHS, 2001). Under-reporting of adverse events may be for the 
following reasons. A lack of consumer awareness of the importance of reporting 
adverse events of HS or even about the unavailability of a reporting system. Even if 
the reporter is aware of the system, a lack of familiarity with the form or a lack of 
clarity about the required information might deter submission. Patients are often 
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reluctant to report the use of alternative treatments to their healthcare providers. Some 
consumers believe HS are inherently safe since they are natural, and consumers 
therefore fail to make a connection between the use of a dietary supplement and its 
adverse events and, as a result, do not report it. Neither is there a clear, common 
understanding of what constitutes an adverse event. For example, for some, only death 
or permanent disability qualify, while others include discomfort leading to absence 
from work or admission to an emergency room for treatment of a symptom such as 
dehydration. Nor is the recording of the history or asking about HS use a routine part 
of medical history in either emergency room or follow-up ambulatory visits (Oria, 
2008). 
Apart from the above-mentioned reasons, the introduction of a dietary 
supplement, media attention, and the level of educational or regulatory activity 
recently presented could be other factors that indirectly affect the report rate. There are 
many psychological and professional issues that contribute to under-reporting. 
Healthcare professionals fear that ADR reporting may reflect negatively on their 
competence or even attract litigation. Even although it is essential that all suspected 
adverse reactions be reported, healthcare professionals are sometimes reluctant to 
report them because of doubts regarding the causal role of the drug (WHO, 2012). 
Under-reporting of ADRs is widespread and a remains a daunting challenge in 
pharmacovigilance (PV). There are patient-related reasons for UR like failure to 
recognise ADR or the inability to link the ADR with a drug. 
2.9.2 Quality of data collected 
The quality of information reported depends on the reporter’s judgment as well 
as familiarity with medical reporting, signs, and symptoms. Forms filled by consumers 
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often include incomplete or inaccurate information about an adverse event. Consumers 
may lack the information to complete the form with the correct medical terms and 
standard codes for data entry of adverse event reporting. The form may not collect data 
about brand name, dose, and other products or medications being taken concomitantly 
(Oria, 2008). 
The 2001 OIG report highlighted the difficulties presented by poor data quality. 
Adverse event report data were categorised as suboptimal, specifically providing 
limited medical information, limited information on products and manufacturers, 
limited information about the consumer, and limited ability to analyse trends. The 
report found that in 1999, the FDA recorded only 400 adverse events from dietary 
supplements through MedWatch 3500A forms. Of those, medical records were 
unavailable in 58% of cases, ingredients could not be determined in 32%, and there 
was no patient follow-up information available for 27% (DHHS, 2001). The user 
guidance recently issued on how to fill in the MedWatch 3500A forms improve this 
situation by helping those reporting adverse events to submit accurate and appropriate 
information. 
These challenges can be overcome by raising the awareness of consumers about 
the adverse events reporting system. An on-line reporting system could reduce errors 
with HS associated adverse events reports. If information about the use of HS and 
adverse events can be collected by healthcare professionals as part of their daily 
practice and they can report this using correct medical terminology to the adverse 
events monitoring system, this would raise the quality of reports to the authority and 
would improve the process of generating signals for the analysis of adverse events 
(Oria, 2008) 
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2.10 Benefits of Having Adverse Drug Reaction Reporting System 
ADRs have a major impact on public health and are an important cause of 
hospital admissions. An ongoing ADR monitoring and reporting program can provide 
benefits to the organization, pharmacists, other healthcare professionals and, more 
importantly, to patients. These benefits include (but are not limited to) the following: 
providing an indirect measure of the quality of pharmaceutical care through 
identification of preventable ADRs and anticipatory surveillance for high-risk drugs 
or patients, complementing organizational risk management activities and efforts to 
minimise liability, assessing the safety of drug therapies, especially recently approved 
drugs, measuring ADR incidence, educating healthcare professionals and patients 
about drug effects and increasing their level of awareness regarding ADRs, providing 
quality-assurance screening findings for use in drug-use evaluation programs, and 
measuring the economic impact of ADR prevention as manifested through reduced 
hospitalisation, optimal and economical drug use, and minimised organizational 
liability (ASHP, 1995). 
The impact assessment proposal for Directive of the European Parliament and 
of the Council for the amendment of pharmacovigilance system clearly states the 
benefits and positive outcomes of having a surveillance or adverse event monitoring 
system. The document states that 30% of the adverse events associated with drugs and 
medical substances may be preventable. They assume that they can reduce the health 
burden by enhancing the European pharmacovigilance system including early 
detection of fatal adverse reactions, fast implementation of EU-wide decisions on the 
safety labelling of medicines, clear warnings like not to prescribe a certain medicine 
to a certain at-risk group of patients, or not to prescribe together two medicines 
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dangerous in combination, to reach 10% of preventable ADRs in an optimistic scenario 
and 1% in a conservative scenario (EUROUPA, 2008). 
Five percent of total hospital admissions are associated with ADRs and about 
5% of hospitalised patients suffer ADR. Another study has highlighted the public 
health importance of ADRs by estimating that ADRs caused over 100,000 hospital 
deaths in the United States in 1994 (EUROUPA, 2008). 
A proactive and robust pharmacovigilance system could reduce mortality and 
morbidity, prevent potential disabilities, and improve access to safe and effective 
medicines for unmet medical needs. The importance of pharmacovigilance/ADR 
monitoring systems in reducing or preventing drug induced human suffering cannot 
be understated. Still, the very purpose might be undermined by under-reporting or poor 
quality of data. The factors contributing to these may vary, but are a potential risk to 
patient safety and may result in an increased financial burden. Through customer 
awareness programs and continuing medical education for healthcare professionals, 
ADR reporting can be made efficient. The establishment of a proactive 
pharmacovigilance system reduces not only the ADR economic burden but also 
considerably reduces mortality and morbidity (EUROUPA, 2008; Pirmohamed et al., 
2004). 
2.11 Summary 
This chapter compiled information regarding the consumption of HS and the 
existing rules and regulations that were exercised in different countries. Various 
surveys mentioned here implicate the existence of misconceptions about the safety of 
HS, among both consumers and healthcare professionals. Many developed countries 
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have various monitoring systems in place to tackle the issue of lack of awareness and 
under-reporting of adverse events. The quality of data collected is of prime importance 
and educating healthcare professionals is an important step in this direction. It might 
be noted that the increasing HS consumption among the Dubai population also 
significantly increases the potential risks that might be related to HS. The role of CPSS 
at Dubai Municipality in promoting the safe use of HS through import regulations and 
field inspections was discussed in this chapter. Apart from the HS import data at CPSS, 
no studies exist, to date, to establish the extent of HS consumption in Dubai and the 
occurrence of adverse events, if any, that might be caused by their use. This warrants 
the need for an extensive study to assess the wide spread use of HS and to educate 
health professionals and consumers about their safe use. The information collected 
could be of high significance and could also justify the creation of an ADR reporting 
system for HS, which in turn could promote the safe use of HS in Dubai. 
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Chapter 3: Methods 
3.1 Introduction 
This chapter describes the methodology and research design used in the study. 
The study aims to evaluate the public health importance of HS product consumption 
related adverse events in the Emirate of Dubai. The study aims to fulfill the following 
objectives: measure both healthcare professionals’ and the Dubai population’s 
knowledge of HS products, the levels of consumption of HS by the Dubai population, 
and the incidence of adverse events in the Dubai population. The study additionally 
aims to identify the level of KAP among Dubai healthcare professionals regarding HS 
products, any related adverse events, and the reporting of such events.  
To find answers to the research questions of the research, the study included the 
following two cross-sectional surveys: a survey of HS products consumption in the 
population of Dubai, and a survey of healthcare professionals to assess knowledge, 
attitude and practice of HS product related adverse events. 
3.2 Study 1: Survey of Health Supplement Use in the Dubai Population 
3.2.1 Study design 
A cross-sectional study design was used to determine the prevalence and 
characteristics of HS product consumption in Dubai and to study HS product adverse 
events among consumers. The sampling units were households. A new survey tool was 
developed based on earlier studies with similar objectives, as shown in Figure 3.1. 
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Figure 3.1: Process of questionnaire development 
 
3.2.2 Study setting 
This population-based survey included both nationals and non-nationals resident 
in all areas of Dubai in 2016. The population of Dubai is approximately 2.1 million 
(DSC, 2014). Dubai Statistic Centre provided the necessary mobile phone numbers for 
all registered residents in Dubai. Data collection took place between 1 May 2016 and 
1 July 2016. 
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3.2.3 Study participants/population 
All residents of Dubai aged 16 and above who were willing to participate were 
included in the study. In addition, participants had to be willing to disclose their height 
and weight so that their body mass index (BMI) could be calculated. This was needed 
to assess HS consumption which is BMI dependent. 
3.2.3.1 Population contact database 
The co-operation with an established and experienced survey institution was 
important in this research process as the survey required skilled expertise resources. 
Dubai Statistical Centre (DSC), a Government of Dubai entity, was selected as the sole 
official source for the collection, analysis and publication of statistical information and 
data in the Emirate of Dubai, UAE. Joint meetings with the DSC team were held to 
clarify the survey objective, questionnaire outline, survey team constitution and 
timeframe (DSC, 2014). 
DSC maintains a regularly updated central database of the contact telephone 
numbers of all Dubai residents with a fixed landline, and individual mobile telephone 
numbers. 
3.2.4 Sampling 
Sampling is one of the most important parts of the survey. A survey is only as 
good as the quality of its sample. The sample design and the implementation were 
carried out with the utmost care to avoid possible mistakes. Both nationals and non-
nationals were included for a more accurate cross-sectional representation of the Dubai 
population and, additionally, to maximise generalizability (UN, 2008). 
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The DSC central database was used in the making of the sampling frame from 
which geographical areas, households and individuals were selected for sampling 
purposes. The sample frame covered Dubai geographically and socio-economically 
(CPSS, 2015) and formed six areas, three in Deira and three in Bur-Dubai. 
Stratified sampling was used. Contacts were randomly selected avoiding any 
duplication that might negatively affect the validity of the result. Pre-survey 
evaluations, tests and pilot surveys were carried out. Sampling procedure was 
monitored and the survey was conducted appropriately. 
For the purposes of statistical gathering and cost efficiency, the DSC population 
database was organized geographically and divided into regions. In total, six regions 
were selected as survey areas for data collection (DM, 2015), three in Deira and three 
in Bur-Dubai. Area One, Deira, included Al-Qusais and Al-Muhaisina where non-
nationals mainly resided. Area Two, Diera, included Mirdif, Al-Mizhar and Al-Warqa 
where mainly nationals resided. Area Three, Diera, included Hor-Al-Ans and Al-
Baraha where both nationals and non-nationals resided. Area Four, Bur-Dubai, 
included Al-Karama and Satwa where non-nationals mainly resided. Area Five, Bur-
Dubai, included Jumeira and Umm-Suqeim where mainly a mixture resided. Area Six, 
Bur-Dubai, included Al-Quoz and International City where mainly non-nationals 
lived. The area selection considered the following factors that might influence the 
survey: the extent and representation of Dubai emirate, Nationals Vs non-nationals in 
residential areas, and socio-economic status (CPSS, 2015). 
The Dubai geographic map constructed by Planning and Survey Departments of 
Dubai Municipality (DM) was used. Dubai households were divided almost equally 
into six geographically defined areas. The agreed sample size determined for this study 
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was 1,200 individuals. The targeted respondents for the survey were Dubai residents, 
randomly selected from contacts in the DSC database. The database contained 
necessary information for this survey including name of the house owner, gender, 
employment status, income range, landline number, house number, several mobile 
numbers of house residents, area number, and number of residents, etc. (DSC, 
2014).The populations of the selected areas were of similar sizes. The sample size per 
area was proportional to the population of the area. Sampling was completely random 
within the population of the areas. In each of the six areas, 200 random households 
were selected using SPSS software, version 20. Each house was registered with mobile 
numbers ranging from one to maximum 20 different numbers. Mobile numbers for 
each house were selected randomly. Respondents aged only 16 years or older were 
included for the purposes of this study. This age detail was not available from the DSC 
database. Upon enquiry with both Etisalat and Du, the only two mobile phone service 
operators in the UAE, mobile numbers were not issued to individuals aged under 21 
years. Four researchers were therefore hired. They were given random mobile numbers 
to call, explain the purpose of the survey and ask about ages. Individuals found to be 
under 16 were subsequently excluded. Another random number from the same house 
was chosen. About 6,200 mobile numbers were contacted during the three-month 
period prior to data collection. It would be helpful in future studies if DSC contained 
this age-related information in their database. 
In each selected household, researchers negotiated with respondents regarding 
their agreement to complete a telephone interview. Interviews were then successfully 
concluded. Where contact was not made and interviews were not successfully 
concluded, researchers would call the same number a maximum of three times over 
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three consecutive days. In the event of failure to contact, another random sample from 
the same house was selected. 
3.2.5 Sample size 
As the prevalence of HS product consumption may range from 10% to 30% 
according to Kemper et al. (2006) and around 19% according to Hara et al. (2011), it 
was estimated that there may be approximately a 30% prevalence of HS product 
consumption among both nationals and non-nationals in Dubai.. The required sample 
size was calculated as alpha=0.05, the desired precision of the confidence interval set 
to 5%, the population size of nationals and non-nationals in Dubai was 200,000 and 
1,900,000, respectively, and the non-response rate to such surveys was estimated to be 
12% from previous similar surveys (DSC, 2014). 
The sample size was calculated using computer software called OpenEpi. 
Sample size and power were selected. The size of population was entered as 2,100,000. 
The expected frequency was entered as an estimate of the true prevalence (30% 
according to Kemper et al., 2006). The margin of error was set to no more than 3%. 
The sample size was equal to 1,067 with 95% confidence level. A 12% increase in the 
sample size was calculated to overcome the non-response rate expected from previous 
studies in which the total sample size was 1,200. 
3.2.6 Survey tool 
The survey tool used for this study was a questionnaire. The following describes 
the process of the survey tool development including the literature/expert review, 
producing ane-form, reviewing, pilot testing and changes, and the translation of the 
final questionnaire. This section also presents the questionnaire administration 
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including the recruitment and training of researchers, the process of the interview, and 
the ensuring and checking of data quality. 
3.2.6.1 Questionnaire development 
The process of questionnaire development included some critical stages as 
illustrated in Figure 3.1. 
Literature/expert review: A primary draft version of the questionnaire was 
developed as a Microsoft Word document based on previous research and input from 
professionals and experts in the field of HS products. The draft questionnaire was 
reviewed by PhD Research Committee Members at United Arab Emirates University. 
Producing e-form questionnaire: Upon successful review by the UAEU, the 
draft questionnaire was submitted to the DSC for digital transfer into an electronic 
version allowing CAPI researchers to conduct telephonic surveys. DSC was a survey 
partner in this research. The questionnaire was completed by DSC on 17 June 2015. 
E-form questionnaire review: The e-form questionnaire was reviewed by a 
panel of information technology specialists at DSC. Thirty HS specialists from the 
Consumer Products Safety Section of DM worked with researchers. They checked 
accessibility, order of questions, and spelling. 
Changes in the questionnaire: Upon receiving feedback from information 
technology specialists, Consumer Products Safety Section HS specialists, and the 
researchers regardingchanges to the questionnaire, the DSC was asked to modify the 
numbering of the questions and pages, to replace the field name, Sex, by Gender, 
replace the term Surveillance by Reporting, add a progress bar at the top of the survey 
page, show notification if a mandatory question was not answered, change the 
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formatting, order and context of some questions and answers, and link some questions 
to each other, and end the questionnaire at certain answers. 
Pilot testing: After discussion, the DSC made the required amendments and 
CAPI was ready to use by 23 July 2015. The pilot study was started on 27 July 2015 
aiming to achieve 120 responses. By the 4 August 2015, 74 responses had been 
received from non-nationals and 60 responses from nationals. This pilot study did not 
identify any further problems or technical issues with the questionnaire. 
Translation: In Dubai, the local language of communication is Arabic, and non-
nationals mainly speak English. The questionnaire was therefore produced in both 
Arabic and English. Translation was carried out to the highest level by the Arab-
speaking researcher involved in the survey. The translated questionnaire was proof-
checked by language experts at Dubai Municipality. The translated questionnaire was 
corrected with required changes after proof reading, tests and pilot surveys (UN, 
2008). 
Questionnaire approval: The final version of the questionnaire was approved 
and made available for data collection. The questionnaire was subsequently approved 
by the Social Sciences Research Ethics Committee at UAE University, an authorised 
agent able to issue approval to students/researchers wishing to conduct social science 
related research in the UAE. 
3.2.6.2 Questionnaire administration 
The questionnaire administration process included certain stages such as 
recruitment and training of researchers, process of the interview, instructions to 
researchers, and ensuring and checking the data quality. 
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Recruitment and training of researchers: To ensure the quality of the survey, 
two teams of researchers/interviewers were hired at DSC for the telephonic survey. 
One team was Arabic speaking experts and assigned to do the survey for nationals who 
mainly speak Arabic. The second team was multi-lingual experts who speak both 
Arabic and English. They were assigned to do the survey for non-nationals. This 
arrangement increased the quality of communication and helped in clarifying such 
things as medical terms mentioned in the survey. 
One key element of the survey was training. The training process started before 
the survey and continued during the entire data collection process. During selection of 
the interviewers, the qualification of a Bachelor degree was listed as a requirement. 
Training sessions for the interviewers were conducted for supervisors and the 
coordinators at the DSC to make sure that everyone associated with the survey were 
clear about their role and the aim of the survey. Training methods included role-play 
in interviews with various scripts. The training process motivated the interviewers and 
their practical suggestions were accepted. This training improved the overall quality 
of the data collection (UN, 2005). 
Process of the interview: Survey implementation requires great attention to 
obtain quality data. The entire survey process was monitored in real time by the writer 
and problems were addressed as they arose. The supervisor/interviewer ratio was 1:5. 
Input from the telephonic survey were entered on the specially created Microsoft Excel 
file during the survey itself (UN, 2005). 
A principal concern was how to increase the response rate. It was assumed that 
unemployed respondents may be more available between 11 AM and 1 PM, and for 
employed respondents, it was assumed that they may be more available between 3 PM 
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and 6 PM. This method of approach was successful and increased the response rate in 
the survey. 
Ensuring and checking data quality: The quality of the survey is vital and 
ensures accuracy, reliability and validity of the results. To ensure quality, World 
Health Organization (WHO) guidelines were followed using World Health Survey 
(WHS) (UN, 2005). To achieve the maximum quality, the following principles were 
adopted: quality standards which need to be adhered to each step of survey, quality 
assurance procedures ongoing throughout the survey from preparation and sampling 
through to data collection and data analysis and on to report writing, and evaluation of 
the quality assurance procedures (UN, 2005). 
In the survey procedure, great attention was paid to quality in every respect. 
Random participants, for example, were re-surveyed to check the quality and veracity 
of their original answers. Of the 1,200 residents surveyed, 40 were re-surveyed. 
The survey was conducted through CAPI and designed such that, if data were 
missing, interviewers would be alerted, allowing the survey to be completed correctly 
and with confidence. 
The research outcome is entirely based on data from the survey. To ensure the 
quality of data collected, it was important to obtain accurate data timely. After 
sampling and before starting the survey, call sheets were provided for each telephone 
number. The interviewer could make notes related to the survey. These notes might 
play a vital role in the quality of survey itself. In the event, call sheets did indeed play 
an important role in the data collection by: recording the status of each telephone 
number participating in the survey, providing helpful information to the next 
interviewer like convenient time to call back, seeking attention for feedback and 
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supervision if needed, and marking the number of attempts with time and response, 
and recording the outcome of each telephone number enquiry (including completed 
interviews, refusals etc.) (UN, 2005). 
This call sheet worked as a cover page to the questionnaire for each telephone 
number used in the survey. Upon completion of the questionnaire, data were directly 
input into the computer using user-friendly software, Epidata. To minimize errors in 
transferring data, a special data entry team was created from the interviewer team, 
supervised by one of the supervisors from the survey team. 
3.2.7 The questionnaire 
The following sections present a summary of the survey tool, its various sections, 
variables, questions, related scales and coding. 
3.2.7.1 Questionnaire sections: summary 
A questionnaire (Appendix A) composed of six sections was used to measure 
HS product consumption and other required variables in the study population. The 
section, as shown in Table 3.1, asked about demographic information including age, 
gender, marital status, nationality, occupation, health insurance coverage, income, 
education, weight and height. All data were nominal except age, height, and weight 
which were interval. Additionally, income was presented as an ordinal scale. Height 
and weight were used to present the Body Mass Index (BMI). All data were used to 
measure the demographic characteristic. 
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Table 3.1: Population demographic data, scales & variables 
Question Scale Variables measured 
Age Interval 
Demographic - characteristics 
Gender Nominal 
Marital status Nominal 
Nationality Nominal 
Occupation Nominal 
Health insurance coverage Nominal 
Income Ordinal 
Education Nominal 
Weight (kg) Interval 
Height (cm) Interval 
 
The section on health and lifestyle, as shown in Table 3.2, assessed the general 
health status of the responder including allergies, clinic visits during the previous year, 
chronic diseases, consumption of drugs and smoking habit. All data were nominal 
except for clinic visits and smoking habit which were presented as ordinal scale. All 
data were used to measure health and lifestyle. 
Table 3.2: Population health and lifestyle, scales & variables 
Question Scale 
Variables 
measured 
Having any allergy Nominal 
Health and 
life style 
Specifying the type of allergy Nominal 
Frequency of visiting a doctor in the past 12 months Ordinal 
Whether been diagnosed with chronic medical 
condition 
Nominal 
Whether taken prescription drugs in the past month Nominal 
Smoking status Ordinal 
 
62 
 
The section, as shown in Table 3.3, focused on HS consumption and comprised 
questions covering the following points: knowledge of HS, HS consumption including 
duration, frequency, number and amount, discontinuation of HS consumption, 
categories, forms and names of HS consumed, ingredients of HS consumed, reason for 
consuming HS and location of purchasing HS. All data were categorical except for 
duration of using HS which was presented as ordinal scale. All data were used to 
measure the HS use except the question - Do you know what HS are?- which was used 
to measure consumer knowledge regarding HS. 
In the section Information about HS Products, as shown in Table 3.4, questions 
covered the following points: the identity of the person, if any, who recommended HS 
to the responder, the frequencies of prescribing HS by healthcare professional, HS 
information source, opinion about information on label including product information 
and nutritional facts, label information of concern to the responder and, finally, the 
level of compliance with label recommendations. All data were nominal except for 
frequency of HS prescribed for the consumer by healthcare practitioner, which was 
presented as ordinal scale. All data were used to measure consumer knowledge 
variable on HS. 
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Table 3.3: Health supplement consumption, scales & variables 
Question Scale Variables measured 
Knowing what HS are Nominal 
Consumer 
knowledge on HS 
Reasons for taking HS Nominal 
Consumption 
characteristics 
Reasons for discontinuing HS Nominal 
Ever using HS Nominal 
Duration of using HS Ordinal 
Frequency of using HS Nominal 
Which HS categories been using Nominal 
Which HS forms been used  Nominal 
Which HS ingredient been using Nominal 
Where purchasing HS Nominal 
How many HS products been using Ordinal 
Enter the full name of HS including brand 
name 
Nominal 
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Table 3.4: Information about health supplement, scales & variables 
Question Scale Variables 
measured 
Who advised you to take HS Nominal 
Consumer 
knowledge on 
HS 
Times HS prescribed by healthcare practitioner Ordinal 
Where seeking HS product information Nominal 
Whether finding sufficient information on HS 
label 
Nominal 
Whether nutrition information on HS useful Nominal 
Which label information concerns you Nominal 
Whether following recommended label 
information 
Nominal 
 
The section Adverse Events Related to Health Supplement Consumption, as 
shown in Table 3.5, asked whether the responder had experienced any adverse event 
related to HS use. If the respondent answered yes, further questions enquired about the 
nature, severity, frequency and onset time of the adverse events reported. There are 
also questions about the exact relation between the adverse event and the HS 
consumed, and what HS product is confirmed or suspected to have caused the adverse 
event. Finally, in this section, the responder is asked about the resolution of the adverse 
event and any period of hospitalisation that was necessary. All data were nominal 
except for severity of the adverse events, frequency of encountering adverse events, 
and onset time of adverse events which were presented as ordinal scale. All data were 
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used to measure the variable of level of experiencing an adverse event, potential 
deleterious effects on human health in the Dubai population, except for healthcare 
practitioner investigation on HS consumption at any visiting time, and the resolution 
of the adverse event. 
The section Reporting Adverse Events, as shown in Table 3.6, asked whether 
the responder had reported an adverse event related to HS and, if so, how this was 
done. A final question asked for the responder’s opinion about establishing a reporting 
system for any adverse event related to HS. 
All data were nominal except for practice of population on establishment of a 
reporting system of adverse events related to HS consumption, which was presented 
as ordinal scale. All data were used to measure the reporting of suspected HS-related 
adverse events, except for establishment of a reporting system of adverse events 
related to HS consumption, which was used to measure the consumer knowledge on 
HS variable. 
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Table 3.5: Adverse event related to health supplement use, scales & variables 
Question Scale Variables measured 
Whether experiencing any AE related to HS 
use 
Nominal 
Potential deleterious 
effects of HS on 
human health 
Which AE of HS use been ever experienced 
Nominal 
Severity of the AE Ordinal 
Frequency of encountering AE due to HS use 
Ordinal 
Onset time of AE after consuming HS Ordinal 
How was the relation between HS 
consumption and the AE confirmed 
Nominal 
Which of the HS you have used was 
suspected/confirmed to cause the AE 
Nominal 
When visiting your healthcare practitioner 
for any reason, whether asked you about 
your HS consumption 
Nominal 
Reporting of 
suspected HS-related 
AE 
How did the AE resolve Nominal 
 
Table 3.6: Reporting adverse event, scales & variables 
Question Scale Variables measured 
Have you ever informed your physician 
about your HS use 
Nominal 
Reporting of 
suspected HS-related 
AE 
Have you ever reported an AE related to HS 
use 
Nominal 
Where did you report the AE Nominal 
What do you think about the establishment of 
a reporting system of AE related to HS use Ordinal 
Consumer knowledge 
on HS 
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3.2.7.2 Variables 
The dependent variables within the population-based survey include 
consumption rate, consumer knowledge of HS, the level of experiencing adverse event, 
and the potential deleterious effects on human health in the Dubai population. The 
independent variables or correlates include: age, gender, marital status, nationality, 
occupation, health insurance, income, education level, and BMI. 
For the three dependent variables, knowledge of HS was defined as an 
affirmative answer to Q2 - Do you know what HS are? HS use was defined as an 
affirmative answer to Q23 - Have you ever used HS? and ever having had an HS 
adverse event was defined as an affirmative answer to Q41 - Have you ever 
experienced an adverse event from HS? 
3.2.8 Data management 
Data were managed through SPSS version 20. All data were coded in such a way 
as to interpret the variables. 
3.2.8.1 Re-coding and interpretation of the variables 
Some of the variables were re-coded during the analysis. For instance, the 
nationality category was re-coded as Emirati, Middle East/ North Africa, South Asia, 
East Asia/ Pacific, Central Asia/ Europe, Africa, Western Europe/ North America/ 
Australia, and Latin America/ Caribbean. Also, the HS ingredients categories were 
merged together and re-coded within four different main categories. Moreover, the 
forms of HS categories of drinks, liquids, caplets, granules, lozenges, and gels were 
merged and re-coded into one category. Finally, the HS current and past consumption 
categories were merged into a re-coded ever used category. 
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Question 29, - HS ingredient have you used? - had a large answer list of 60 
different ingredient names. This was re-coded in terms of risk assessment module 
classification into four main categories of low, medium, high, and extreme ingredients’ 
overall risk estimation. 
The risk assessment process for the presence of some ingredients in HS products 
began with hazard identification, the hazards being the ingredients in the supplement 
products, as shown in appendix B. Some ingredients can induce certain risks to human 
health under certain conditions or at certain doses. 
The hazard characterisation based on associated risks in response to 
dose/response relationship and the probability of adverse outcomes include short-term 
toxicity from reported side effects, long-term toxicity from evidence-based published 
sources, interactions of food and/or drugs, contamination with toxicants such as heavy 
metals, and pesticide residue. The risk characterisation within the risk assessment 
module was calculated as the multiple of the likelihood and severity of the adverse 
events related to the ingredient. To calculate the risk score, a risk matrix was adopted. 
The risk matrix had four ranges for severity, as shown in appendix C. 
The risk score range was low, medium, high and extreme. As many of the 
ingredients had several risk factors, either in the impact field or in the probability field, 
the risk scoring method field was used as a calculation to obtain an overall impact 
value. This value was then used along with the probability to determine the score used 
to evaluate project risk. The overall impact value was calculated using average impact. 
The overall impact was determined by calculating the average of all impact values. 
As per above mentioned method, the associated risk(s) with the ingredient in 
terms of short-term toxicity, long-term toxicity, interactions of food/drugs, 
69 
 
contamination with heavy metals, and pesticide residue are shown in appendix D for 
each individual ingredient. 
Table 3.7 presents a summary of all the above-mentioned ingredients as 
classified, according to the induced risk, into low, medium, high and extreme risks in 
which Glandular extract (Hadayer & Schaal, 2016; Gangwar et al., 2015; CPSS, 2015), 
yohimbe (NIH, 2016; CPSS, 2015; Wongkrajang et al., 2014) was considered as a 
potential for extreme risk. 
Table 3.7: Ingredients overall risk estimation 
Level of 
risk 
Ingredient(s) 
Low Bilberry, Methylsulfonyl Methane, Garlic, Oxymatrine, Creatine, 
Folic Acid, Vitamin B6, Potassium, Vitamin B12, Vitamin E, Zinc, 
Grape Seed Extract, Siberian Ginseng, Lecithin, L-Carnitine, 
Morinda Citrifolia, Lycopene 
Medium Alfalfa, Saw Palmetto, Tryptophan, Amino Acids, Iron, Spirulina, 
Calcium, Magnesium, Vitamin C, Caffeine, Echinacea, Chondroitin, 
Vitamin D, Glucosamine, Cayenne Pepper, Vitamins A & D, 
Cimicifuga Racemosa, Parsley, Pygeum Africanum, Ginkgo Biloba, 
Panax Ginseng, L-Cysteine, L-Methionine, Lysine, Chromium, 
Lutein, Royal Jelly, Bee Pollen, Guarana, Kelp, Fructus Cynosbati, 
Ginger, Liquorice, Melatonin 
High Gentian, Ephedra, Selenium, Conjugated Linolenic Acid, St. John’s 
Wort, Damiana Folia, Fish Oils 
Extreme Glandular Extract, Yohimbe 
 
70 
 
3.2.9 Statistical analysis 
Data were exported from the computer application as a Microsoft Excel 2010© 
spreadsheet and analyses were conducted using STATA version 14.2. Data were 
cleaned prior to analysis. Data were nominal, interval (for age, height, weight, and 
BMI) or ordinal. Answers to the following questions were ordinal data: Q11 Income, 
Q17 Frequency of visiting a doctor, Q20 Smoking, Q25 Duration of HS use, Q35 
Frequency of HS been prescribed by practitioner, Q43 Severity of adverse events, Q44 
Frequency of encountering adverse events, Q45 Onset time of adverse events, Q54 
Practice of establishing a reporting system. Descriptive statistics were used to describe 
the demographic characteristics of the sample using frequencies (percentages) or 
means (standard deviation) as appropriate. If differences were found between sub-
groups of the sample (age, gender, educational status, nationality, etc.), these 
differences were tested for statistical significance using chi-square test for categorical 
variables and ANOVA for continuous variables. The distribution of the characteristics 
of the study population for each of the outcome variables was tabulated. Again, for 
characteristics that are categorical variables, frequencies and percentages are shown, 
and for characteristics that are continuous variables, means are shown. Chi-square test 
or ANOVA was used as appropriate to test for statistical differences. Simple logistic 
regression analysis was performed to assess the association between HS use (outcome 
variable) and selected correlates (independent variables). The variables having p value 
<0.10 were included in a stepwise logistic regression model to identify the independent 
factors associated with HS use. The confidence interval of 95% and p value <0.05 were 
used to determine statistical significance. 
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3.2.10 Data limitations 
Bias is the expected difference between an estimated characteristic of a 
population and that population’s true characteristic. Bias may occur in any step of the 
research. In this research, care was taken to minimise the risk of bias as much as 
possible. 
Information bias: To collect accurate data from the respondents, researchers 
must be able to understand and identify possible errors in the design of the 
questionnaire as a research tool. Any errors in the questionnaire design may be 
considered as information bias and researchers should be able to prevent or minimise 
this kind of bias. 
In the current survey, attention was paid to or even ting any errors arising during 
the questionnaire preparation stage. Possible biases in the questionnaire were 
identified like complex questions, double-barrelled questions, and short questions 
which might not be accurately answered in the population-based survey and an 
upcoming healthcare professional survey. The questionnaire was limited to the scope 
of the research questions. In the e-mail survey, respondents tended to choose the first 
few options from the list (primary bias) and in the telephonic survey, respondents were 
more likely to answer the later options (recency bias). To minimise this bias, the 
number of options was reduced and the order of options randomized. 
In the population-based survey, the questionnaire was designed in such a way as 
to afford the interviewer an easy means of conducting it while offering respondents an 
easy means of responding to questions. The use of technical and complicated clinical 
terms was kept to a minimum for ease of understanding. 
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To minimise bias, the questionnaire was evaluated by HS experts at Dubai 
Municipality. The questionnaire underwent pre-testing and was modified accordingly. 
In the population-based survey, stratified sampling was used to minimise the 
bias associated with sampling. One of the challenging areas in bias was the use of 
landline phone numbers or mobile phone numbers to conduct the survey. Mobile 
phones alone were selected for the survey. Many peoplecarry their mobile phones with 
them for long periods of time daily, and a mobile number may be used as an individual 
identifier. This minimised the bias associated with a landline phone survey where 
several people in the same household might use the same number with a resultant 
difficulty arising in identifying specific individuals. 
Interviewer bias: Interviewer bias was considered a concern in telephonic 
surveys. During the survey, an interviewer might communicate with the respondent in 
such a way as to obtain a tailored answer. This might lead to unreliable results. 
Interviewers should have enough knowledge of the questionnaire to be able to 
communicate with respondents clearly and succinctly to obtain a truthful and accurate 
answer. 
In the telephonic survey for this research, there was a possibility of serious 
interviewer bias. As interviewers read the questions to the respondent, answer choices 
were offered. In one question, a large list of answer options was offered. The list was 
so long that interviewers compromised the question and answer by failing to make all 
options clear. This was spotted and rectified during the pilot survey. All interviewers 
were further trained in scientific terminologies included within the survey. This 
training program improved surveyor skills and minimized the incidence of errors. 
Interviewers were selected from employees of DSC. They underwent a smart training 
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program to improve their knowledge of the questionnaire and to enhance their survey 
skills. 
Non-response bias: Non-response bias is the error which may occur due to non-
response of contacted individuals. If steps are not taken to prevent non-response bias, 
the result of the survey may be biased in a way that the opinion of the respondents does 
not reflect the actual opinion of the source population. 
In the population-based survey, care was taken to minimize non-response bias. 
As discussed in the sampling section, six areas were randomly chosen for sampling. 
Where there was no response from the respondent, attempts to contact were made over 
the three following days. Where respondents were unwilling to participate or non-
responsive, another random sample was chosen to continue the survey. 
To reduce the non-response rate, it was assumed that unemployed people, as 
shown in DSC directory based on employment status, might be more availablefrom 11 
AM to 1 PM, and, similarly, employed people might also be more available from 3 
PM to 6 PM. Contact was therefore arranged accordingly for the telephonic survey. 
3.2.11 Ethical approval and safeguarding participants 
The consent and information details were given to respondents prior to starting 
the survey. 
3.2.11.1 Informed consent 
Informed consent, for the purposes of this study, included a participant computer 
generated dedicated identification number. Informed consent also included the title of 
the project and the main researcher’s name. It also explained that the study would take 
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place at the United Arab Emirates University, College of Medicine & Health Sciences, 
School of Public Health, Al-Ain, UAE, and that participation in the study would take 
up to 30 minutes: five minutes for set-up/explanation, around 20 minutes for the 
questionnaire itself, and five minutes for a discussion with the researcher afterwards. 
In addition, it included the following: an easily understood information sheet dated 5th 
March 2015 and designed in such a manner as to allow participants to ask questions 
of the interviewer, an explanation that participation in the survey was voluntary and 
that participants were free to withdraw at any stage, confirmation that information and 
opinions provided during the survey would be kept strictly confidential and used only 
for research purposes, confirmation that names and details would not be linked to this 
survey and would not be identified in any report/publication, and consent to agree to 
take part in the study. 
This information was provided to the participant verbally, by phone. Participant 
decision to continue with the survey was deemed consent. 
3.2.11.2 Information for participants 
The nature and purpose of the survey, as shown in appendix E, were fully 
explained to participants verbally, by phone. Prospective respondents were cordially 
invited to take part in the research study. The purpose of the study was 
comprehensively explained to them. Prospective respondents were given ample time 
to consider the invitation. A confidentiality code was assigned to each prospective 
respondent. 
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3.2.11.3 Ethics review 
A Research Ethics Review Form, available at UAE University website, was 
completed and submitted to Al Ain Medical District Social Sciences Research Ethics 
Committee at UAE University. Approval to conduct the study was received in June 
2015. 
3.3 Second study: Knowledge, Attitude and Practice of Health Supplements 
Related Adverse Event Among Healthcare Professionals 
3.3.1 Study design 
A cross-sectional study design was also used in the second study to assess 
knowledge, attitude and practice (KAP) regarding HS products among healthcare 
professionals including physicians, pharmacists in hospitals and clinics, both public 
and private, and community pharmacies. To be included in the study, healthcare 
professionals had to be employed as such for at least three months. A questionnaire 
was devised for this survey using the same principles adopted in the questionnaire for 
the population-based study, as shown in Figure 3.1. 
3.3.2 Study setting 
The survey was carried out in public or private hospitals and pharmacies in 
Dubai. 
3.3.3 Study participants/population 
The study population comprised all physicians in all specialties and all 
pharmacists and assistant pharmacists registered with DHA, with a minimum of three 
months’ experience and who worked in public orprivate hospitals, clinics or healthcare 
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centres. The inclusion criteria included individuals who were employed in DHA or 
any other governmental or private health sector who had registration with DHA. 
Individuals who worked in other free zone health sectors and not registered with DHA 
were excluded from the study. Additionally, any individual on work probation was 
excluded. 
3.3.4 Sampling 
DHA provided the e-mail contact details for all registered physicians and 
pharmacists working at DHA. Data were collected during the period 2 May 2016 to 23 
November 2016. Dubai Municipality additionally provided e-mail contact details for 
all private pharmacies in Dubai (CPSS, 2015) as well as e-mail contact details for 
managers at private hospitals and clinics in Dubai. Data for these sectors were 
collected from 3 May 2016 to 23 November 2016.  
3.3.5 Sample size 
The latest published numbers of physicians working in public hospitals and 
clinics in Dubai was 1,096 (DSC, 2012) and the latest published numbers of physicians 
working inprivate hospitals and clinics in Dubai was 1,288 (DSC, 2012). The number 
of registered pharmacists in Dubai was 3,155 (DHA, 2014) yielding a total of N= 
5,539. All physicians and pharmacists registered with DHA were contacted for this 
survey. To calculate a sample size for this survey, a pilot study was used. A 
questionnaire was sent to 85 physicians and pharmacists and 83 replied, producing a 
response rate of 97%. The questions on which the sample size calculation was based 
were: 
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1. Do you know about adverse events of HS? 
2. Do you sell/prescribe/dispense any HS at practice site? 
3. Do you think it is important to report all adverse events of HS products? 
The knowledge of physicians regarding HS products was recorded as 15% 
according to Clement et al. (2005) and 70% according to Kemper et al. (2006). 
According to the Dubai pilot study, the levels of knowledge, attitude, and practice 
(KAP) for healthcare providers towards HS products were 78%, 78%, and 74%. The 
alpha=0.05 and, as per the results of the pilot study, the level of KAP was estimated 
as 50%. It was expected that the proportions of respondents answering yes to the above 
questions 1, 2 and 3 would be around 50%, 50% and 50%. The alpha level is set to 5% 
and has a 95% confidence interval. The precision (D) of the 95% CI is fixed at 5% so 
that the width of the 95% CI will be at maximum 10%. According to the assumptions 
and with 5,000 physicians and pharmacists registered with DHA, a sample size of 
n=385 was needed to guarantee the desired precision, assuming a non-response rate of 
around 3%. 
3.3.6 Survey tool 
In terms of questionnaire development, this survey underwent a similar process 
as the previous survey. It included the phases of literature/expert review, producing e-
form questionnaire, e-form questionnaire review, and changes in the questionnaire. 
Upon receipt of feedback and comments, DSC made the necessary amendments and 
activated the survey link on 23 July 2015. The translation process was similar to that 
used in the first survey. 
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3.3.6.1 Pilot testing 
This pilot study was started on 27 July 2015 in two private hospitals. This was 
because of a delay in receiving approval to conduct the survey in public healthcare 
settings. By 4 August 2015, 83 respondents had completed the questionnaire 
satisfactorily and no problems had been reported. The results of this pilot study were 
used to calculate the required sample size for the second survey. 
3.3.6.2 Questionnaire administration 
This survey was designed to be self-completed by respondents through a web-
based electronic link sent to respondents’e-mails addresses. 
Ensuring and checking data quality: In this e-mail-based survey, the 
questionnaire was designed to be particularly user-friendly and easily understood. The 
format was compatible for computer, tablet and mobile phone use. 
3.3.7 The questionnaire 
The following sections present a summary of the survey tool, its different 
sections, variables, questions, related scales and coding. 
3.3.7.1 Questionnaire sections: summary 
A questionnaire composed of four sections was developed to assess healthcare 
professionals’ KAP of HS products, related adverse events and other required 
variables. This survey was performed electronically by an on-line link sent by e-mail. 
The first section, as shown in Table 3.8, asked about demographic information 
(age, gender, marital status, nationality, employment status, title, years of job 
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experience, insurance coverage and education). All data were nominal except for age, 
which was interval. Work experience was presented as ordinal scale. All data were 
used to measure demographic characteristics. 
In the second section, as shown in Table 3.9, a set of questions was developed 
to measure the level of knowledge of HS products and adverse events. Questions 
highlighted the following aspects: HS product general information and whether they 
were harmless or not, whether reporting systems existed, whether there were reporting 
systems in their workplace, whether respondents knew to whom to report an adverse 
event, and information on continuous education (articles, training, etc.) related to 
adverse events of HS products. All data in this section were nominal. The data 
collected in this section were used to measure the knowledge variable. 
Table 3.8: Healthcare professionals’ demographic data, scales & variables 
Question Scale Variables measured 
Age Interval 
Demographic - characteristics 
Gender Nominal 
Marital status Nominal 
Nationality Nominal 
Employment status Nominal 
Title Nominal 
Work experience Ordinal 
Insurance coverage Nominal 
Education Nominal 
 
The third section, Practice, as shown in Table 3.10, included the following: types 
and forms of HS prescribed and/or dispensed, a system to record HS use, discussing 
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HS use with patients/customers and information sources for these discussions, adverse 
events encountered in relation to HS consumption, their types and how they are dealt 
with. All data were nominal except for frequent HS discussion with patients, frequent 
encountering HS related adverse events and frequent recording HS adverse events, 
which were presented as ordinal scale. The data collected in this section were used to 
measure the practice variable. 
Table 3.9: Healthcare professionals’ knowledge scales & variables 
Question Scale Variables 
measured 
Do you know what HS are? Nominal 
Knowledge 
 
List as many HS as you can. Nominal 
Do you agree with the statement that HS are 
harmless? 
Nominal 
Do you know about adverse events of HS? Nominal 
List as many adverse events of HS as you can. Nominal 
Do you know what surveillance system is? Nominal 
Do you know about any existing surveillance 
system in the UAE? 
Nominal 
Do you know about any adverse event reporting 
system in your organization? 
Nominal 
Do you know to whom you can report adverse 
event? 
Nominal 
Have you received continuing education on HS? Nominal 
Have you read a scientific article related to 
adverse events of HS in the last 6 months? 
Nominal 
Have you ever received training on reporting 
adverse event? 
Nominal 
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Table 3.10: Healthcare professionals’ practice scales & variables 
  Question Scale Variables 
measured 
Do you sell/prescribe/dispense any HS at practice site? Nominal 
Practice 
Which type of HS do you usually prescribe/ dispense? Nominal 
Which form of HS do you usually prescribe/ dispense? Nominal 
Do you have a system to record HS use? Nominal 
How often discussing HS use with patients? Ordinal 
Topic of discussion about HS use with patients? Nominal 
Which of HS information sources are helpful for patients? Nominal 
Barriers limiting discussing HS with patients? Nominal 
Ever experienced HS related AE in patients? Nominal 
How frequently encountered AE related to HS use? Ordinal 
What was the AE? Nominal 
How often have you recorded HS AE? Ordinal 
Which authority/personnel you report HS AE? Nominal 
Is AE reporting form available when you are at the job of 
prescribing/dispensing medicines to the patients? 
Nominal 
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In the last section, Attitude, as shown in Table 3.11, questions relate to the 
reporting of adverse events related to HS. These included reasons for not reporting an 
adverse event and the importance of reporting such events. For some questions, 
participants selected their answers from a five-point ordered scale. All data were 
ordinal except for reason of reporting/not reporting adverse events and the importance 
of reporting, which were nominal. Data collected in this section were used to measure 
the attitude variable. 
Table 3.11: Healthcare professionals’ attitude scales & variables 
Question Scale Variables 
measured 
You report HS related adverse events to the higher 
authority/personnel. 
Ordinal 
Attitude 
What is the reason if you don’t/wouldn’t report an 
adverse event? 
Nominal 
Do you think it is important to report all adverse events 
of HS? 
Nominal 
What do you think about the establishment of a 
surveillance system of adverse events related to HS 
consumption? 
Ordinal 
Are you concerned about legal problems of reporting 
an adverse event? 
Ordinal 
Do /would you feel confident when reporting an 
adverse event? 
Ordinal 
83 
 
3.3.7.2 Variables 
In this survey, the dependent variables were: healthcare professionals’ 
knowledge of HS adverse events, attitude to HS adverse events, practice related to HS 
adverse events, and reporting level of adverse events. The independent variables or 
correlates included: age, gender, marital status, nationality, employment status, job 
category, work experience, insurance coverage, and educational level. 
3.3.8 Statistical analysis 
In this study two approaches (descriptive and analytical) were used for data 
analysis. 
Descriptive approach: first of all, the frequencies and percentages for all 
questions (variables) in the study questionnaire were determined. We reported the 
percentage of each demographic characteristics, the frequency and the percentage of 
each question related to healthcare professional’s knowledge of HS and the frequency 
and the percentage of each question related to HS adverse events reported by 
respondents. We also reported the frequency and the percentage of each question 
related to healthcare professionals’ practice with respect to selling, prescribing or 
dispensing HS, and types of HS and dosage, record keeping and discussions with 
patients/consumers. The frequency and the percentage of each question related to 
respondents’ experience of HS adverse events was reported. The second part in 
statistical analysis plan illustrates the assessment of the knowledge, attitude and 
practice (KAP) of healthcare providers towards HS. In this regard two measures were 
calculated: The overall knowledge, attitude and practice score: (knowledge, attitude 
and practice (KAP) score toward HS related adverse event were assessed by 10-item 
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questions. A scoring mechanism was used to understand overall KAP level. Each 
correct answer was given one score, and the range of the score varied between 0 (with 
no correct answer) to 10 (for all correct answers). Respondents with all correct 
response get a maximum of 10 points; higher points indicate good knowledge. Based 
on total score, a score of 70% and above was judged to be good, 50%-69% fair and 
<50% poor.  
Analytical approach: this part of statistical analysis was designed to determine 
the differences in participants’ responses in term of demographic. Before running the 
comparisons, the normality of our dependent variable (KAP score) among the groups 
of independent variables were tested by visual inspection of their histogram, Q-Q plot 
and box plot. The results showed that the data were approximately normally 
distributed. In total three tests were used to find the associations between KAP scores 
and selected socio-demographic factors (independent t-test, ANOVA and Pearson 
correlation).  
The independent t-test used when we have one continuous (scale) dependent 
variable (mean KAP score) and one categorical independent variable with two level 
(gender, nationality, marital status, employment status, work experience and 
education). The one way ANOVA used when we have one continuous (scale) 
dependent variable (mean KAP score) and one categorical independent variable with 
more than two level (occupation). Pearson correlation used when we have one 
independent variable (mean KAP score) and one independent variable (age). Here both 
variables are continuous variable.  
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3.3.9 Data limitations 
In the healthcare professional survey, sampling was done from the total number 
of pharmacists and physicians registered with Dubai Health Authority (DHA), the 
local health governing body in Dubai. All pharmacists and physicians working at DHA 
received an e-mail with a link to a web-based questionnaire from the Head of the 
Human Resources Department at DHA inviting them to participate in the survey. 
Pharmacists and physicians working in the private sector in Dubai received the 
questionnaire link from their management identified through Dubai Municipality 
database details of private healthcare providers. This minimised the selection bias 
related to low response in the healthcare professional survey. There was no incidence 
of interviewer bias as the survey was completed directly by the respondent without the 
supervision or help of an interviewer. There was, however, the possibility of a high 
non-response rate. The tailored design method involving multiple communication with 
respondents to amplify the response rate was utilised in this research. Reminder e-
mails were sent to non-respondents every two weeks from the start of the survey. This 
reduced the non-response rate. 
3.3.10 Ethical approval and safeguarding participants 
Every physician and pharmacist registered with DHA was contacted by e-mail 
by the Head of the Human Resource Department at DHA inviting them to participate 
in the survey. Healthcare professionals in the private sector were contacted through 
their managers. The e-mail contained a link to the web-based questionnaire (see 
Appendix F). 
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3.3.10.1 Informed consent 
The nature and purpose of the study were explained within the first page of the 
survey and if participants continued to the following page this was taken as their 
consent to participate in the study. 
Around 14 communication e-mails with DHA were made to circulate the survey 
to government healthcare professionals. The first e-mail was dated 2 May 2016, and 
the last follow-up reminder e-mail was dated 23 November 2016. DHA circulated the 
survey link to all government hospitals and medical centres in the Emirate of Dubai 
by e-mail on 2 May 2016. The on-line survey took a long time to reach completion 
due to the onerous workloads of the healthcare professionals. 
Healthcare professionals in the private sector received the survey link by e-mail 
from their management sourced from Dubai Municipality database. Contact numbers 
were issued. Reminder e-mails were sent every month from the start of survey on 3 
May 2016 until 23 November 2016. At the end of the survey, a message of thanks was 
issued to all respondents. No incentives were offered for completing the survey. 
Around 15 e-mails were issued to private sector managers, then circulated to 
pharmacies, clinics and hospitals. The first e-mail was sent on 3 May 2016 and the last 
follow-up was on 23 November 2016. 
A total of 500 pharmacies registered in Dubai Municipality database received a 
survey link sent by the official e-mail of consumer products safety section at Dubai 
Municipality. The first e-mail was sent on 4 May 2016 and a reminder e-mail was sent 
on 23 June 2016. 
87 
 
3.3.10.2 Information for participants 
Informed consent contained a dedicated participant identification number. It also 
included the title of the project, Survey of Healthcare Professionals’ Knowledge, 
Attitude and Practice of Health Supplement Products Related Adverse Events, and the 
main researcher’s name, all as shown in appendix G. It was explained that the study 
would take place at United Arab Emirates University, College of Medicine & Health 
Sciences, School of Public Health located in Al-Ain, UAE and that participation in 
this study would take 15 minutes. In addition, it contained an explanatory information 
sheet dated 5 March 2015. Participation was voluntary and participants were free to 
withdraw at any stage. Information provided was strictly confidential. Names and 
details would not be linked to this survey and would not be identified in any 
report/publication. It also contained a statement of participant’s agreement to take part 
in the study. 
This information was delivered to participants on the first page of the on-line 
questionnaire. Continuing the survey was deemed agreement to participate and acted 
as signature of the consent form. 
3.3.10.3 Ethics review 
Approval to conduct this study was received in June 2015 from the University 
Student Research Committee at DHA. 
3.4 Summary 
This chapter discussed the main two surveys used to achieve the objectives of 
this research. All related sampling and sample size were discussed. Statistical analysis 
was used to measure dependent variables in the population-based survey including 
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consumption rate, consumers’ knowledge on HS, level of experience of adverse events 
and to measure the dependent variables of healthcare professional knowledge, attitude, 
and practice of HS adverse events, and reporting level of adverse events. 
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Chapter 4: Results 
The following section describes the demographic information of the two surveys 
and display the main results.  
4.1 Results of Survey of Health Supplements Consumption in Dubai 
Population 
4.1.1 Participants’ demographic characteristics 
The demographic information of participants is shown in Table 4.1. A total 
number of 1,203 participated in the survey. The average age of respondents was 39.2 
± 9.1 SD. The participants were predominantly male (n=1002, or 83.3%). Most of the 
participants were married (n=1039, or 86.4%). South Asians (n=579, or 48.1%) 
constituted the largest ethnic group in the study, followed by Middle East/ North Africa 
(n=301, or 25.0%), UAE (n=142, or 11.8%), Western Europe/ North America/ 
Australia (n=94, or 7.8%), East Asia/ Pacific (n=41, or 3.4%), Africa (n=32, or 2.7%), 
Central Asia/ Europe (n=12, or 1.0%), and Latin America/ Caribbean (n=2, or 0.2%). 
Most of the respondents in the survey were employed (n=1123, or 93.3%) and 41.5% 
(n=499) had an income in the range of 5,000-<10,000AED, 319 participants (26.5%) 
earned between10,000-20,000AED, 221 participants (18.4%) had an income higher 
than 20,000 AED. 164 participants (13.6%) earned less than 5,000 AED. 
Educational qualifications of the participants also varied. Nearly half of the 
participants (48.7%, 586) held graduation certificates, 269 were post graduates 
(22.4%), 139 were high school education holders (11.5%), 76 non-high school 
education holders (6.3%), 68 diploma holders (5.7%), 46 higher diploma holders 
(3.8%), and 19 PhD holders (1.6%). Most participants had health insurance coverage 
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(n= 1028, or 85.5%). Average height was 171.3 centimetres ±8.9 SD. Average weight 
was 78.7 kg ±15.3 SD. Average body mass index was 26.8 kg/m2 ±4.4 SD. There were 
546 (45.4%) overweight respondents (25-29.9 kg/m2), 431 (35.8%) of normal weight 
(<25 kg/m2) and 226 (18.8%) were obese (≥30 kg/m2). 862 participants (71.7%) were 
non-smokers, 183 were current regular smokers (15.2%), 108 were current occasional 
smokers (8.9%) and 50 were past smokers (4.2%). 
Of the total participants, 115 (9.6%) had an allergy, mainly to aerosols or 
perfume. Allergy to drugs accounted for 21 participants (1.7%). Allergy to dust 
accounted for 22 participants (1.8%). 106 had diseases (8.8%), mainly diabetes 
mellitus (n= 69, or 5.7%) and hypercholesterolemia (n= 31, or 2.6%). 
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Table 4.1: Characteristics of population based survey participants (N=1203) 
Variables                                                              categories n/Avg %/SD 
Age – years 39.2 ±9.1 
Gender 
Male 1002 83.3 
Female 201 16.7 
Marital Status 
Married 1039 86.4 
Single 150 12.5 
Divorced 9 0.7 
Widow 5 0.4 
Nationality 
Emirati 142 11.8 
Middle East/North Africa 301 25.0 
South Asia 579 48.1 
East Asia/Pacific 41 3.4 
Central Asia/Europe 12 1.0 
Africa 32 2.7 
Latin America/Caribbean 2 0.2 
Western Europe/North America/Australia 94 7.8 
Occupation 
Employed 1123 93.3 
Unemployed 60 5.0 
Student 9 0.7 
Retired 11 0.9 
Income (AED) 
<5000 164 13.6 
5000-<10000 499 41.5 
1000020000 319 26.5 
>20000 221 18.4 
Education 
< High school 76 6.3 
High school 139 11.5 
Diploma 68 5.7 
Higher Diploma 46 3.8 
Bachelor 586 48.7 
Master 269 22.4 
PhD 19 1.6 
Health insurance coverage 1028 85.5 
Height – cm 171.3 ±8.9 
Weight – kg 78.7 ±15.3 
Body Mass Index – kg/m2 26.8 ±4.4 
Body Mass Index – cat kg/m2 
Normal (<25) 431 35.8 
Overweight (25-29.9) 546 45.4 
Obese (≥30) 226 18.8 
Smoking status 
Non-smoker 862 71.7 
Past smoker 50 4.2 
Current occasional 108 8.9 
Current regular 183 15.2 
Any allergy 115 9.6 
 Drug allergy 21 1.7 
Aerosol & perfume allergy 23 1.9 
Contact allergy 7 0.6 
Dust allergy 22 1.8 
Others 26 2.2 
Diseases 
Diabetes Mellitus 69 5.7 
High cholesterol levels 31 2.6 
Cardiovascular disease 5 0.4 
Cancer 1 0.1 
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4.1.2 Use of health supplements among the participants in Dubai population 
The use of the HS among participants varied, as shown in Table 4.2. Around 748 
(62.2%) participants had never used HS and 455 (37.8%) participants had used HS at 
least once. Among these 455 participants, 377 were currently using and 138 had 
consumed HS in the past. 
The purpose of HS consumption among the 455 participants who had a history 
of HS usage was as follows: 301 (66.1%) used HS to improve health, 45 (9.9%) male 
participants used HS for body building, 11 (2.4%) female participants used HS during 
pregnancy, 31 (6.8%) used HS to prevent diseases, 27 (5.9%) used HS for diet 
supplementation, 24 (5.3%) used HS for maintaining weight, 18 (4.0%) used HS for 
energy boosting and the rest of the participants for other reasons. 
The duration of HS usage among the 455 known HS consumers was as follows: 
189 (41.5%) used HS for a month, 165 (36.3%) consumed HS anywhere between one 
to five years, 52 (11.4%) used HS for less than a month, and 45 (9.9%) used HS for 
more than five years. A breakdown of duration of usage among past and current users 
was also available. Duration of HS use among the current users varied as follows: 118 
(37.2%) used HS for a month, 136 (42.9%) used HS between one to five years, 21 
(6.6%) used HS for less than a month, and 40 (12.2%) used HS for more than five 
years. Among the past users, 71 (51.5%) used HS for a month, 29 (21.0%) used HS 
for one to five years, 31 (22.5%) used HS for less than a month, and five (3.6%) used 
HS for more than five years. 
Of the 455 participants, 288 (63.3%) were daily users, 116 (25.5%) used HS for 
one to four times in a week, 22 (4.8%) used HS for one to three times in a month, and 
17 (3.7%) consumed seasonally. The number of HS used by the 455 participants 
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differed. While 388 (85.3%) participants used one to two types of HS, 59 (13.0%) used 
three to five types, six (1.3%) participants used six to 10 types, and two participants 
(0.4%) had a history of using more than 10 types of HS. 
The reasons for discontinuing HS use were mainly allergy, skin disease, and cost. 
Participants who used HS (n=455) mainly purchased them from pharmacies (88.3%). 
The remaining purchase sources were from clinics (9.9%) and nutrition shops (6.7%). 
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Table 4.2: Use of health supplement among population of Dubai (N=1203) 
Variables N n (%) 
HS use 1203  
Ever used (Including current and past users)  455 (37.8) 
Current  317 (26.3) 
Past  138 (11.5) 
Never  748 (62.2) 
Reasons for using HS 455  
To improve health  301 (66.1) 
Body building (Male only)  45 (9.9) 
Diseases prevention  31 (6.8) 
Diet supplementation  27 (5.9) 
Weight management  24 (5.3) 
Energy  18 (4.0) 
Pregnancy (Female only)  11 (2.4) 
Immunity booster  8 (1.8) 
To prevent cold  8 (1.8) 
Ageing  5 (1.1) 
Anaemia  4 (0.9) 
High blood pressure  3 (0.7) 
High cholesterol  5 (1.1) 
Digestive  6 (1.3) 
Other  8 (1.7) 
Reasons for discontinuing HS   
Allergy  4 (0.3) 
Skin disease  4 (0.3) 
Cost  3 (0.2) 
Duration of HS use, overall 455  
Less than a month  52 (11.4) 
Month  189 (41.5) 
1-5 years  165 (36.3) 
More than 5 years  45 (9.9) 
Do not know  4 (0.9) 
Duration of HS use, Current users 317  
Less than a month  21 (6.6) 
Month  118 (37.2) 
1-5 years  136 (42.9) 
More than 5 years  40 (12.2) 
Do not know  2 (0.6) 
Duration of HS use, Past users   
Less than a month  31 (22.5) 
Month  71 (51.5) 
1-5 years  29 (21.0) 
More than 5 years  5 (3.6) 
Do not know  2 (1.5) 
Frequency of HS use 454  
Seasonally  17 (3.7) 
<1 a month  9 (2.0) 
1-3 times a month  22 (4.8) 
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Table 4.2: Use of health supplement among population of Dubai (N=1203) 
(Continued) 
 
Variables N n (%) 
1-4 times a week  116 (25.5) 
Daily  288 (63.3) 
Number of HS use 455  
1-2 supplements  388 (85.3) 
3-5 supplements  59 (13.0) 
6-10 supplements  6 (1.3) 
>10 supplements  2 (0.4) 
Purchasing of HS 455  
Pharmacy  402 (88.3) 
Clinic  45 (9.9) 
Nutrition shop  29 (6.7) 
Gym  12 (2.6) 
Super market  5 (1.1) 
Other  9 (2.0) 
 
4.1.3 Knowledge of consumers on health supplements 
The knowledge or source of information about HS among consumers of HS in 
Dubai is shown in Table 4.3. Among the 455 participants who had ever used HS, 212 
(46.6%) were prescribed HS, 204 (44.8%) were self-advised HS, 49 (10.8%) were 
advised by healthcare professionals, 35 (7.7%) advised by friends and/or relatives, 30 
(6.6%) advised from the internet, and 10 (2.2%) from other sources, like 
advertisements. 
The participants sought information about HS from various sources. Of the 455 
participants who had ever used HS, 274 (60.2%) found out information about HS from 
pharmacies, 145 (31.9%) from the internet, 129 (28.3%) from physicians, 39 (8.6%) 
from a relative and/or friend, four (0.9%) from other sources and none of them from 
government centres. Most participants, 355 (78.0%) who had ever used HS, responded 
in the survey that the labelling information of the HS was very informative, 68 (14.9%) 
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responded somewhat informative and 28 (6.1%) responded that they did not read the 
label. Very few responded that it was not informative (0.9%). 
Most of the participants were concerned about the labelling information of HS. 
They checked the labelling information before use. From the labelling information, 
they were more concerned about of the ingredients, durability, adverse events, 
indications, precautions and dosing information. Nutrition information on the label 
was useful for most participants (94.7%). Of the 455 participants who had ever used 
HS, 334 (73.4%) always and 64 (14.1%) often followed recommended labelling 
information. 
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Table 4.3: Knowledge/sources of information about health supplement (N=455) 
Variables N n (%) 
Who advised to take HS 455  
Self  204 (44.8) 
Friend/Relative  35 (7.7) 
Advertisement  5 (1.1) 
Internet  30 (6.6) 
Prescribed  212 (46.6) 
Health professional  49 (10.8) 
Other  5 (1.1) 
From where do you seek HS information 455  
Pharmacy  274 (60.2) 
Physician  129 (28.3) 
Product helpline  10 (2.2) 
Internet  145 (31.9) 
Relative/Friend  39 (8.6) 
Government centre  0 (0.0) 
Other  4 (0.9) 
Sufficient information on the label 455  
Do not read the label  28 (6.1) 
Not informative  4 (0.9) 
Somewhat informative  68 (14.9) 
Very informative  355 (78.0) 
Type of label information of HS concerns   
Ingredients of supplement  375 (82.4) 
Indications of supplement  245 (53.9) 
Dosage of supplement  237 (52.1) 
Adverse events of supplement  291 (64.0) 
Durability of supplement  312 (68.6) 
Dietary sources of supplement  226 (49.8) 
Claims of supplement  199 (43.7) 
Precautions of supplement  233 (51.2) 
Dosing instructions of supplement  227 (49.9) 
No information concerns  41 (9.1) 
Nutrition information on the label is useful  431 (94.7) 
Do you follow recommended label information? 455  
Never  22 (4.8) 
Sometimes  35 (7.7) 
Often  64 (14.1) 
Always  334 (73.4) 
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4.1.4 Forms and ingredients of health supplements 
Forms and ingredients of HS used by the participants are shown in Table 4.4. 
Vitamins were the most commonly used HS among the participants (87.9%). Both 
minerals and sport nutrition were consumed by 48 participants each (10.5%). Herbal 
products and dietetic foods were used by nine participants each (2.0%). Five 
participants (1.1%) used energy drinks and 12 (2.6%) used miscellaneous types. The 
most widely used dosage form was tablet, at 85.5%. Capsules were taken by 53 
participants (11.7%). HS in powder form was used by 46 participants (10.1%) and 16 
participants (3.5%) used drinks/ liquids/ caplets/ granules/ gels etc. 
Ingredients of HS used by the participants in the survey were as follows: 195 
(42.9%) vitamin D, 104 (22.9%) vitamin E, 104 (22.9%) vitamin A & D, 58 (12.7%) 
calcium & vitamins, 56 (12.3%) vitamin B12, 52 (11.4%) vitamin C, 45 (9.9%) 
vitamin B6, 27 (5.9%)amino acids, 32 (7.0%) fish oil, 24 (5.3%) calcium & 
magnesium, 20 (4.4%) vitamin E multi component, 14 (3.1%) zinc.14 (3.1%) were 
unaware of ingredients. The remainder responded with miscellaneous ingredients. 
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Table 4.4: Forms and ingredients of health supplement (N=455) 
Variables N n (%) 
Categories of HS 455  
Vitamins  400 (87.9) 
Minerals  48 (10.5) 
Herbal products  9 (2.0) 
Sports nutrition  48 (10.5) 
Energy drinks  5 (1.1) 
Dietetic food  9 (2.0) 
Miscellaneous  12 (2.6) 
Forms of HS 455  
Tablets  389 (85.5) 
Capsules  53 (11.7) 
Powder  46 (10.1) 
Drinks/Liquids/Caplets/Granules/Lozenges/Gels  16 (3.5) 
Ingredients of HS 455  
Vitamin D  195 (42.9) 
Vitamin E  104 (22.9) 
Vitamin A & D  104 (22.9) 
Calcium & Vitamins  58 (12.7) 
Vitamin B12  56 (12.3) 
Calcium  52 (11.4) 
Vitamin C with/without rose  48 (10.5) 
Vitamin B6  45 (9.9) 
Fish oil  32 (7.0) 
Amino acids  27 (5.9) 
Calcium & Magnesium  24 (5.3) 
Vitamin E multicomponent  20 (4.4) 
Zinc/zinc gluconate  14 (3.1) 
Magnesium  7 (1.5) 
Folate/Folic acid  6 (1.3) 
Potassium  6 (1.3) 
Carnitine  5 (1.1) 
Alfalfa  1 (0.2) 
Chondroitin  2 (0.4) 
Creatinine  7 (1.5) 
Other  14 (3.1) 
Do not know about ingredient  14 (3.1) 
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4.1.5 Adverse events of health supplements 
Adverse events of HS are as shown in Table 4.5. Of the 455 participants who 
had ever used HS, 442 (97.1%) had experienced no adverse events from HS use. 13 
participants (2.9%) had experienced adverse events from HS use. Of these 13 
participants, six graded their experience of adverse events as mild (46.1%), five 
(38.5%) graded their experience of adverse events as moderate, while two (15.4%) 
graded their experience of adverse events as severe. Additionally, of these 13 
participants, two (15.4%) had frequent adverse events, nine (69.2%) experienced 
adverse events only once and for two (15.4%) adverse events occurred occasionally. 
Among these 13 participants, two (15.4%) self-confirmed a co-relation of HS 
with an adverse event and one (7.7%) confirmed the co-relation by physician. Of these 
13 participants, four (30.8%) suspected or confirmed that vitamins had caused the 
adverse event while one (7.7%) suspected or confirmed slimming tea as the cause. For 
most of the participants (76.9%), the adverse event resolved after discontinuing 
supplement intake. Two participants (15.4%) discontinued intake ofthe supplement on 
medical advice and for one participant (7.7%) intake was discontinued after treatment.  
Of these 13 participants, only a few reported the adverse events and only to their 
physician (23.1%). Regarding the establishment of an adverse event reporting system 
for HS, 550 (45.7%) participants responded as unsure about any benefit deriving there 
from, 464 (38.6%) responded as definitely beneficial and 163 (13.5%) responded as 
somewhat beneficial. These results show that most participants expressed that the 
establishment of an adverse event reporting system for HS would be beneficial. 
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Table 4.5:Adverse events of health supplements (N=455) 
Variables N n (%) 
Adverse events from HS 455 13 (2.9) 
Type of AE 13  
Abdominal pain  1 (7.7) 
Dermatitis  2 (15.4) 
Diarrhoea  2 (15.4) 
Constipation  2 (15.4) 
Urticaria  3 (23.1) 
Other  3 (23.1) 
Severity of AE from HS 13  
Mild  6 (46.1) 
Moderate  5 (38.5) 
Severe  2 (15.4) 
Frequency of AE from HS 13  
Once  9 (69.2) 
Occasionally  2 (15.4) 
Frequently  2 (15.4) 
Onset time of AE 13  
< 1 hour  5 (38.5) 
1 hour – 1 day  3 (23.1) 
> 1 day  6 (46.1) 
Relation between HS use and AE confirmed 13  
Self  2 (15.4) 
Physician  1 (7.7) 
Lab  0 (0.0) 
Clinic  0 (0.0) 
HS suspected/confirmed to cause AE 13  
Vitamins  4 (30.8) 
Slimming tea  1 (7.7) 
How did the AE resolve?   
Self-discontinuing the supplement  10 (76.9) 
Discontinuing the supplement after medical advise  2 (15.4) 
Treatment  1 (7.7) 
Ever reported AE 13 3 (23.1) 
Where did you report AE 3  
Physician  3 (100.0) 
Benefits of establishing AE reporting system 1203  
Definitely not beneficial  15 (1.3) 
Not beneficial  11 (0.9) 
Unsure  550 (45.7) 
Somewhat beneficial  163 (13.5) 
Definitely beneficial  464 (38.6) 
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4.1.6 Factors associated with health supplement use 
Table 4.6 shows the bivariate analysis in which HS use dependent variable is 
tabulated against independent variables. The mean age of the participants who used 
HS was 38.9 ± 9.0 SD. There was no effect of age on HS use (P=0.307). There was an 
effect shown of gender on HS use (P<0.001). Females were more likely to be HS users 
(133 users among 201 respondents, 66.2%) compared to males (322 users out of 1002 
respondents, 32.1%). There was no effect of marital status on HS use (P=0.051). Single 
and divorced/widowed respondents were more likely to report HS use. There was an 
effect seen of nationality on HS use (P<0.001). Persons of Latin America/ Caribbean/ 
Western Europe/ North America/ Australia origin were more likely to be users. 
Persons of South Asian origin were less likely to report use. There was an effect seen 
of employment status on HS use (P=0.003). There was an effect seen of income on HS 
use (P<0.001). Those with incomes over 10,000 AED per month were more likely to 
be users compared to those on lower salaries. 
Educational attainment was also significantly associated with HS use (P<0.001). 
Those educated to higher diploma level and above were more likely to report HS use 
compared to those of lower educational attainment. Health insurance was significantly 
associated with HS use (P=0.017). Those with health insurance were more likely to 
report HS use. Those with an allergy were also more likely to report HS use (P=0.008). 
Similarly, those who had visited a doctor and those taking medicines were more likely 
to report HS use. However, body mass index, smoking, and self-reports of medical 
conditions were not associated with HS use. 
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Table 4.6: Factors associated with health supplement use 
Variables All  
N 
Users 
(N=455) n 
(%) 
Non-users 
(N=748) n 
(%) 
P 
Value 
Age – years 1203 38.9±9.0 39.4±9.1 0.307 
Gender     
Male 1002 322 (32.1) 680 (66.9) <0.001 
Female 201 133 (66.2) 68 (33.8)  
Marital Status     
Married 1039 379 (36.5) 660 (63.5) 0.051 
Single 150 69 (46.0) 81 (54.0)  
Divorced/Widow 14 7 (50.0) 7 (50.0)  
Nationality     
Emirati 142 68 (47.9) 74 (52.1) <0.001 
Middle East/ North Africa 301 144 (47.9) 157 (52.1)  
South Asia 579 141 (24.4) 438 (75.6)  
East Asia/ Pacific/ Central Asia/ 
Europe 
53 28 (52.8) 25 (47.2)  
Africa 32 14 (43.7) 18 (56.3)  
Latin America/ Caribbean/ Western 
Europe/ North America/ Australia 
96 60 (62.5) 36 (37.5)  
Occupation     
Employed 1123 413 (36.8) 710 (63.2) 0.003 
Unemployed 60 35 (58.3) 25 (41.7)  
Student/Retired 20 7 (35.0) 13 (65.0)  
Income     
<5000 AED 164 33 (20.1) 131 (79.9) <0.001 
5000-<10000 AED 499 149 (29.9) 350 (70.1)  
10000-20000 AED 319 153 (48.0) 166 (52.0)   
>20000 AED 221 120 (54.3) 101 (45.7)  
Education     
< High school 76 13 (17.1) 63 (82.9) <0.001 
High school 139 39 (28.1) 100 (71.9)  
Diploma 68 18 (26.5) 50 (73.5)  
Higher Diploma 46 22 (47.8) 24 (52.2)  
Bachelor 586 245 (41.8) 341 (58.2)  
Master/ PhD 288 118 (41.0) 170 (59.0)  
Health insurance coverage 1028 403 (39.2) 625 (60.8) 0.017 
Body Mass Index – kg/m2 1203 26.9±4.5 26.7±4.3 0.348 
Body Mass Index – cat     
Normal (<25  kg/m2) 431 165 (38.3) 266 (61.7) 0.496 
Overweight (25-29.9  kg/m2) 546 198 (36.3) 348 (63.7)  
Obese (≥30 kg/m2) 226 92 (40.7) 134 (59.3)  
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Table 4.6: Factors associated with health supplement use (Continued) 
Variables All  
N 
Users 
(N=455) n 
(%) 
Non-
users 
(N=748) n 
(%) 
P 
Value 
Smoking status     
Non-smoker 862 326 (37.8) 536 (62.2) 0.059 
Past smoker 50 27 (54.0) 23 (46.0)  
Current occasional smoker 108 34 (31.5) 74 (68.5)  
Current regular smoker 183 68 (37.2) 115 (62.8)  
Any allergy 115 57 (49.6) 58 (50.4) 0.008 
Drug allergy 20 13 (65.0) 7 (35.0) 0.129 
Aerosol & perfume allergy 20 7 (35.0) 13 (65.0) 0.152 
Contact allergy 7 2 (28.6) 5 (71.4) 0.252 
Dust allergy 23 7 (30.4) 16 (69.6) 0.040 
Others 14    
Visited a doctor in last 12 
months 
    
Did not visit doctor in last 12 
months 
322 79 (24.5) 243 (75.5) <0.001 
Less than monthly 806 342 (42.4) 464 (57.6)  
1-3 times a month/At least once a 
week 
75 34 (45.3) 41 (54.7)  
Diseases     
Diabetes Mellitus 69 25 (36.2) 44 (63.8) 0.779 
High cholesterol levels 31 9 (29.0) 22 (71.0) 0.352 
Cardiovascular disease 31 14 (45.2) 17 (54.8) 0.393 
Medicines 226 115 (50.9) 111 (49.4) <0.001 
Analgesic 41 17 (41.5) 24 (51.5) 0.309 
Anti-biotic 28 15 (53.6) 13 (46.4)  
Anti-diabetic 31 17 (54.8) 14 (45.2)  
Anti-hypertensive 14 6 (42.9) 8 (57.1)  
Cholesterol lowering 10 4 (40.0) 6 (60.0)  
Vitamins 12 9 (75.0) 3 (25.0)  
Anti-allergic 8 3 (37.5) 5 (62.5)  
Other 24 16 (66.7) 8 (33.3)  
The association between HS use as an outcome variable and selected population 
characteristics as independent variables is summarized in Table 4.7. There was 
positive association of HS use with female gender, higher income, higher educational 
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level, having health insurance, being a past-smoker, having an allergy, more frequent 
doctor visits, taking prescribed medications and HS knowledge.  
There was a negative association of HS use with being married and Emirati, 
Middle East/North Africa or South Asian nationality. After adjustment in the 
multivariate model, the positive association with female gender, higher income, being 
a past-smoker, having an allergy, more frequent doctor visits, taking prescribed 
medications and HS knowledge and the negative association with South Asian 
nationality and Emirati nationality remained (Table 4.8). 
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Table 4.7: Crude odds ratios for HS use, cross-sectional study of HS use and HS-
related adverse events, Dubai, 2015 (N=1203) 
Variables 
 
All Users   
N N (%) COR 
(95%CI) 
Age – years 1203 38.9±9.0 0.99 (0.98-
1.01) 
Gender Male 1002 322 (32.1) 1 
Female 201 133 (66.2) 4.13 (3.00-
5.69)** 
Marital Status Single  150 69 (46.0) 1 
Married 1039 379 (36.5) 0.67 (0.48-
0.95)* 
Divorced/ Widow/ Widower 14 7 (50.0) 1.17 (0.39-
3.51) 
Nationality Emirati 142 68 (47.9) 0.55 (0.33-
0.93)* 
Middle East/ North Africa 301 144 (47.8) 0.55 (0.34-
0.88)* 
South Asia 579 141 (24.3) 0.19 (0.12-
0.30)** 
East Asia/Pacific/Central 
Asia/Europe 
53 28 (52.8) 0.67 (0.34-
1.33) 
Africa 32 14 (43.7) 0.47 (0.21-
1.05) 
Latin 
America/Caribbean/Western 
Europe/North America/Australia 
96 60 (62.5) 1 
Occupation Employed 1123 413 (36.8) 1.08 (0.43-
2.73) 
Unemployed 60 35 (58.3) 2.60 (0.91-
7.44) 
Student/Retired 20 7 (35.0) 1 
Income <5000 AED 164 33 (20.1) 1 
5000-<10000 AED 499 149 (29.9) 1.69 (1.10-
2.59)* 
>10000-20000 AED 319 153 (48.0) 3.66 (2.35-
5.68)** 
>20000 AED 221 120 (54.3) 4.72 (2.96-
7.50)** 
Education < High school 76 13 (17.1) 1 
High school 139 39 (28.1) 1.89 (0.94-
3.81) 
Diploma 68 18 (26.5) 1.74 (0.78-
3.90) 
Higher Diploma 46 22 (47.8) 4.44 (1.93-
10.20)** 
 Bachelor 586 245 (41.8) 3.48 (1.87-
6.47)** 
Master/PhD 288 118 (41.0) 3.36 (1.77-
6.39)** 
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Table 4.7: Crude odds ratios for HS use, cross-sectional study of HS use and HS-
related adverse events, Dubai, 2015 (N=1203) (Continued) 
Notes. *P<.05 **p<.01 
  
Variables 
 
All Users   
N N (%) COR 
(95%CI) 
Health 
insurance  
Yes 1028 403 (39.2) 1.53 (1.08-
2.16)* 
No 175 52 (29.7) 1 
BMI – cat Normal (<25  kg/m2) 431 165 (38.3) 1 
Overweight (25-29.9  kg/m2) 546 198(36.3) 0.92 (0.71-
1.19) 
Obese (≥30 kg/m2) 226 92 (40.7) 1.11 (0.80-
1.54) 
Smoking status Non-smoker 862 326 (37.8) 1 
Past smoker 50 27 (54.0) 1.93 () 
Current occasional smoker 108 34 (31.5) 0.75 (0.49-
1.16) 
Current regular smoker 183 68 (37.2) 0.97 (0.70-
1.35) 
Any allergy Yes 115 57 (49.6) 1.71 (1.16-
2.51)* 
No 1081 395 (36.5) 1 
Visited a doctor 
in last 12 
months 
Did not visit doctor in last 12 
months 
322 79 (24.5) 1 
Less than monthly 806 342 (42.4) 2.27 (1.70-
3.03)** 
1-3 times a month/ At least 
once a week 
75 34 (45.3) 2.55 (1.51-
4.29)** 
Diabetes 
Mellitus 
Yes 69 25 (36.2) 0.93 (0.56-
1.94) 
No 1134 430 (37.9) 1 
High cholesterol  Yes 31 9 (29.0) 0.67 (0.30-
1.46) 
No 1172 446 (38.1) 1 
Cardiovascular 
disease 
Yes 31 14 (45.2) 1.37 (0.66-
2.80) 
No 1172 441 (37.6) 1 
Prescribed 
Medicines 
Yes 226 115 (50.9) 1.94 (1.45-
2.60)** 
No 977 340 (34.8) 1 
Knowledge of 
HS 
No 174 19 (10.9) 1 
Yes 1029 436 (42.7) 6.00 (3.67 – 
9.81)** 
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Table 4.8: Adjusted odds ratios for HS use, cross-sectional study of HS use and HS-
related adverse events, Dubai, 2015 (N=1203)  
 
Notes. Stepwise regression method was applied to identify significant correlates 
(p<0.10) of HS use *P<0.05 , **p<0.01 
 
Variables  
AOR (95%CI) 
Gender  
Male 1 
Female 3.26 (2.26-
4.70)** 
Nationality  
Emirati 0.55 (0.30-1.00)* 
Middle East/North Africa 0.66 (0.39-1.12) 
South Asia 0.51 (0.28-0.93)* 
East Asia/Pacific/Central Asia/Europe 1.16 (0.53-2.52) 
Africa 0.50 (0.21-1.22) 
Latin America/Caribbean/Western Europe/North America/ 
Australia 
1 
Income  
<5000 AED 1 
5000-<10000 AED 1.18 (0.71-1.98) 
>10000-20000 AED 1.83 (0.98-3.41) 
>20000 AED 2.41 (1.20-4.83)* 
Allergy  
Yes 1.75 (1.14-2.66)* 
No 1 
Smoking status  
Non-smoker 1 
Past smoker 2.39 (1.27-
4.48)** 
Current occasional smoker 0.85 (0.52-1.36) 
Current regular smoker 0.93 (0.64-1.36) 
Visited to a doctor in last 12 months  
Did not visit doctor in last 12 months 1 
Less than monthly 1.37 (0.96-1.94) 
1-3 times a month/ At least once a week 1.86 (1.02-3.39)* 
Prescribed Medicines  
Yes 1.47 (1.04-2.06)* 
No 1 
Knowledge of HS  
Yes 3.91 (2.26-
6.76)** 
No 1 
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4.1.7 Factors associated with adverse events 
The factors associated with adverse events of HS are as shown in Table 4.9. The 
average age of participants who experienced an adverse event was 39.3. There was no 
effect of age found on the occurrence of an adverse event (P=0.533). Male participants 
experienced adverse events more than female participants. Of the 322 male 
participants, 11 (3.4%) experienced adverse events. Of the 133 female participants, 
only two (1.5%) experienced adverse events. There was no effect of gender on the 
occurrence of an adverse event (P=0.363). 
Of the 379 married participants, only 10 (2.6%) and of the 69 single participants, 
only three (4.3%) experienced adverse events. Among the seven divorced/ widowed 
participants, none experienced adverse events. There was no effect of marital status on 
the occurrence of an adverse event (P=0.538). 
In terms of nationality, of the participants, three UAE nationals (4.1%), five 
Middle East/ North Africa nationals (3.5%), two South Asia nationals (1.4%), one 
African national (7.1%) and two Latin America/ Caribbean/ Western Europe/ North 
America/ Australia nationals (3.3%) experienced adverse events. No East Asia/ 
Pacific/ Central Asia/ Europe national participant experienced adverse events. There 
was no effect of nationality on the occurrence of an adverse event (P=0.467). 
Among 413 employed, 35 unemployed and seven students or retired 
participants,12 (2.9%) from employed, and one (2.9%) from unemployed participants 
experienced adverse events. No student or retiree experienced adverse events. There 
was no effect of occupation on the occurrence of an adverse event (P=1.0). 
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Participants who had an income greater than 10,000 to 20,000 AED experienced 
more adverse events: eight participants (5.2%) of 153. Four participants (3.3%) had an 
income greater than 20,000 AED and one participant (0.7%) had an income of between 
5,000 and 10,000 AED experienced adverse events. No participant experienced an 
adverse event and had an income less than 5,000 AED. There was no effect of income 
on the occurrence of an adverse event (P=0.088). 
In terms of educational level, of the total 13 recorded adverse events, one was 
experienced by a participant who had a diploma, seven were experienced by 
participants who had a bachelor’s degree, and five were experienced by participants 
who were of post graduate level. There was no effect of education on the occurrence 
of an adverse event (P=0.667).  
Among the 455 participants who had ever used HS, 403 had insurance cover. Of 
the 13 participants who experienced adverse events, 12 had insurance coverage. There 
was no effect of insurance coverage on the occurrence of an adverse event (P=1.0). 
The adverse events rate was higher in participants with normal body mass index (BMI) 
(<25 kg/m2), seven of 165 (4.2%). The BMI mean was 27.1 ± 2.1 SD. BMI showed no 
effect on the occurrence of an adverse event (P=0.922). 
The smoking status of the participant did not play a role in the occurrence of 
adverse events. Of this group, eight non-smokers (2.5%), two past smokers (7.4%), 
two current regular smokers (2.9%) and one current occasional smoker (2.9%) 
experienced adverse events. Smoking status showed no effect on the occurrence of an 
adverse event (P=0.321). 
In terms of allergic status, of the 57 participants who had an allergy, only two 
experienced an adverse event (3.5%). Of the 455 participants who had ever used HS, 
111 
 
13 were allergic to drugs. Of these, two experienced adverse events (15.4%). There 
was an effect of drug allergy on the occurrence of an adverse event (P=0.049). 
Of the participants who experienced adverse events, nine (2.6%) who had visited 
a doctor, saw a doctor in a frequency of less than a month. Two (5.9%) who had visited 
a doctor one to three times a month/ at least once a week, saw a doctor in a frequency 
of one to three times a month/ at least once a week. Two (2.5%) who did not visit a 
doctor in the last 12 months, did not see a doctor in the last 12 months. There was no 
effect of visiting the doctor on the occurrence of an adverse event (P=0.449). 
Participants who experienced an adverse event did not suffer from any common 
major disease like diabetes mellitus, high cholesterol levels or cardiovascular disease. 
There was no effect of disease on the occurrence of an adverse event (P=1.0). 
Participants who experienced an adverse event and who were taking medicine 
numbered five (4.3%). There was no effect of taking medicines on the occurrence of 
an adverse event (P=0.329). 
4.1.8 Factors associated with health supplement knowledge 
Table 4.10 shows the association between knowledge of HS and selected socio-
demographic and other characteristics of respondents where knowledge is defined by 
an affirmative answer to the question: Do you know what health supplements are? 
Overall, 1,029 (86%) respondents knew what HS were. There was a significant 
positive association between knowledge and female gender. Those of south Asian 
nationality, on lower income, with lower educational attainment, lacking health 
insurance and who had not visited a doctor were less likely to report familiarity with 
HS. 
112 
 
Table 4.9: Factors associated with adverse events 
Variables All  
N 
Adverse events n 
(%) 
No adverse events  
n (%) 
P Value 
Age – years 455 38.0±5.0 38.9±9.1 0.533 
Gender    0.363 
Male 322 11 (3.4) 311 (96.6)  
Female 133 2 (1.5) 131 (98.5)  
Marital Status     
Married 379 10 2.6() 369 (97.4) 0.538 
Single 69 3 (4.3) 66 (95.6)  
Divorced/Widow/er 7 0 (0.0) 7 (100.0)  
Nationality    0.467 
Emirati 68 3(4.1) 65 (95.6)  
Middle East/ North Africa 144 5(3.5) 139 (96.5)  
South Asia 141 2(1.4) 139 (98.6)  
East Asia/ Pacific/ Central 
Asia/ Europe 
28 0(0.0) 28 (100.0)  
Africa 14 1(7.1) 13 (92.9)  
Latin 
America/Caribbean/Western 
Europe/North 
America/Australia 
60 2(3.3) 58 (96.7)  
Occupation    1.000 
Employed 413 12 (2.9) 401 (97.1)  
Unemployed 35 1 (2.9) 34 (97.1)  
Student/Retired 7 0 (0.0) 7 (100.0)  
Income    0.088 
<5000 AED 33 0 (0.0) 33 (100.0)  
5000-<10000 AED 149 1 (0.7)   148 (99.3)  
10000-20000 AED 153 8(5.2) 145(94.8)   
>20000 AED 120 4 (3.3) 116 (96.7)  
Education    0.667 
< High school 13 0 (0.0) 13 (100.0)  
High school 39 0 (0.0) 39 (100.0)  
Diploma 18 1 (5.6) 17 (94.4)  
Higher Diploma 22 0 (100.0) 22 (100.0)  
Bachelor 245 7 (2.9) 238 (97.1)  
Master/PhD 118 5 (4.2) 113 (95.8)  
Health insurance coverage    1.00 
Yes 403 12 (3.0) 391 (97.0)  
No 52 1 (1.9) 51 (98.1)  
Body Mass Index – kg/m2 1203 27.1±2.1 26.9±0.2 0.922 
Body Mass Index – cat     
Normal (<25 kg/m2) 165 7 (4.2) 158 (95.8)  
Overweight (25-29.9 kg/m2) 198 3 (1.5) 195 (98.5)  
Obese (≥30 kg/m2) 92 3 (3.3) 89 (96.7)  
Smoking status    0.321 
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Table 4.9: Factors associated with adverse events (Continued) 
Variables All  
N 
Adverse events n 
(%) 
No adverse 
events  n (%) 
P 
Value 
Non-smoker 326 8 (2.5) 318 (97.5)  
Past smoker 27 2 (7.4) 25 (92.6)  
Current occasional smoker 34 1 (2.9) 33 (97.1)  
Current regular smoker 68 2 (2.9) 66 (97.1)  
Any allergy 57 2 (3.5) 55 (96.5) 0.654 
Drug allergy 13 2 (15.4) 11 (84.6) 0.049 
Aerosol & perfume allergy 7 0 (0.0) 7 (100.0) 1.00 
Contact allergy 7 0 (0.0) 2 (100.0) 1.00 
Dust allergy 7 0 (0.0) 7 (100.0) 1.00 
Visited a doctor in last 
12 months 
   0.449 
Did not visit doctor in last 
12 months 
79 2 (2.5) 77 (97.5)  
Less than monthly 342 9 (2.6) 333 (97.4)  
1-3 times a month/At least 
once a week 
34 2 (5.9) 32 (94.1)  
Diseases     
Diabetes Mellitus 9 0 (0.0) 9 (100.0) 1.00 
High cholesterol levels 25 0 (0.0) 25 (100.0) 1.00 
Cardiovascular disease 14 0 (0.0) 14 (100.0) 1.00 
Medicines 115 5 (4.3) 110 (95.7) 0.329 
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Table 4.10: Factors associated with health supplement knowledge 
Variables All 
(455) 
Knowledge 
(n=1029) n 
(%) 
No Knowledge 
(n=174) n (%) 
P 
Value 
Age – years 1203 39.3±0.3 38.7±0.7 0.365 
Gender    <0.001 
Male 1002 837 (83.5) 165 (16.5)  
Female 201 192 (95.5) 9 (4.5)  
Marital Status    0.282 
Married 1039 884 (85.1) 155 (14.9)  
Single 150 131 (87.3) 19 (12.7)  
Divorced/Widow/er 14 14 (100.0) 0 (0.0)  
Nationality    <0.001 
Emirati 142 131 (92.3) 11 (7.7)  
Middle East/North Africa 301 287 (95.3) 14 (4.7)  
South Asia 579 443 (76.5) 136 (23.5)  
East Asia/Pacific/Central 
Asia/Europe 
53 48 (90.6) 5 (9.4)  
Africa 32 31 (96.9) 1 (3.1)  
America/Caribbean/Western 
Europe/Australia 
96 89 (92.7) 7 (7.3)  
Occupation    0.067 
Employed 1123 954 (84.9) 169 (15.1)  
Unemployed 60 57 (95.0) 3 (5.0)  
Student/Retired 20 18 (90.0) 2 (10.0)  
Income    <0.001 
<5000 AED 164 85 (51.8) 79 (48.2)  
5000-<10000 AED 499 440 (88.2) 59 (11.8)  
10000-20000 AED 319 296 (92.8) 23 (7.2)  
>20000 AED 221 208 (94.1) 13 (5.9)  
Education    <0.001 
< High school 76 26 (34.2) 50 (65.8)  
High school 139 102 (73.4) 37 (26.6)  
Diploma 68 60 (88.2) 8 (11.8)  
Higher Diploma 46 41 (89.1) 5 (10.9)  
Bachelor 586 542 (92.5) 44 (7.5)  
Master/PhD 286 258 (89.6) 30 (10.4)  
Health insurance coverage    <0.001 
Yes 1028 897 (87.3) 131 (12.7)  
No 175 132 (75.4) 43 (24.6)  
Body Mass Index – kg/m2  26.8±0.1 26.3±0.3 0.104 
Body Mass Index – cat    0.367 
Normal (<25  kg/m2) 431 362 (84.0) 69 (16.0)  
Overweight (25-29.9  kg/m2) 546 468 (85.7) 78 (14.3)  
Obese (≥30 kg/m2) 226 199 (88.1) 27 (11.9)  
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Table 4.10: Factors associated with health supplement knowledge (Continued) 
 
Variables All 
(455) 
Knowledge 
(n=1029) n (%) 
No Knowledge 
(n=174) n (%) 
P 
Value 
Smoking status    0.320 
Non-smoker 862 733 (85.0) 129 (15.0)  
Past smoker 50 43 (86.0) 7 (14.0)  
Current occasional smoker 108 89 (82.4) 19 (17.6)  
Current regular smoker 183 164 (89.6) 19 (10.4)  
Any allergy    0.323 
Yes 115 102 (88.7) 13 (11.3)  
No 1081 922 (85.3) 159 (14.7)  
Visited to a doctor in last 
12 months 
   <0.001 
Did not visit doctor in last 
12 months 
322 230 (71.4) 92 (28.6)  
Less than monthly 806 732 (90.8) 74 (9.2)  
1-3 times a month/At least 
once a week 
75 67 (89.3) 8 (10.7)  
Diseases     
Diabetes Mellitus    0.156 
Yes 69 55 (79.7) 14 (20.3)  
No 1134 974 (85.9) 160 (14.1)  
High cholesterol levels    0.299 
Yes 31 29 (93.5) 2 (6.5)  
No 1172 1000 (85.3) 172 (14.7)  
Cardiovascular disease    0.073 
Yes 31 30 (96.8) 1 (3.2)  
No 1172 999 (85.2) 173 (14.8)  
Medicines    0.233 
Yes 226 199 (88.1) 27 (11.9)  
No 977 830 (84.9) 147 (15.1)  
Respondent knowledge of HS stratified by information source (prescription 
advice) is shown in Table 4.11. The impact of information source on knowledge of HS 
among different demographic variables was investigated by askingthe participants 
who had advised them to take HS. A statistically significant difference was found in 
the knowledge between males and females when the information sources were self-
recommendation and prescription (P˂0.001), (P=0.004), respectively. A similar 
pattern of results was observed in employment status (P=0.004), (P=0.001) and 
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education level (P˂0.001), (P˂0.001), respectively. Age of the respondents also 
showed a statistically significant difference in knowledge when the sources of 
information were relatives and healthcare personnel (P=0.011), (P˂0.006), 
respectively. 
The nationality of the respondents also showed a statistically significant 
difference in knowledge when the source of information was self-recommendation 
(P=0.014), relatives (P=0.029), prescription (P˂0.001), and healthcare personnel 
(P˂0.001). Moreover, a statistically significant difference was found in the knowledge 
of respondents and their monthly income when the information sources were 
prescription (P=0.010) and healthcare personnel (P=0.026). A similar pattern of results 
was observed in health insurance coverage variable (P=0.022), (P=0.030), 
respectively. BMI, as a continuous variable, showed a statistically significant 
difference in the knowledge of HS when the information source was self-
recommendation (P=0.043). Also, when BMI was converted and categorised, a 
statistically significant difference was found in the knowledge of the respondents when 
the information source was the internet (P=0.027). In relation to smoking status, 
respondents showed a significant difference in the knowledge of HS when they 
obtained their information from the internet (P=0.022). 
Regarding visiting the doctor in the last 12 months, respondents showed a 
statistically significant difference in the knowledge of HS when the source of 
information towards HS was self-recommendation (P=0.008), internet (P=0.001) and 
prescription (P=0.014). Among co-morbidities (chronic medical conditions) 
respondents suffering from only diabetes mellitus showed a statistically significant 
difference in the knowledge of HS when the source of information towards HS was 
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prescription (P=0.002). When the respondents were asked about medication history, a 
statistically significant difference in the knowledge of HS was observed among the 
respondents when the sources of information towards HS were self-recommendation 
and prescription (P˂0.001), (P˂0.001), respectively. Conversely, there was no 
statistically significant difference in the knowledge of HS in other demographic 
specifications (marital status, allergy history) and source of information towards HS. 
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Table 4.11: Knowledge by prescription advice 
Variables All 
(455) 
Self 
(n=204) 
P 
Value 
Relative 
(n=35) 
P 
Value 
Internet 
(n=30) 
P 
Value 
Prescribed 
(n=212) 
P 
Value 
Health 
professional 
(n=49) 
P 
Value 
  n (%)  n (%)  n (%)  n (%)  n (%)  
Age – years 455 38.9±0.6 0.995 35.1±4.5 0.011 37.3±1.3 0.328 39.2±9.7 0.511 42.2±1.3 0.006 
Gender   <0.001  0.445  0.303  0.004  0.373 
Male 322 162 
(50.3) 
 27 (8.4)  24 (7.5)  136 (42.2)  32 (9.9)  
Female 133 42 (31.6)  8 (6.0)  6 (4.5)  76 (57.1)  17 (12.8)  
Marital Status   1.00  0.343  0.609  0.266  0.839 
Married 379 170 
(44.9) 
 27 (7.1)  26 (6.7)  181 (47.8)  42 (11.1)  
Single/Divorced/Widow/er 69 34 (44.7)  8 (10.5)  4 (5.3)  31 (40.8)  7 (9.1)  
Nationality   0.014  0.029  0.139  <0.001  <0.001 
Emirati 68 27 (39.7)  9 (13.2)  4 (5.9)  38 (55.9)  2 (2.9)  
Middle East/North Africa 144 60 (41.7)  12 (8.3)  10 (6.9)  67 (46.5)  24 (16.7)  
South Asia 148 56 (39.7)  4 (2.8)  5 (3.5)  82 (58.2)  3 (2.1)  
East Asia/Pacific/Central Asia/Europe 28 20 (71.4)  4 (14.3)  4 (14.3)  3 (10.7)  4 (14.3)  
Africa 14 8 (57.1)  2 (14.3)  0 (0.0)  4 (28.6)  2 (14.3)  
America/Caribbean/Western 
Europe/Australia 
60 33 (55.0)  4 (6.7)  7 (11.7)  18 (30.0)  14 (23.3)  
Occupation   0.004  0.759  0.097  0.001  1.000 
Employed 413 194 
(47.0) 
 33 (8.0)  30 (7.3)  182 (44.1)  45 (10.9)  
Other 42 10 (23.8)  2 (4.8)  0 (0.0)  30(71.4)  4 (9.5)  
Income   0.156  0.701  0.293  0.010  0.026 
<5000 AED 33 9 (27.3)  1 (3.0)  2 (6.1)  23 (69.7)  2 (6.1)  
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Table 4.11: Knowledge by prescription advice (Continued) 
Variables All 
(455) 
Self 
(n=204) 
P 
Value 
Relative 
(n=35) 
P 
Value 
Internet 
(n=30) 
P 
Value 
Prescribed 
(n=212) 
P 
Value 
Health 
professional 
(n=49) 
P 
Value 
5000-<10000 AED 149 67 (45.0)  10 (6.7)  7 (4.7)  72 (48.3)  8 (5.4)  
>10000-20000 AED 153 75 (49.0)  13 (8.5)  15 (9.8)  59 (38.6)  22 (14.4)  
>20000 AED 120 53 (44.2)  11 (9.2)  6 (5.0)  58 (48.3)  17 (14.2)  
Education   <0.001  0.123  0.967  <0.001  0.385 
≤ Higher Diploma 92 29 (31.5)  11 
(12.0) 
 6 (6.5)  52 (56.5)  11 (12.0)  
Bachelor 245 101 (41.2)  19 (7.8)  17 (6.9)  123 (50.2)  22 (9.0)  
Master/PhD 118 74 (62.7)  5 (4.2)  7 (5.9)  37 (31.4)  16 (13.6)  
Health insurance coverage   0.326  1.00  0.558  0.022  0.030 
Yes 403 184 (45.7)  31 (7.7)  28 (6.9)  180 (44.7)  48 (11.9)  
No 52 20 (38.5)  4 (7.7)  2 (3.9)  32 (61.5)  1 (1.9)  
Body Mass Index – kg/m2  27.4±0.3 0.043 25.9±1.0 0.157 25.6±0.8 0.089 26.9±4.4 0.885 26.7±0.6 0.695 
Body Mass Index – cat   0.069  0.089  0.027  0.126  0.604 
Normal 165 71 (43.0)  19 
(11.5) 
 18 
(10.9) 
 70 (42.4)  21 (12.7)  
Overweight 198 82 (41.4)  11 (5.6)  8 (4.0)  103 (52.0)  20 (10.1)  
Obese 92 51 (55.4)  5 (5.4)  4 (4.3)  39 (42.4)  8 (8.7)  
Smoking status   0.128  0.096  0.022  0.155  0.742 
Non-smoker 326 135 (41.4)  21 (6.4)  21 (6.4)  160 (49.1)  36 (11.0)  
Past smoker 27 15 (55.6)  5 (18.5)  5 (18.5)  11 (40.7)  2 (7.4)  
Current occasional smoker 34 19 (55.9)  4 (11.8)  3 (8.8)  10 (29.4)  2 (5.9)  
Current regular smoker 68 35 (51.5)  5 (7.3)  1 (1.5)  31 (45.6)  9 (13.2)  
Any allergy   0.690  1.00  1.000  0.693  1.00 
Yes 57 27 (47.4)  31 (7.9)  3 (5.3)  183 (46.3)  6 (10.5)  
No 395 176 (44.6)  4 (7.0)  37 (6.8)  28 (49.1)  43 (10.9)  
Visited to a doctor in last 12 
months 
  0.008  0.062  0.001  0.014  0.137 
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Table 4.11: Knowledge by prescription advice (Continued) 
 
Variables All 
(455) 
Self 
(n=204) 
P 
Value 
Relative 
(n=35) 
P 
Value 
Internet 
(n=30) 
P 
Value 
Prescribed 
(n=212) 
P 
Value 
Health 
professional 
(n=49) 
P 
Value 
Did not visit doctor in last 12 
months 
79 47 (59.5)  9 (11.4)  13 
(16.5) 
 25 (31.7)  4 (5.1)  
Less than monthly 342 146 (42.7)  21 (6.1)  14 (4.1)  170 (49.7)  40 (11.7)  
1-3 times a month/At least once a 
week 
34 11 (32.3)  5 (14.7)  3 (8.8)  17 (50.0)  5 (14.7)  
Diseases            
Diabetes Mellitus   0.099  0.244  1.000  0.002  0.502 
Yes 25 7 (28.0)  0 (0.0)  0 (0.0)  19 (76.0)  1 (4.0)  
No 430 197 (45.8)  35 (8.1)  30 (6.7)  193 (44.9)  48 (11.2)  
High cholesterol levels   0.196  1.00  3.96  0.089  0.606 
Yes 9 2 (22.2)  0 (0.0)  0 (0.0)  205 (46.0)  0 (0.0)  
No 446 202 (45.3)  35 (7.9)  30 (7.0)  7 (77.8)  49 (11.0)  
Cardiovascular disease   0.591  0.614  0.613  0.276  0.381 
Yes 14 5 (35.7)  0 (0.0)  0 (0.0)  9 (64.3)  0 (0.0)  
No 441 199 (45.1)  35 (7.9)  30 (6.8)  203 (46.0)  49 (11.1)  
Medicines   <0.001  0.156  0.830  <0.001  0.407 
Yes 115 35 (30.4)  5 (4.3)  8 (7.0)  73 (63.5)  39 (11.5)  
No 340 169 (49.7)  30 (8.8)  22 (6.5)  139 (40.9)  10 (8.7)  
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4.1.9 Risk assessment of health supplement use 
Respondents’ HS use were assigned a risk score based on the activity of the 
ingredient and the frequency of use. Scores ranged from one to a maximum of 12. Data 
were available to assign scores to 408 HS users in this way. Scores were then arranged 
into three categories or tertiles. Tertile one represented HS use with the lowest risk, 
tertile two represented HS use with an intermediate risk, while tertile three represented 
HS use with the highest risk. Overall, 148 (36.3%) of participants consumed HS with 
ingredients within the lowest risk tertile, 219 (53.7%) of participants consumed HS 
with ingredients within the intermediate risk tertile, and 41 (10.1%) of participants 
consumed HS with ingredients within the highest risk tertile. HS use in each risk tertile 
is shown in Table 4.12 by selected socio-demographic and other characteristics of the 
respondents.  
Gender, income, smoking status, having allergy, having high cholesterol, HS 
capsule-form consumption, purchasing from clinic are significantly associated with 
HS risk.  Compared to males, females were more likely to consume HS in the 
intermediate risk tertile. Those earning between 5,000 and 10,000 AED were more 
likely to be in the higher risk categories. Past smokers, those who consumed their HS 
in capsule-form and those who obtained their HS from a clinic were more likely to be 
in the high risk tertile, while those with an allergy or high cholesterol were more likely 
to be in the low risk tertile, although numbers were small. 
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Table 4.12: Health supplement risk tertile by characteristics of participants 
Variables Lowest 
Tertile 
n% 
Middle 
Tertile 
n% 
Highest 
Tertile 
n% 
P 
Value 
All 148 
(36.3) 
219 
(53.7) 
41 (10.1)  
Age – years 39.0±8.7    
Gender Male 120 
(42.4) 
129 
(45.6) 
34 (12.0) <0.001 
Female 28 (22.4) 90 (72.0) 7 (5.6) 
Marital Status Married 131 
(38.8) 
174 
(51.5) 
33 (9.8) 0.064 
Other 17 (24.3) 45 (64.3) 8 (11.4) 
Nationality Emirati 27 (41.5) 35 (53.9) 3 (4.6) 0.239 
Non-Emirati 121 
(35.3) 
184 
(53.6) 
38 (11.1) 
Occupation Employed 134 
(36.6) 
192 
(52.5) 
40 (10.9) 0.148 
Other 14 (33.3) 27 (64.3) 1 (2.4) 
Income (AED) <5000 16 (55.2) 12 (41.4) 1 (3.4) 0.042 
5000-<10000 33 (25.8) 77 (60.2) 18 (14.1) 
10000-20000 54 (39.1) 71 (51.5) 13 (9.4) 
>20000 45 (39.8) 59 (52.2) 9 (8.0) 
Education ≤ Higher 
Diploma 
38 (46.9) 35 (43.2) 8 (9.9) 0.093 
Bachelor 80 (35.9) 124 
(55.6) 
19 (8.5) 
Master/PhD 30 (28.9) 60 (57.7) 14 (13.5) 
Health insurance coverage Yes 136 
(25.5) 
189 
(63.8) 
36 (10.6) 0.261 
No 12 (37.7) 30 (52.3) 5 (10.0) 
BMI – kg/m2 (cat) Normal 51 (38.6) 70 (53.0) 11 (8.3) 0.261 
Overweight 62 (32.3) 105 
(54.7) 
25 (13.0) 
Obese 35 (41.7) 44 (52.4) 5 (6.0) 
Smoking status Non-smoker 95 (33.0) 167 
(58.0) 
26 (9.0) 0.049 
Past smoker 8 (33.0) 10 (41.7) 6 (25.0) 
Current 
occasional 
15 (50) 12 (40.0) 3 (10.0) 
Current regular 30 (45.5) 30 (45.5) 6 (9.0) 
Any allergy Yes (n=53) 29 (54.7) 20 (37.7) 4 (7.5) 0.013 
No (n=352) 117 
(33.2) 
199 
(56.5) 
36 (10.2) 
Visited to a doctor in last 12 
months 
No doctor 
visits in last 12 
months 
23 (34.3) 39 (58.2) 5 (7.5) 0.524 
Less than 
monthly 
119 
(37.8) 
163 
(51.7) 
33 (10.5) 
At least once a 
month/week 
6 (23.1) 17 (65.4) 3 (11.5) 
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Table 4.12: Health supplement risk tertile by characteristics of participants 
(Continued) 
Variables Lowest 
Tertile 
n% 
Middle 
Tertile 
n% 
Highest 
Tertile 
n% 
P 
Value 
Diabetes Mellitus Yes 10 (43.5) 11 (47.8) 2 (8.7) 0.760 
No 138 
(35.8) 
208 
(54.0) 
39 (10.1) 
High cholesterol Yes (n=8) 7 (87.5) 1 (12.5) 0 (0.0) 0.010 
No (n=400) 141 
(35.3) 
218 
(54.4) 
41 (10.3) 
Cardiovascular disease Yes 4 (30.8) 8 (61.5) 1 (7.7) 0.914 
No 144 
(36.5) 
211 
(53.4) 
40 (10.1) 
Medicines Yes (n=109) 32 (29.4) 68 (62.4) 9 (8.3) 0.103 
No (n=299) 116 
(38.8) 
151 
(50.5) 
32 (10.7) 
Adverse events Yes (n=13) 8 (61.5) 5 (38.5) 0 (0.0) 0.144 
No (n=395) 140 
(35.4) 
214 
(54.2) 
41 (10.4) 
Forms of 
HS 
Tablet Yes (n=349) 130 
(37.2) 
189 
(54.1) 
30 (8.6) 0.055 
No (n=59) 18 (30.5) 30 (50.9) 11 (18.6) 
Capsule Yes (n=47) 10 (21.3) 21 (44.7) 16 (34.0) <0.001 
No (n=361) 138 
(28.2) 
198 
(54.9) 
25 (6.9) 
Powder Yes (n=40) 16 (40.0) 22 (55.0) 2 (5.0) 0.588 
No (n=368) 132 
(35.9) 
197 
(53.5) 
39 (10.6) 
Purchase 
of HS 
Pharmacy Yes (n=360) 133 
(36.9) 
193 
(53.6) 
34 (9.4) 0.474 
No (n=48) 15 (31.3) 26 (54.2) 7 (14.6) 
Clinic Yes (n=43) 16 (37.2) 18 (41.9) 9 (20.9) 0.041 
No (n=365) 132 
(36.2) 
201 
(55.1) 
32 (8.8) 
Nutrition shop Yes (n=28) 7 (25.0) 17 (60.7) 4 (14.3) 0.366 
No (n=408) 141 
(37.1) 
202 
(53.2) 
37 (9.7) 
Advise of 
using HS 
Self Yes (n=175) 66 (37.7) 87 (49.7) 22 (12.6) 0.222 
No (n=233) 82 (35.2) 132 
(56.7) 
19 (8.1) 
Friend/Relative Yes (n=27) 11 (40.7) 15 (55.6) 1 (3.7) 0.616 
No (n=381) 137 
(36.0) 
204 
(53.4) 
40 (10.5) 
Internet Yes (n=22) 7 (31.8) 11 (50.0) 4 (18.2) 0.424 
No (n=386) 141 
(36.5) 
208 
(53.9) 
37 (9.6) 
Prescribed Yes (n=198) 76 (38.4) 106 
(53.5) 
16 (8.1) 0.381 
No (n=210) 72 (34.3) 113 
(53.8) 
25 (11.9) 
Health 
Professional 
Yes (n=45) 13 (28.9) 27 (60.0) 5 (11.1) 0.550 
No (n=363) 135 
(37.2) 
192 
(52.9) 
36 (9.9) 
 
124 
 
 
Figure 4.1 shows a flow chart of the total number of participants in the n survey. 
Among a total of 1203 participants 455 consumed HS of whom 13 experienced adverse 
events. Of those who experienced adverse events, three visited a healthcare centre 
which proved the adverse event to be associated with the consumption of HS. All three 
reported the adverse events. 
 
Figure 4.1: Structure of observed outcomes for population survey 
 
4.2 Results of Second Study: Cross-Sectional Study Among Healthcare 
Professionals 
This cross-sectional study was conducted among physicians and pharmacists in 
Dubai both registered with Dubai Health Authority and those working in the private 
sector. A total of 427 participants responded to the on-line questionnaire. Of those, 
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205 (48%) were pharmacists, 49 (11.47%) were physicians and 173 (40.5%) were 
other healthcare professionals. 
4.2.1 Demographic characteristics 
Among the 427 respondents, there was a relative equality of numbers in terms 
of gender: 221 (51.75%) were male and 206 (48.2%) were female. Mean age was 35.43 
(SD ±8.43) with a range of 22-67. The socio-demographic characteristics of 
participants are shown in Table 4.13. 
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Table 4.13: Demographic characteristics of healthcare professionals 
Demographic N (%) 
Age 
Mean age ± S.D 
(22 -67) 
(35.43±8.43) 
Gender 
Male 
Female 
 
221 (51.75%) 
206 (48.2%) 
Nationality 
Emirati 
Middle East/North Africa 
South Asia 
East Asia/Pacific 
Central Asia/Europe 
Africa 
Western Europe/North America/Australia 
Not specific 
 
69 (16.2%) 
47 (11%) 
260 (60.8%) 
32 (7.5%) 
1 (0.23%) 
12 (2.8%) 
2 (0.46%) 
4 (0.93%) 
Marital status 
Married 
Single 
Divorced 
Widow 
 
315 (73.77%) 
103 (24.12%) 
6 (1.41%) 
3 (0.7%) 
Employment status 
Government 
Private 
Self-employed 
 
161 (37.7%) 
264 (61.8%) 
2 (0.5%) 
Occupation 
Specialised physician 
Physician 
Pharmacist 
Assistant pharmacist 
Other 
 
32 (7.5%) 
17 (4.0%) 
192 (45.0%) 
13 (3%) 
173 (40.5) 
Work experience 
1-2 years 
3-4 years 
5-6 years 
Less than 1 year 
More than 6 years 
 
62 (14.5%) 
60 (14.1%) 
47 (11.0%) 
19 (4.4%) 
239 (56.0%) 
Insurance coverage 
Yes 
No 
 
405 (94.8%) 
22 (5.2%) 
Education 
Graduate 
Post graduate 
 
273 (63.9%) 
154 (36.1%) 
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4.2.2 Knowledge on health supplements 
Table 4.14 summarises healthcare professionals’ knowledge of HS, HS safety, 
HS adverse events and adverse event reporting.  Of the participants, 352 (82.4%) knew 
what HS are and 183 (42.9%) believed HS to beharmless. Around half, 192 (45.0%) 
knew what a reporting system was, but fewer could identify reporting systems either 
within the UAE or within their organization. Around 40% had attended educational 
sessions on HS and read journal articles, but only about a quarter knew how to report 
adverse events or had training on the process. 
Table 4.14: Descriptive data on healthcare professional’s knowledge 
Knowledge on HS N (%) 
Do you know what HS are (n=427) Yes 352 (82.4%) 
No 75 (17.5%) 
Do you agree with the statement that HS are harmless 
(n=427) 
Yes 183(42.9%) 
No 244 (57.1%) 
Do you know what reporting system is (n=427) Yes 192 (45.0%) 
No 235 (55%) 
Do you know about any existing reporting system in 
the UAE (n=192) 
Yes 68 (35.4%) 
No 124 (64.6%) 
Do you know about any AE reporting system in your 
organization (n=427) 
Yes 96 (22.5%) 
No 331 (77.5%) 
Do you know to whom you can report an AE (n=427) Yes 112 (26.2%) 
No 315 
(73.77%) 
Have you ever received any continuing education on 
HS products (n=427) 
Yes 191 (44.7%) 
No 236 (55.3%) 
Have you read a scientific article related to AE of HS 
in the last 6 months (n=427) 
Yes 189 (44.3%) 
No 238 (55.7%) 
Have you ever received training on how to report an 
AE (n=427) 
Yes 108 (25.3%) 
No 319 (74.7%) 
 
Table 4.15 shows that around two-thirds of respondents (277, 65%) reported that 
they knew of adverse events associated with HS use and could list common adverse 
events. 
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Table 4.15: Health supplement adverse events reported by respondents 
Adverse events N (%) 
Do you know about adverse events of HS 
(n=427) 
Yes 277 
(64.9%) 
 No 150 
(35.1%) 
Adverse events (n=277) 
Adverse event N (%) Adverse event N (%) 
Abdominal pain 179 (64.6%) Headache 120 
(43.32%) 
Anorexia 57 (20.57%) Hypertension 84 
(30.32%) 
Anxiety 59 (21.29%) Hypotension 47 
(16.96%) 
Chest pain 32 (11.55%) Muscle 
cramping 
54 
(19.49%) 
Convulsions 27 (9.74%) Muscle pain 35 
(12.63%) 
Dermatitis 65 (23.46%) Nausea 169 
(61.01%) 
Diarrhoea 179 (64.6%) Palpitations 89 
(32.12%) 
Dizziness 93 (33.57%) Pyrexia 13 
(4.69%) 
Dyspnea 25 (9.02%) Sedation 58 
(20.93%) 
Edema 45 (16.24%) Tingling 25 
(9.02%) 
Fatigue 70 (25.27%) Urticaria 94 
(33.93%) 
Hair loss 61 (22.02%) Vomiting 150 
(54.15%) 
Among the 191 healthcare professionals who reported that they have received 
one or more types of continuing education on HS products, 120 (63%) reported that 
they had official training courses, 118 (62%) reported that had workshops on product 
orientation, and 108 (56%) reported their continuing education on HS products through 
electronic learning.   
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4.2.3 Practice towards health supplements 
Table 4.16 summarises healthcare professionals’ practice with respect to selling, 
prescribing and dispensing HS, types of HS and dosage, record keeping and 
discussions with patients/consumers. 
A total of 232 respondents (54.3%) prescribed or dispensed HS. Most commonly 
these were vitamins, herbal supplements, and minerals. Tablets (n=165, or 71.12%), 
soft gels (n=160, or 68.96%), capsules (n=151, or 65.08%), chews/gummies (n=128, 
or 55.17%), chewable tablets (n=126, or 54.31%) and caplets (n=126, or 54.31%) were 
the most identified formulations. 41.81% of the participants stated that they had a 
system to record HS use. Most respondents (195, 85%) always or often discuss HS use 
with their patients/customers and product effect is the most discussed topic. The 
Internet was the most used source of information on HS. Literacy was cited as the most 
important barrier limiting discussion between practitioners and patients/customers. 
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Table 4.16: Descriptive data on healthcare professionals’ practice 
Practice N (%) 
Sell/prescribe/dispense HS at practice 
site (n=427) 
Yes 232 (54.3%) 
No 195 (45.7%) 
Types of HS prescribed (232) Dietetic 94 (40.50%) 
Herbal 149 (34.9%) 
Vitamin 221 (64.22%) 
Energy drink 46 (19.82%) 
Mineral 132 (30.9%) 
Food 84 (36.2%) 
Sport nutrition 86 (37.01%) 
Dosage forms of HS prescribed (n=232) Caplets 126 (54.31%) 
Chews/ Gummies 128 (55.17%) 
Gel 46 (19.82%) 
Liquid 102 (43.96%) 
Soft gels 160 (68.96%) 
Vegi-caps 112 (48.27%) 
Capsule 151(65.08%) 
Drink 56 (24.13%) 
Gel caps 49 (21.12%) 
Lozenges 52 (22.41%) 
Spray 31 (13.36%) 
Wafers 32 (13.79%) 
Chewable tablets 126 (54.31%) 
Drops 77 (33.18%) 
Granules 54 (23.27%) 
Powder 98 (42.24%) 
Tablet 165 (71.12%) 
Availability of a system to record HS 
use (n=232) 
Yes 97 (41.81%) 
No 135 (58.18%) 
Discussion with patients/ consumers on 
HS (n=232) 
Always 111 (47.84%) 
Often 86 (37.06%) 
Sometimes 30 (12.93%) 
Never 5 (2.15%) 
Discussion topic of HS use with 
patients/ customers (n=227) 
Product effect 208 (91.62%) 
Product AE 99 (43.61%) 
Product quality 165 (72.68%) 
Product price 91 (40.08%) 
Information sources of HS (n=227) Internet 186 (81.93%) 
Printed material 145 (63.87%) 
Multimedia 73 (32.15%) 
Barriers limiting discussing HS with 
patients/ customers (n=227) 
Literacy 100 (44.05%) 
Cultural ethics 45 (19.82%) 
Language 84 (37.0%) 
Social level 63 (27.75%) 
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Table 4.17 summarises respondents’ experience of HS adverse events. Of the 
232 who had prescribed HS, 55 (23.70%) of their patients/ customers had experienced 
an adverse event related to HS use. Of these, 39 (70.90%) occasionally or rarely 
encountered adverse events while 12 (21.8%) reported frequent encounters. Asthenia 
(weakness, lack of strength) was the commonest reported event followed by 
gastrointestinal symptoms. Of the 55 respondents who reported experience of patient 
adverse events, 24 (44%) never reported them. Only 10 (18%) always reported Patient 
adverse events. Most reports were made internally within the practitioner’s 
organization, usually to a more senior staff-member. Among the 232 who prescribed 
or dispensed HS, only 58 (25%) said they had access to reporting forms at work. 
4.2.4 Attitude towards health supplement 
Table 4.18 summarises respondents’ attitude towards the reporting of adverse 
events associated with HS use. Total 369 respondents (91%) agreed or strongly agreed 
that adverse events associated with HS use should be reported to a higher authority. 
The most common reasons given for not reporting was not knowing where to report 
and difficulty in confirming that an adverse event was related to HS use. There was 
good agreement on the importance of reporting and of the likely benefits of setting up 
a reporting system. There were concerns about possible legal problems, but most 
respondents were confident that they would be able to report an adverse event. 
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Table 4.17: Reported adverse event related to health supplement 
Reported AE related to HS N% 
Ever experiencing AE related to HS use in 
patients/customers during practice (232) 
Yes 55 (23.70%) 
No 177 
(76.29%) 
Frequency of encountering AE related to HS use (55) 
Once  16 (29.09%) 
Occasionally  39 (70.90%) 
AE N% AE  
Abdominal pain 25 (45.45%) Edema 1 (1.81%) 
Alopecia 4 (7.27%) Headache 14 (25.45%) 
Anorexia 5 (9.09%) Hypotension 2 (3.63%) 
Asthenia 55 (100%) Nausea 22 (40%) 
Chest pain 4 (7.27%) Pain 2 (3.63%) 
Convulsion 1 (1.81%) Pruritus 4 (7.27%) 
Dermatitis 7 (12.72%) Pyrexia 1 (1.81%) 
Diarrhea 18 (32.72%) Sedation 2 (3.63%) 
Dizziness 12 (21.81%) Urticaria 7 (12.72%) 
Dyspnea 5 (9.09%) Vomiting 14 (25.45%) 
How often have you 
recorded HS AE (55) 
Always 10 (18.18%) 
Never 24 (43.63%) 
Often 2 (3.63%) 
Sometimes 19 (34.54%) 
Which higher authority did 
you report HS AE (31) 
Ministry of Health 3 (9.67%) 
Senior physician 8 (25.80%) 
Pharmacist in-charge 23 (74.19%) 
Availability of AE 
reporting form at the work 
(232) 
Yes 58 (25%) 
No 138 
(59.48%) 
Don’t know 36 (15.51%) 
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Table 4.18: Descriptive data on healthcare professional’s attitude 
Attitude N (%) 
Reporting HS 
related AE to the 
higher authority 
(n=427) 
Strongly disagree 3 (0.7%) 
Disagree 5 (1.2%) 
Neutral 50 (11.7%) 
Agree 182 (42.6%) 
Strongly agree 187 (43.8%) 
Reason of not 
reporting AE 
(n=427) 
It’s not important 20 (4.7%) 
Don’t know where to report 172 (40.3%) 
Don’t know what is AE of HS 78 (18.3%) 
Concerned that the report is a false alert 38 (8.9%) 
Lack of time to investigate the case 76 (17.8%) 
Consider as extra work 12 (2.8%) 
Difficulty in confirming AE 139 (32.6%) 
Importance of 
reporting all AE 
of HS (n=330) 
No 3 (0.90%) 
Only when hospitalisation is needed 23 (6.96%) 
Only when it is life threatening 16 (4.84%) 
Yes (all) 288 (87.27%) 
Establishment of 
AE reporting 
system related to 
HS use (n=330) 
Definitely beneficial 271(82.12%) 
Not beneficial 1 (0.30%) 
Not sure 24 (7.27%) 
Somewhat beneficial 34 (10.30%) 
Concerning 
about legal 
problems of 
reporting AE 
(n=330) 
Definitely 104 (31.51%) 
Definitely not 21 (6.36%) 
Not 33 (10%) 
Not sure 89 (26.96%) 
Somewhat 83 (25.15%) 
Feeling confident 
when reporting 
AE (n=330) 
Definitely 209 (63.33%) 
Definitely not 1 (0.30%) 
Not 5 (1.51%) 
Not sure 31 (9.39%) 
Somewhat 84 (25.45%) 
 
4.2.5 Overall knowledge, attitude and practice 
Based on the questions in Table 4.19, a summary score was created for the KAP 
of respondents. A correct option scored 1, an incorrect response zero. A total score of 
10 was obtainable. For all study participants (427), KAP scores were normally 
distributed (see Figure 4.2) with a mean score of 4.85 (standard deviation ± 1.88). 
Scores were grouped into three categories: good (>7), fair (5-6) and poor (0-4). 
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(Olowokere et al., 2014). Overall, 78 (18.3%) respondents had good KAP, 166 (39%) 
had fair KAP, while 166 (40%) had poor KAP. 
Table 4.19: Knowledge, attitude, and practice assessment 
KAP Items N% Correct 
answer 
Knowing what HS are 352 (82.4%) 
Whether HS are harmless 244 (56.7%) 
Knowledge about adverse events of HS 277 (64.9%) 
Definition of reporting system 192 (45.0%) 
Knowing any AE reporting system in organization 96 (22.5%) 
Knowing to whom reporting AE 112 (26.2%) 
Receiving any continuing education on HS 191 (44.7%) 
Reading scientific article related to AE of HS in the last 6 
months 
189 (44.3%) 
Receiving training on how to report an AE 108 (25.3%) 
Reporting HS related AE to higher authority/personnel 369 (86.42%) 
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Figure 4.2: Distribution of healthcare professionals’ knowledge, attitude and practice 
score 
4.2.6 Factors associated with knowledge, attitude and practice score 
Table 4.20 summarises the association between KAP scores and selected socio-
demographic factors. Scores were significantly higher among non-UAE nationals 
compared to UAE nationals, among physicians and pharmacists compared to other 
healthcare practitioners and among practitioners with six or fewer years of experience 
compared to those with more than six years of experience. No association was found 
between KAP scores and age, marital status, government/private employment status 
or graduate/non-graduate educational level. 
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Table 4.20: Factors associated with KAP score 
KAP Score 
 Mean     ± (SD) P-Value 
Age 35.43   ±(8.428) 0.113 
Gender 
Male 4.9      ±(1.82) 0.352 
Female 4.76     ±(1.92)  
Nationality 
UAE national 4.14    ±(2.1) 0.001 
Non-UAE national 4.98   ±(1.81)  
Marital status 
Single 4.59   ±(1.81) 0.141 
Married 4.91   ±(1.91)  
Employment status 
Government 4.62    ±(2.2) 0.051 
Private 4.98    ±(1.7)  
Occupation  
Physicians 5.5   ±(0.264) 0.000 
Pharmacists 5.1   ±(0.129)  
Other healthcare 4.4   ±(0.140)  
Work experience  
Six year and less 5.04   ±(1.97) 0.017 
More than six years 4.6   ±(1.7)  
Education  
Graduate 4.78   ±(1.83) 0.361 
Post Graduate 4.96   ±(1.91)  
4.2.7 Comparisons between occupational groups 
Table 4.21 summarises the experience of HS related adverse events among 
various occupational sub-groups making up the sample. Most of those reporting 
adverse events (46/55, 84%) were pharmacists. Generally, all occupational groups 
agreed or strongly agreed that adverse events should be reported. 
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Table 4.21: Experience of health supplement related adverse events among various 
occupational sub-groups 
 All 
N=427 
Pharmacis
t 
N=205 
Physician 
N= 49 
Others 
N= 173 
Ever experiencing AE 
related to HS use in 
patients/customers 
during practice 
N= 232 
 
55 (23.7%) 
N=189 
 
46 (24.3%) 
N=18 
 
4 (22.2%) 
N=25 
 
5 (20%) 
Frequency of 
encountering AE 
related to HS use 
 
N=55 
 
N=46 
 
N=4 
 
N=5 
Once 16 
(29.09%) 
13 (28.3%) 0 3 (60%) 
Occasionally 39 
(70.90%) 
33 (71.7%) 4 (100%) 2 (40%) 
Frequency of 
recording HS AE  
N=55 N=46 N=4 N=5 
Always 10 
(18.18%) 
7 (15.2%) 1(25%) 2 (40%) 
Never 24 
(43.63%) 
22 (47.8%) 1(25%) 1 (20%) 
Often 2 (3.63%) 2 (4.3%) 0 0 
Sometimes 19 
(34.54%) 
15 (32.6%) 2 (50%) 2 (40%) 
Reporting HS related 
AE to higher authority 
 
N= 427 
 
N=205 
 
N=49 
 
N= 173 
Strongly disagree 3 (0.7%) 1(0.48%) 0 2 
(11.5%) 
Disagree 5 (1.2%) 1 (0.48%) 0 4 (2.3%) 
Neutral 50 (11.7%) 21 
(10.24%) 
7 (14.3%) 22(12.7
% 
Agree 182 
(42.6%) 
96 
(46.83%) 
24 
(48.9%) 
62(35.8
% 
Strongly agree 187 
(43.8%) 
86 
(41.95%) 
18 
(36.7%) 
83(47.9
% 
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Chapter 5: Discussion 
5.1 Introduction 
This dissertation reports findings from two large cross-sectional studies that 
were designed and carried out in Dubai to quantify HS use and any related adverse 
events. The first study consisted of a computer assisted personal interview conducted 
by telephone and involved 1,203 Dubai residents. The study investigated HS 
consumption, knowledge and the reporting of any HS related adverse events. The 
second study used an on-line questionnaire to assess HS knowledge, HS related 
adverse event knowledge, as well as knowledge, attitude and practice (KAP) among 
427 Dubai healthcare professionals. The stimulus for this research arose from the 
writer’s work with consumer safety in Dubai Municipality, a strongly held belief of 
the public health importance of HS use in Dubai and the need to raise awareness among 
healthcare professionals to improve patient safety. It is believed that no similar study 
has previously been carried out in UAE. 
5.2 Key Results 
5.2.1 First study: survey among Dubai population 
In the general population sample, the prevalence of ever having used HS was 
38% and the prevalence of current use was 31%. These levels were similar to findings 
from studies in other countries. There are few data on HS use and adverse events in 
the UAE. Although in one study, conducted among university students, the 
consumption rate of HS was 39%. (Alhomoud et al., 2016). In one recent study 
conducted among the female college students in Saudi Arabia 76.6% of the 
participants were using HS (Alfawaz et al., 2017). A cross-sectional household survey, 
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conducted among Saudi residents of the Riyadh region resulted with 73% of alternative 
medicines which includes herbal supplements (Al-faris et al., 2008). The consumption 
rate of HS among students in Qatar was 49.6% (Mamtani et al., 2015) while the rate 
in the US has been increasing yearly and, in 2009, was 69% (Gahche et al., 2011).  
In one of the community based survey study conducted in the rural population 
of United States, 61% of the HS using participants were aware that HS products were 
not much regulated by controlling authorities and they were getting information about 
HS from internet, family / friends, physicians and pharmacists (Owens et al., 2014). In 
a study conducted among the US army soldiers, 48% of the respondents had 
knowledge about the HS and they were getting it from the leading magazines, 
friends/team mates, physicians/ para medical staff or from internet (Tharion et al., 
2004). It is difficult to assess overall knowledge and awareness of HS in the sample, 
but about half of HS users had been prescribed HS while 60% had received information 
about HS from a pharmacist, suggesting a reasonable level of awareness.  
Of the users surveyed, only 13 (3%) reported experiencing adverse events and 
most were not serious.  
The published literatures, identifies a high risk of adverse events associated with 
HS, especially herbal supplements, as they have a higher risk of contaminations, drug 
interaction and adulterations. Heavy metal contamination occurs mainly through the 
substandard cultivation and manufacturing practices. One study identified that the high 
dose consumption of heavy metals can cause several diseases, they may be 
carcinogenic or have adverse reproductive effects (Ejeatuluchukwu et al., 2011). 
Pesticide residue contamination which is occurring due to excessive use of pesticides 
during the cultivation of the herb and from lack of good agriculture practices (GAP). 
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Organochlorine pesticide residues which may lead serious health issues if consumed 
above the limit, have also been found in a number of Chinese herbal plants cultivated 
in China and sold in Hong Kong (Leung et al., 2005) 
A number of studies identified the adverse events associated with intended 
adulteration of HS for the best result with banned medicinal ingredients or medicinal 
ingredient which need medical supervision. In 2009, a division of the US Food and 
Drug Administration (FDA), the Internet and Health Fraud Team conducted an internet 
survey of HS products intended for sexual enhancement. They found that one third of 
such supplements which are marketed as dietary supplements to promote sexual 
activity and treat erectile dysfunction, despite having no disclosure of any medicinal 
content on the label, nevertheless contained the medicinal ingredient sildenafil, the 
active ingredient in Viagra (USFDA, 2009). In Germany, a research carried out by the 
government authority controlling HS products (Deutsches Aerzteblatt International) 
found 17 incidents of illness with vomiting, arterial hypertension, headache, malaise, 
nausea, chest pressure, dyspnea, tachycardia, insomnia and high fever associated with 
consumption of Chinese slimming products, such as slimming tea and slimming herbal 
capsules which have a banned medical ingredient sibutramine (Muller et al., 2009). 
A study conducted in United States by searching the published articles of herb-
drug interaction stated that common herbal remedies that produce adverse effects on 
the cardiovascular system include St. John’s wort, motherwort, ginseng, gingko biloba, 
garlic, grapefruit juice, hawthorn, saw palmetto, danshen, echinacea, tetrandrine, 
aconite, yohimbine, gynura, licorice, and black cohosh (Tachjian et al., 2010). In 2001, 
the FDA issued warnings and an import alert that herbal products are unsafe if they 
contain or are suspected to contain aristolochic acid (USFDA, 2001).  
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The literature suggests a rate of adverse events with HS consumption of up to 
10%. It was somewhat surprising, therefore, that the rate in this study was only 3%. 
One reason for the lower rate found here may be because of the better monitoring and 
control of HS availability in the Dubai market-place by the health authorities compared 
to other countries with higher reported rates. Other reasons may be because consumers 
are more knowledgeable and/or are using HS under pharmacist supervision. 
The findings that adverse events often go unreported is noteworthy and may be 
linked to the lack of an adverse events monitoring system in Dubai. One FDA-
commissioned study estimated that FDA receives less than 1% of all adverse events 
associated with dietary supplements. The study suggested that the factors that may 
contribute to under-reporting are that many consumers presume supplements to be 
safe, use these products without the supervision of a healthcare professional, and may 
be unaware that FDA regulates them (DHHS, 2001). This strengthens the case for 
raising awareness among consumers of the importance of reporting adverse events to 
the appropriate authority and of establishing an HS adverse events monitoring system. 
5.2.2 Second study: survey among healthcare professionals 
In the healthcare professionals’ survey, although most respondents knew what 
HS were and a fair proportion had participated in HS education or read journal articles 
about them, the composite knowledge score indicated that only 20% could be 
described as having good KAP towards HS use while 43% considered that HS were 
harmless. This low level of knowledge is of concern. The findings reported here are 
consistent with a study among community pharmacists in Ajman and Sharjah, UAE 
(Qassim et al., 2014). These results were also similar to findings in the US and Canada 
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where the knowledge towards HS was reported to be unsatisfactory (Kwan et al., 
2006). 
Previous studies have likewise obtained results consistent with this view in 
which poor knowledge about pharmacovigilance and ADRs reporting was reported 
among community pharmacists (Afifi et al., 2014; Vessal et al., 2009; Toklu & Uysal., 
2008; Bawazir, 2006; Li et al., 2004). However, some research findings are contrary 
to our results and showed good knowledge about how to report ADRs (Evans et al., 
2006; Zolezzi & Parsotam, 2005; Green et al., 2001). This difference may be due to 
different study area, different sample sizes with varied demographic characteristics 
and scales. 
In a further study in Gujarat, India, it was found that 65% of participants were 
knowledgeable about the terminology of adverse drug reactions (ADR) and 63% knew 
about the role of the National Pharmacovigilance Centre, but that 60% of community 
pharmacists considered all herbal products to be free from ADRs (Rathod & Panchal, 
2014). Moreover, several research studies have revealed gaps in information on HS 
and adverse event reporting among healthcare professionals (Cellini et al., 2013; 
Oshikoya & Awobusuyi, 2009). This poor knowledge about HS may indicate a need 
for improved education and training both as part of continuing professional 
development and within the basic curriculum. 
Nearly all healthcare professionals in this study agreed that reporting HS related 
adverse events was necessary, but only 40% said they did not know where to submit 
any report. The findings of US study (Cellini et al., 2013) reported that 70% of 
healthcare professionals do not know where to report the adverse events associated 
with HS.  
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Regarding the healthcare professionals knowledge about how and where to 
report ADR, our study showed that 60% of respondents were knowledgeable about the  
existence of national PV program. This is in accordance with 59.3% of Ting et al., 
(2010) study and 55.9% of Qassim et al., (2014) study,  whereas only 28% of 
healthcare professionals in SathviK et al., ( 2014) study were knowledgeable about  
ADR reporting system in the UAE. However, some research findings  are contrary to 
our results and showed more knowledge and awareness about local PV system 
(Bawazir, 2006; Van et al., 2002; Green et al., 2001). The implications of this factor 
results in that ADR go unnoticed and left unreported. 
Furthermore, a KAP survey among healthcare professionals in a teaching 
hospital in India reported that fewer than half (40%) of the respondents knew how to 
report ADRs (Bajaj & Kumar, 2013). A possible explanation for this negative practice 
in this study might be due to the fact the most healthcare professionals (77.5%) did not 
know to whom to report an adverse event. In addition, most of them (74.7%) had no 
training on how to report adverse events. Further, onerous demands of other work 
duties coupled within adequate professional conduct compromise the reporting rate of 
HS related adverse events. This may cause pharmacists to execute their services in too 
short a time. Therefore, there is an essential need for educational interventions among 
healthcare professionals to improve their knowledge and increase their reporting rate 
of HS. 
According to a study performed in Ras Al Khaimah, UAE, 18% of participant 
pharmacists indicated that they reported ADR to different set-ups and 6% of them 
reported ADR on at least two occasions. Moreover, only 3.6% of community 
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pharmacists from Ajman and Sharjah have submitted ADR report to Ministry of Health 
or pharmaceutical companies (Osama & Rana, 2014).   
About half of the sample prescribed or supplied HS to patients or consumers and, 
of these, about a quarter had experience of adverse events in their patients or 
consumers. These are lower than the results reported by another study conducted 
among military physicians, where 60% observed adverse events in their patients 
associated with HS (Cellini et al., 2013). In this study, only about one fifth of those 
experiencing an adverse event always reported these events.  
Experiences towards HS product related adverse events play an important role 
in the perception of ADR and influence how healthcare professionals will report 
ADRs. In the sample, the majority reported that they felt confident when reporting an 
adverse event, similar to findings in a study conducted among community pharmacists 
that assessed their knowledge and attitude about ADR. It showed a positive attitude 
towards ADR reporting and that respondents felt that they had an important role to 
play in ADR reporting (Qassim et al., 2014). 
Findings and reports from other studies have shown that a lack of knowledge 
was one of the important factors that prevented healthcare professionals from advising 
patients/customers on herbs and herbal preparation use in a positive way (Ghia & Jha, 
2013). These findings, however, differ from the findings in this study, where literacy 
and language were the most commonly identified barriers limiting discussion of HS 
products. Also, a study carried out in Saudi Arabia among community pharmacists 
concluded that a lack of time and a lack of reliable resources were the commonly 
identified barriers (Al-Arifi, 2013). The differences with the study reported here may 
be due to cultural differences. 
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5.3 Strengths 
An important strength of the first survey was that it used a large random sample 
of the general population and, therefore, there can be confidence that the findings are 
generalizable to the whole Dubai population. The sampling frame was a list of 
households and mobile telephone numbers registered to each of those households. 
Lists are regularly updated by the Dubai Statistics Centre. Households were randomly 
sampled from each of six geographical areas in Dubai. Telephone numbers were 
randomly sampled from each household. The sample obtained mirrors what is known 
of the population of Dubai in terms of age, gender, nationality, education and income. 
The sample size was estimated before the start of the study and was considered of 
adequate power. The questionnaire was adapted from published instruments and 
revised by experts to ensure content validity. It was accurately translated into Arabic 
and tested to ensure the clarity of the questions and the respondents' ability to provide 
accurate answers. Interviewers were trained to increase reliability and reduce 
interviewer bias. The CAPI telephone interview helped to ensure a good response rate, 
minimise interviewer effects and provided a good level of anonymity. The use of 
mobile telephone numbers rather than fixed telephone numbers further minimised 
selection bias since response was not open to those who just happened to be at home 
when calls were made. Finally, the entry of data directly into the database reduced the 
incidence of data entry errors and facilitated rapid data processing and analysis. 
The second survey was completed on-line by participants who were invited by 
e-mail to take part. Although the e-mail lists were complete and included the entire 
target population, as expected, the response rate was low, selection bias affecting the 
external validity of the results. Care was taken with the construction of the 
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questionnaire and anonymity of the respondents was assured so that there could be 
greater confidence in the internal validity of the results. Despite the lower response 
rate, the sample obtained still provided adequate power. 
5.4 Limitations 
There were several limitations to the study. First, as with any cross-sectional 
design, it is not possible to infer cause and effect or the direction of any associations 
between dependent and independent variables. While there is reasonable confidence 
in the generalisability of the results, selection and response bias may affect this. It has 
not been possible to compare non-responders with responders to investigate further 
this source of bias. Also, since the study was conducted in Dubai, it will not be directly 
generalizable to other Emirates. Although based on questionnaires that had been used 
in other studies, the questionnaires used in this study had not been separately validated. 
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Chapter 6: Conclusion 
This study included two cross-sectional surveys. The firststudy was a population 
based survey with a cross-sectional design which aimed to measure HS use in Dubai 
and the incidence of related adverse events. The survey was conducted by telephone 
with the participation of 1,203 residents of Dubai. The study attempted to gather 
information on HS consumption, local knowledge of HS, adverse events related to HS 
consumption, and the reporting habit of adverse events among the population in Dubai. 
The consumption of HS products is common in many countries such as the USA. 
As per the findings of this study, however, this is not the case in Dubai, UAE which 
has a consumption rate of only 38%. The degree of knowledge of participants about 
HS may play a vital role in the reduction of adverse events associated with HS use, as 
85.54% of participants in this study who had used HS had knowledge about HS. 
The second study was a survey based on a cross-sectional descriptive study using 
an on-line questionnaire to assess the levels of knowledge, attitude and practice (KAP) 
of Dubai healthcare professionals regarding HS products and any perceived related 
adverse events. The inspiration for this cross-sectional study came from a belief in the 
importance of raising the awareness of HS and any related adverse events among 
healthcare professionals to improve the quality of patient care. Regarding the 
healthcare professional survey, improper behaviour towards HS was one of the 
markers of poor knowledge. The present study revealed poor knowledge among 
healthcare professionals towards HS products and HS product related adverse events. 
Health professionals appear to be insufficiently knowledgeable about HS use and 
any related risks among their patients/consumers. Health professionals should be 
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attentive to any possible adverse health events from the use of such supplements. It is 
recommended that physicians and healthcare professionals include questions about the 
use of HS when acquiring a medical history from patients/consumers. It is further 
recommended that all HS producers clearly label ingredients and any known side 
effects of their use. Finally, and importantly, it is recommended that those considering 
the use of HS in future should have their lifestyle assessed by a healthcare professional 
prior to any such use. 
The overall attitude of healthcare professionals was perceived to be relatively 
negative. Few included HS in an adverse report to the related authorities as most did 
not know to whom to report such an event. This reporting behaviour highlights several 
issues and calls for a safety monitoring system for HS products. In addition, it is 
possible that consumers fail to tell their physicians or pharmacists about any adverse 
events arising from their use of HS. This means that the current situation may not 
reveal many HS-related adverse events. There is, therefore, a need for initiatives to 
raise awareness among professionals and HS users of an avenue for reporting adverse 
events. Ad hoc reporting systems are at present a mainstay of detecting signals of 
safety concerns associated with HS. If a suspected adverse event associated with HS 
does not reach the appropriate personnel, or if a proper reporting system is not in place, 
either through direct patient reporting or through reporting from healthcare 
professionals, then patient safety is at risk with resultant important implications for 
public health. 
6.1 Managerial Implications 
It is anticipated that this thesis will make a positive contribution to HS product 
research and reform debate in the UAE. By assessing the current consumption rate 
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among the population and the levels of knowledge of such products, by exposing some 
of the related adverse events and by shedding light on the KAP levels of healthcare 
professionals in Dubai, it is felt that an important knowledge gap has been filled. The 
resultant recommendations should help to focus future debate and decision making at 
the highest level within and among both national and local government departments 
and health authorities. 
6.2 Research Implications 
It is hoped that this study will provide a platform for future HS research in the 
UAE. The study may set the scene for an objective approach to a better understanding 
of HS products eligible for inclusion in the reporting system. The study also allows 
researchers to identify challenges through academic research and to make evidence-
based policy recommendations that support reporting system reform activities in the 
UAE. In addition, future research may be presented to policy makers at national and 
international meetings, seminars and conferences. 
In conclusion, this study offers a valuable contribution to HS, KAP, and 
reporting system research in the UAE, and allows for international comparisons and 
global benchmarking. 
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Appendices 
Appendix A: Prints of the Population-based Questionnaire 
Section A- Demographic Data 
Age  
Gender Male  □ Female  □ 
Marital status Married □ Single □ Divorced  □ Widow □ 
Nationality UAE national 
□ 
Non UAE national □   (Specify ……………..) 
Occupation Student  □     Employed  □     Non-employed  □    Retired  □ 
Health insurance 
coverage 
Yes  □ No  □ 
Income < 5000  
AED □ 
5000 - < 
10000 AED □ 
10000 - < 20000 
AED □ 
20000 > AED □ 
Education  Less than high 
school □ 
High school 
□ 
Graduate □ Post graduate □ 
Weight (kg)  
Height (cm)  
 
 
Section B- Health and Lifestyle 
1 Do you have any allergy? 
Yes   □   (if yes, please choose from 
below options)     
No □ Don’t know □ 
Food □ Drug □ Aerosol □ Contact □ Other □  Specify  
 
2 How frequently have you visited a doctor in the past 12 months? 
 
At least once a 
week 
□ 1-3 times a 
month 
□ Less than 
monthly 
□ Never □ 
 
3 Have you ever been diagnosed with any chronic medical condition? (you can choose 
more than one answer) 
 
Respiratory disease No  □ Yes      □ Specify (…) 
Skin disorder No  □ Yes      □ Specify (…) 
Disease of the digestive 
system 
No  □ Yes      □ Specify (…) 
Diabetes                                                                             No  □ Yes   □ Specify (…) 
Cardiovascular disease No  □ Yes      □ Specify (…) 
Cancer                                                                                No  □ Yes      □ Specify (…) 
Other                                                                                No  □ Yes    □ Specify (…) 
 
4 Have you taken prescription drugs in the past month? 
Yes  □   Specify    (………)    No □ Don’t know □       
 
5 Do you smoke? 
Every day  □     Occasionally   □ In the past  □          Never  □        
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Section C- Health Supplements Consumption 
 
1 
Do you know what health supplements are? 
Yes □                                                       No □  
 
2 
Have you ever used health supplement? (if your answer is “Currently”, please proceed to 
question C4, if your answer is “Never”, please proceed to the last question of the 
questionnaire) 
 Currently  □ In the past   □  Never   □ 
 
 
3 
Why did you discontinue using any health supplements? (you can choose more than one 
answer) 
Allergic reactions □ Serious skin disorders 
□ 
Cost  □ Others □ Specify (…) 
 
 
 
4 
For how long have you been using / had you used health supplement? 
Less than a 
month □ 
More than a month 
but less than a year □ 
 
1-5 years □  > 5 years □ Don't know 
□ 
 
 
5 
How frequently do/did you use health supplement? 
Daily or 
almost daily □ 
1-4 times a 
week □ 
1-3 times a 
month □ 
Rarer than 
monthly 
through 
the year □  
Seasonally 
□ 
Don't 
know □ 
 
 
6 
Which categories of health supplements do /did you use? (you can choose more than one 
answer) 
 
Vitamin  □      Mineral □       Herbal  □      Sport nutrition  □     Energy drink    □      Dietetic 
food  □             Others □   Specify (…………………)        
      
 
 
7 
 
 
 
 
 
 
 
 
What is the form of the used product(s)? (you can choose more than one answer) 
 
Tablet 
□ 
Capsule 
□ 
Wafers 
□ 
Powder 
□ 
Gel 
□ 
Chews/ 
Gummy 
□ 
Drops 
□ 
Caplet 
□ 
Chewable 
tablets 
□ 
Granules 
□ 
Drink 
□ 
Spray 
□ 
Lozenges 
□ 
Soft 
gels 
□ 
Vegicaps 
□ 
Gel 
caps 
□ 
Liquid 
□ 
Don’t 
know 
□ 
 
 
8 
Which health supplement ingredient(s) do/did you use? (you can choose more than one 
answer) 
Alfalfa □ Amino Acids □ Bee Pollen □ 
Bilberry/Eyebright 
Combination 
□ 
Caffeine, 
Multicomponent 
□ Calcium □ 
Calcium & Magnesium □ Calcium & Vitamin □ Cayenne Pepper □ 
Chondroitin □ 
Chromium 
(Chromium 
Picolinate) 
□ 
Cimicifuga 
Racemosa 
□ 
Conjugated Linolenic 
Acid 
□ Creatine □ Damiana Folia □ 
Don’t Know □ Echinacea □ Ephedra □ 
Fish Oils □ Folate (Folic Acid) □ Fructus Cynosbati □ 
Garlic □ 
Gentian, Multi-
Component 
□ Ginger □ 
Ginkgo Biloba 
□ 
Glandular Extract, 
Multicomponent 
□ Glucosamine □ 
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Grape Seed Extract 
□ 
Guarana □ 
Herbal Caffeine, 
Alone 
□ 
Iron (Ferrous Xxxate) □ Kelp □ L-Carnitine □ 
L-Cysteine □ Lecithin □ Licorice □ 
L-Methionine □ Lutein □ Lycopene □ 
Lysine □ Magnesium □ Melatonin □ 
Methylsulfonyl Methane 
□ 
Morinda Citrifolia 
(Noni) 
□ Oxymatrine □ 
Panax Ginseng □ Parsley □ Potassium □ 
Pygeum Africanum □ Royal Jelly □ Saw Palmetto □ 
Saw Palmetto (Topical) □ Selenium □ Siberian Ginseng □ 
Spirulina, 
Multicomponent □ 
St. John’s Wort □ 
St. John’s Wort, 
Multicomponent 
□ 
Tryptophan □ Vitamin B6 □ Vitamin B12 □ 
Vitamin C (With Or 
Without Rose Hips) □ 
Vitamin D □ Vitamin E □ 
Vitamin E, 
Multicomponent □ 
Vitamins A & D □ Yohimbe, Alone □ 
Yohimbe, 
Multicomponent 
□ 
Zinc (Zinc 
Gluconate) 
□ 
Others Specify 
(…….) 
 
□ 
 
 
9 
For what reason do/did you take health supplements? (you can choose more than one 
answer) 
 
Body building   □ Control aging  □ Control anemia □ 
Control blood 
pressure  
□ Control cholesterol 
level 
□ Detoxify □ 
Digestive □ Energy booster □ Hormone 
therapy  
□ 
Immune booster  □ Improve overall 
health 
□ Insomnia □ 
Memory 
improvement  
□ Menopausal □ Mental alertness  □ 
Mood alteration  □ Organ health  
Specify 
(……………..) 
□ Pregnancy □ 
Prevent colds □ Prevent health 
problems Specify 
(……………..) 
□ Supplement my 
diet  
□ 
Weight 
management 
□ Others  
Specify (……..) 
 
□   
 
 
10 
Where do/did you purchase health supplement(s)? (you can choose more than one answer) 
Pharmacy □      Clinic □       Gym □       Nutrition shops □         Supermarket □   Other □ 
Specify (…….….) 
     
 
11 
How many health supplement products have you ever used? 
 
1-2 □ 3-5 □ 6-10 □ > 10 □ 
 
 
12 Enter the full name of health supplement(s) you have used, including brand name. 
Supplement name(s) (……………………….……………….)                      
Don't know □ 
 
 
 
 
173 
 
 
Section D- Information about Health Supplement Products 
 
1 
Who advised you to take health supplements? (you can choose more than one 
answer) 
Self-
recommendation 
□            
Friends/ 
Relatives  
□ 
Advertisement    
□      
Internet  
□  
By prescription           
□ 
Health care personnel (nurse, etc.)            
□    
Other  □  
Specify 
(………...)  
    
 
 
2 
How many times have health supplements been prescribed for you by your health 
care practitioner? 
Once  □                             Twice  □               Several times     □                            
Never   □ 
 
3 
Where do you seek health supplements product information? (you can choose more 
than one answer) 
Pharmacy  □        Physician □           Producer helpline □                      Internet □   
Government call center □     Relatives / Friends □          Other □  Specify (...)  
 
 
4 
Do you find sufficient information on the label of health supplement products? 
Very informative  □                  Somewhat informative □     Not informative  □          
Don’t read the label  □ 
    
 
5 
Do you think nutrition information on health supplement products is useful? 
Yes  □                                            No  □ 
 
6 
Which label information concerns you? (you can choose more than one answer) 
      
Ingredients 
□ 
Indication 
□ 
Prescribed 
dosages □ 
Adverse 
reactions □   
  Product 
durability □ 
Dietary  
sources of 
nutrients □ 
Claims □ Precautions □ Dosing instructions □           
None □ 
 
 
7 
Do you follow recommended label information? 
Always  □                 Often □             Sometimes □                                 Never  □    
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Section E- Adverse Events Related to Health Supplement Consumption 
 
1 
Have you ever experienced any adverse event related to health supplement use? (if 
no, please proceed to the last question of the questionnaire) 
 Yes  □                                                        No  □                                       
 
2 
Which adverse event of health supplement use have you ever experienced? (you can 
choose more than one answer) 
 
Abdominal 
pain  
□ Anorexia             □ Anxiety                □ Chest pain           □ Convulsions        □
Dermatitis           □ Diarrhea              □ Dizziness             □ Dyspnea              □ Edema                 □
Fatigue                □ Hair loss            □ Headache           □ Hypertension       □ Hypotension      □ 
Muscle 
cramping 
□ Muscle 
pain       
□ Nausea              □ Palpitations         □ Pyrexia             □ 
Sedation            □ Tingling            □ Urticaria                □ Vomiting           □ Other     □ 
    Specify  
(……..……...) 
     
 
 
3 
What was the severity of the adverse events? (you can choose more than one answer) 
 
Mild    □   Moderate   □   Severe □            Life-threatening □ 
 
4 
How frequently have you encountered adverse events due to health supplement 
consumption? 
 
Once □ Occasionally □ Frequently □  
     
 
 
 
5 
What was the onset time of adverse events after consuming health supplement? (you 
can choose more than one answer) 
Less than 1 hour  □                    1 hour to 1 day □                         More than 1 day □  
 
 
6 
How was the relation between health supplement consumption and the adverse event 
confirmed? (you can choose more than one answer) 
Discontinued use ceased the effect  □      Not confirmed/personal opinion □            
Physician opinion □    Medical diagnosis without lab confirmation □               
Clinical test □   
 
7 
Which of the health supplement(s) you have used was suspected/confirmed to cause 
the adverse event(s)? 
Supplement name(s) (…………………….)                                  Don't know □ 
 
8 
When visiting your health care practitioner for any reason, has he/she ever asked you 
about your health supplement consumption? 
Yes  □                                                         No  □                                              
 
9 
How did the adverse event(s) resolve? (you can choose more than one answer)  (if you 
answered any but not “Hospitalization”, please proceed to question F1) 
Discontinued use by personal decision □      Discontinued use by medical advice □                      
Medical treatment □     Hospitalization □       Resolved spontaneously □              Still 
persists □          Other  □    Specify (………………..) 
 
10 
How long have you been hospitalized due to the adverse event(s)? (you can choose 
more than one answer) 
Less than a day □                       Few days   □                    More than a week  □  
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Section F- Reporting Adverse Events 
 
 
1 
Have you ever informed your physician about your health supplement 
consumption? 
Yes  □                                                         No  □                                           
 
2 
Have you ever reported an adverse event related to health supplement 
consumption? (if no, please proceed to the last question of the questionnaire) 
Yes  □                                                         No  □                                                                                  
 
3 
Where did you report the adverse event(s)? (you can choose more than one 
answer) 
Pharmacy □ Physician □ Producer helpline □ Internet □    Government call center □   
Hospital  □      Clinic  □      Police  □  Others □     Specify ( ……….) 
 
4 
What do you think about the establishment of a surveillance system of adverse 
events related to health supplement consumption? 
Definitely beneficial □   Somewhat beneficial □  Not sure □   Not beneficial □   
Definitely not beneficial□                                          
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Appendix B: Risk Assessment Module 
Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Alfalfa 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Low 
Low 
Low 
Low 
Low 
Low 
High 
High 
Low 
Low 
Medium 
High 
High 
Medium 
(1+2+2+2+2)/5 
= 
1.8 
Low 
(1+1+3+3+1)/5 = 
1.8 
 
Medium 
Medium 
Bilberry/ eyebright 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Low 
Low 
Negligible 
Negligible 
 
Low 
Low 
Medium 
Low 
Low 
Low 
Medium 
Medium 
Low 
Low 
(1+2+2+1+1)/5 
= 
1.4 
Negligible 
 
(1+2+2+1+1)/5 = 
1.4 
 
Low 
Low 
Garlic 
 
Short-term 
toxicity 
Negligible 
Negligible 
Low 
Medium 
Low 
Low 
(1+1+2+1+1)/5 
= 
(1+1+2+1+1)/5 = 
1.2 
Low 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
Negligible 
Negligible 
 
Medium 
Low 
Low 
Medium 
Low 
Low 
1.2 
Negligible 
 
 
Low 
Ginkgo Biloba 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Low 
Moderate 
Low 
Negligible 
Low 
Medium 
Medium 
High 
Low 
Low 
Medium 
High 
High 
Low 
 
(1+2+3+2+1)/5 
= 
1.8 
Low 
 
(1+2+2+3+1)/5 = 
1.8 
 
Medium 
Medium 
 
Grape Seed Extract 
 
Short-term side 
effects 
Long-term 
toxicity 
Interactions of 
medications 
Contamination of 
heavy metals 
Pesticides residue 
Negligible 
Negligible 
Low 
Negligible 
Low 
 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Medium 
Low 
Medium 
 
(1+1+2+1+2)/5 
= 
1.4 
Negligible 
 
(1+1+1+1+1)/5 = 
1 
 
Low 
 
Low 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Panax Ginseng 
 
Short-term side 
effects 
Long-term side-
effects 
Interactions of 
medications 
Contamination of 
heavy metals 
Pesticides residue 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Medium 
Low 
Low 
Medium 
Medium 
Medium 
Medium 
Medium 
(2+2+2+2+2)/5 
= 
2 
Low 
 
(1+1+2+1+1)/5 = 
1.2 
 
Low 
 
Medium 
 
Siberian Ginseng 
 
Short-term side 
effects 
Long-term side 
effects 
Interactions of 
medications 
Contamination of 
heavy metals 
Pesticides residue 
Negligible 
Negligible 
Moderate 
Negligible 
Negligible 
Low 
Low 
Medium 
Low 
Low 
Low 
Low 
High 
Low 
Low 
 
(1+1+3+1+1)/5 
= 
1.4 
Negligible 
 
(1+1+2+1+1)/5 = 
1.2 
 
Low 
 
Low 
 
Pygeum Africanum 
 
Short-term 
toxicity 
Long-term 
toxicity 
Low 
Low 
Negligible 
Negligible 
Low 
Low 
Low 
Low 
Medium 
Medium 
Low 
Low 
(2+2+1+1+2)/5 
= 
1.6 
Low 
(2+2+1+1+2)/5 = 
1.6 
 
Medium 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low Low Medium   
Saw Palmetto 
 
Short-term side 
effects 
Long-term side 
effects 
Interactions of 
medications 
Contamination of 
heavy metals 
Pesticides residue 
Low 
Moderate 
Moderate 
Low 
Low 
Low 
Medium 
Medium 
Low 
Low 
Medium 
High 
High 
Medium 
Medium 
(2+3+3+2+2)/5 
= 2.4 
 
Low 
 
(1+2+2+1+1)/5 = 
1.4 
 
Low 
 
 
 
 
Medium 
L-Cysteine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs, drug 
sensitivity 
Contamination 
with Heavy 
Metals 
Pesticide Residue 
Negligible 
Low 
Moderate 
Moderate 
Low 
Medium      Medium 
Medium 
Medium 
Low 
Medium 
Medium 
High 
High 
Medium 
(1+2+3+3+2)/5 
= 2.2 
 
Low 
 
(2+2+2+2+1)/5 = 
1.8 
 
Medium 
 
 
 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
L-Methionine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants. 
Pesticides residue 
Negligible 
Moderate 
Moderate 
Moderate 
Low 
Low 
Low 
Medium 
Low 
Low 
Low 
Medium 
High 
Medium 
Medium 
(1+3+3+3+2)/5 
=  2.4 
 
Low 
 
(1+1+2+1+1)/5 = 
1.2 
 
Low 
 
 
 
 
Medium 
Lysine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Low 
Low 
Low 
Low 
Medium 
Medium 
Low 
Low 
Low 
Medium 
Medium 
Medium 
Medium 
 
(1+2+2+2+2)/5 
=  1.8 
 
Low 
 
(1+2+2+2+2)/5 = 
1.8 
 
Medium 
 
 
 
 
Medium 
 
Methylsulfonyl Methane 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Negligible 
Negligible 
Negligible 
Negligible 
Negligible 
 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
 
(1+1+1+1+1)/5 
=  1 
 
Negligible 
 
(1+1+1+1+1)/5 
=  1 
 
Low 
 
 
 
 
Low 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Contamination 
with heavy metals 
Pesticides residue 
Chromium 
(ChromiumPicolinate) 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Moderate 
Moderate 
Moderate 
Low 
Low 
Medium 
Low 
Low 
Medium 
Low 
High 
Medium 
Medium 
Medium 
 
(1+3+3+3+2)/5 
=  2.4 
 
Low 
(1+2+1+1+2)/5 
=  1.4 
 
Low 
 
 
 
Medium 
 
Tryptophan 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Moderate 
Moderate 
Moderate 
Low 
Low 
Medium 
High 
High 
Medium 
Low 
High 
High 
High 
Medium 
(1+3+3+3+2)/5 
=  2.4 
 
Low 
(1+2+3+3+2)/5 
=  2.2 
 
Medium 
 
 
 
Medium 
Vitamin C 
 
Short-term 
toxicity 
Long-term 
toxicity 
Negligible 
Low 
Low 
NA 
Low 
High 
Medium 
NA 
Low 
High 
Medium 
NA 
(1+2+2)/3 
=  1.67 
 
Low 
(1+3+2)/3 
=  2 
 
Medium 
 
 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
NA 
 
NA 
 
NA 
 
 
Amino Acids 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Low 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
Low 
Medium 
Medium 
NA 
NA 
 
(1+2+2)/3 
=  1.67 
 
Low 
(1+1+2)/3 
=  1.33 
 
Low 
 
 
 
Medium 
 
 
Caffeine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
High 
Low 
NA 
NA 
Low 
Medium 
Medium 
NA 
NA 
Low 
EXTREME 
Medium 
NA 
NA 
(1+4+2)/3 
=  2 
 
Low 
(1+2+2)/3 
=  1.67 
 
Medium 
 
 
 
Medium 
 
Creatine 
 
Short-term 
toxicity 
Negligible 
Negligible 
Low 
Low 
Low 
Low 
(1+1+2)/3 
=  1.33 
(1+1+2)/3 
=  1.33 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Low 
NA 
NA 
Medium 
NA 
NA 
 
Medium 
NA 
NA 
 
Negligible 
 
 
Low 
 
Low 
 
Folate (Folic Acid) 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Negligible 
Low 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
 
(1+1+2)/3 
=  1.33 
 
Negligible 
 
(1+1+2)/3 
=  1.33 
 
Low 
Low 
 
Gentian 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
 
Moderate 
Moderate 
High 
Moderate 
High 
 
Medium 
Medium 
Medium 
High 
Medium 
 
High 
High 
High 
High 
Extreme 
(3+3+4+3+4)/5 
=  3.4 
 
Moderate 
 
(2+2+2+3+2)/5 
=  2.2 
 
Medium 
 
 
 
 
High 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Lecithin 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Negligible 
Negligible 
Low 
Low 
 
Low 
Low 
Low 
Low 
Medium 
Low 
Low 
Low 
Medium 
Medium 
(1+1+1+2+2)/5 
=  1.4 
 
Negligible 
 
(1+1+1+1+2)/5 
=  1.2 
 
Low 
 
 
 
 
Low 
 
Lutein 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Medium 
Medium 
Low 
Medium 
Medium 
Medium 
Medium 
 
(1+2+2+2+2)/5 
=  1.8 
 
Low 
 
(1+1+1+2+2)/5 
=  1.4 
 
Low 
 
 
 
 
Medium 
 
Royal Jelly 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Negligible 
Low 
Low 
Low 
Medium 
Low 
Low 
Medium 
Low 
Medium 
Low 
Medium 
Medium 
Medium 
High 
 
(1+2+2+2+3)/5 
=  2 
 
Low 
 
(1+1+2+1+2)/5 
=  1.4 
 
Low 
 
 
 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Contamination 
with heavy metals 
Pesticides residue 
Selenium 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
Moderate 
Moderate 
Moderate 
High 
Low 
Medium 
Medium 
Medium 
Medium 
Medium 
High 
High 
High 
Extreme 
(2+3+3+3+4)/5 
=  3 
 
Moderate 
 
(1+2+2+2+2)/5 
=  1.8 
 
Medium 
 
 
 
 
High 
 
Vitamin B6 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Negligible 
Negligible 
NA 
NA 
 
Medium 
Medium 
High 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
(1+1+1)/3 
=  1 
 
Negligible 
 
(2+2+3)/3 
=  2.33 
 
Medium 
 
 
 
 
Low 
 
Vitamin D 
 
Short-term 
toxicity 
Long-term 
toxicity 
Negligible 
Negligible 
Low 
NA 
High 
High 
Medium 
NA 
Medium 
Medium 
Medium 
NA 
(1+1+2)/3 
=  1.33 
 
Negligible 
(3+3+2)/3 
=  2.67 
 
High 
 
 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
NA NA NA    
Glucosamine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Moderate 
Negligible 
Negligible 
Medium 
Medium 
Medium 
Medium 
Medium 
 
Low 
Medium 
High 
Low 
Low 
(1+2+3+1+1)/5 
=  1.6 
 
Low 
 
(2+2+2+2+2)/5 
=  2 
 
Medium 
 
 
 
 
Medium 
 
L-Carnitine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Negligible 
Negligible 
Negligible 
 
High 
Low 
Medium 
Medium 
Medium 
 
Medium 
Medium 
Low 
Low 
Low 
(1+2+1+1+1)/5 
=  1.2 
 
Negligible 
 
(3+1+2+2+2)/5 
=  2 
 
Medium 
 
 
 
 
Low 
Potassium 
 
Short-term 
toxicity 
Negligible 
Negligible 
Low 
Medium 
Low 
Low 
(1+1+2)/3 
=  1.33 
(1+2+2)/3 
=  1.67 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Low 
NA 
NA 
Medium 
NA 
NA 
Medium 
NA 
NA 
 
Negligible 
 
 
Medium 
 
 
Low 
 
Vitamin B12 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Negligible 
Low 
NA 
NA 
Medium 
Medium 
Medium 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
 
(1+1+2)/3 
=  1.33 
 
Negligible 
 
(2+2+2)/3 
=  2 
 
Medium 
 
 
 
 
Low 
 
Vitamin E 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Negligible 
Negligible 
NA 
NA 
Low 
Medium 
High 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
 
(1+1+1)/3 
=  1 
 
Negligible 
 
(1+2+3)/3 
=  2 
 
Medium 
 
 
 
 
Low 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Vitamins A & D 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Low 
NA 
NA 
 
 
Low 
High 
Medium 
NA 
NA 
 
Low 
High 
Medium 
NA 
NA 
 
 
(1+2+2)/3 
=  1.67 
 
Low 
 
(1+3+2)/3 
=  2 
 
Medium 
 
 
 
 
Medium 
 
 
Zinc 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with toxicants 
Pesticides residue 
Negligible 
Low 
Negligible 
NA 
NA 
High 
Medium 
Medium 
NA 
NA 
 
Medium 
Medium 
Low 
NA 
NA 
(1+2+1)/3 
=  1.33 
 
Negligible 
 
(2+2+1)/3 
=  1.67 
 
Medium 
 
 
 
 
Low 
 
Bee Pollen 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Low 
Negligible 
Low 
Low 
Moderate 
Medium 
Low 
Low 
Medium 
Medium 
Medium 
Low 
Medium 
Medium 
High 
(2+1+2+2+3)/5 
=  2 
 
Low 
 
(2+1+1+2+2)/5 
=  1.6 
 
Medium 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Contamination 
with heavy metals 
Pesticides residue 
Spirulina 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
Low 
Low 
Moderate 
Low 
Low 
Low 
Low 
High 
Low 
Medium 
Medium 
Medium 
High 
Medium 
(2+2+2+3+2)/5 
=  2.2 
 
Low 
 
(1+1+1+3+1)/5 
=  1.4 
 
Low 
 
 
 
 
Medium 
 
Echinacea 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
High 
High 
Low 
Negligible 
Medium 
Low 
Low 
Low 
Low 
Medium 
High 
High 
Medium 
Low 
(2+4+4+2+1)/5 
=  2.6 
 
Moderate 
(2+1+1+1+1)/5 
=  1.2 
 
Low 
 
 
 
 
Medium 
 
Glandular Extract 
 
Short-term 
toxicity 
Long-term 
toxicity 
High 
High 
High 
NA 
High 
High 
Low 
NA 
Extreme 
Extreme 
High 
NA 
(4+4+4)/3 
=  4 
 
High 
(3+3+1)/3 
=  2.33 
 
Medium 
 
 
 
Extreme 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
NA NA NA   
Guarana 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
 
Low 
Low 
Moderate 
Low 
Low 
 
Medium 
Medium 
Medium 
Low 
Low 
 
 
 
Medium 
Medium 
High 
Low 
Low 
(2+2+3+2+2)/5 
=  2.2 
 
Low 
 
(2+2+2+1+1)/5 
=  1.6 
 
Medium 
 
 
 
Medium 
 
Kelp 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
 
Moderate 
Moderate 
Moderate 
Low 
Low 
 
 
Low 
Low 
Low 
Low 
Low 
 
Medium 
Medium 
Medium 
Medium 
Medium 
(3+3+3+2+2)/5 
=  2.6 
 
Moderate 
 
(1+1+1+1+1)/5 
=  1 
 
Low 
 
 
 
 
Medium 
 
Morinda Citrifolia 
 
Short-term 
toxicity 
Negligible 
Negligible 
Low 
Low 
Low 
Low 
(1+1+2+1+2)/5 
=  1.4 
(1+1+1+1+1)/5 
=  1 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
Negligible 
Low 
Low 
Low 
Low 
Medium 
Low 
Medium 
 
Negligible 
 
 
Low 
 
 
Low 
 
Parsley 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Negligible 
Moderate 
Negligible 
Moderate 
 
Low 
Low 
Low 
Low 
Low 
Low 
Low 
Medium 
Low 
Medium 
(1+1+3+1+3)/5 
=  1.8 
 
Low 
 
(1+1+1+1+1)/5 
=  1 
 
Low 
 
 
 
 
Medium 
St. John’s Wort 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Moderate 
Moderate 
High 
Low 
Low 
Medium 
Medium 
High 
Low 
Low 
 
High 
High 
Extreme 
Medium 
Medium 
 
 
(3+3+4+2+2)/5 
=  2.8 
 
Moderate 
 
(2+2+3+1+1)/5 
=  1.8 
 
Medium 
 
 
 
 
High 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Cayenne Pepper 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
High 
Moderate 
Low 
Negligible 
Medium 
Low 
Medium 
Low 
Low 
Medium 
High 
High 
Medium 
Low 
(2+4+3+2+1)/5 
=  2.4 
 
Low 
(2+1+2+1+1)/5 
=  1.4 
 
Low 
 
 
 
Medium 
 
Cimicifuga Racemosa 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
High 
High 
Low 
Negligible 
Low 
Low 
Medium 
Low 
Low 
Medium 
High 
Extreme 
Medium 
Low 
(2+4+4+2+1)/5 
=  3 
 
Moderate 
 
(1+1+2+1+1)/5 
=  1.2 
 
Low 
 
 
 
Medium 
 
Damiana Folia 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
 
Low 
High 
Moderate 
Moderate 
Low 
 
Medium 
Low 
Medium 
Medium 
Low 
 
 
Medium 
High 
High 
High 
Medium 
(2+4+3+3+2)/5 
=  2.8 
 
Moderate 
 
(2+1+2+2+1)/5 
=  1.6 
 
Medium 
 
 
 
 
High 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Contamination 
with heavy metals 
Pesticides residue 
Ephedra 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
High 
High 
High 
Low 
Medium 
Medium 
Medium 
Medium 
Low 
Medium 
Extreme 
Extreme 
Extreme 
Medium 
(2+4+4+4+2)/5 
=  3.2 
 
Moderate 
 
(2+2+2+2+1)/5 
=  1.8 
 
Medium 
 
 
 
 
High 
 
Fructus Cynosbati 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
 
Negligible 
Moderate 
Moderate 
Moderate 
Low 
 
 
Medium 
Low 
Medium 
Low 
Low 
 
 
Low 
Medium 
High 
Medium 
Medium 
(1+3+3+3+2)/5 
=  2.4 
 
Low 
 
(2+1+2+1+1)/5 
=  1.4 
 
Low 
 
 
 
 
Medium 
Ginger 
 
Short-term 
toxicity 
Long-term 
toxicity 
Negligible 
Low 
Moderate 
Negligible 
Low 
Low 
Low 
Low 
Low 
Medium 
Medium 
Low 
(1+2+3+1+2)/5 
=  1.6 
 
Low 
(1+1+1+1+1)/5 
=  1 
 
Low 
 
 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
 
Low Medium   
Licorice 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Negligible 
Low 
Moderate 
Negligible 
 
Low 
Low 
Medium 
Medium 
Low 
Low 
Low 
Medium 
High 
Low 
(1+1+2+3+1)/5 
=  1.6 
 
Low 
 
(1+1+2+2+1)/5 
=  1.4 
 
Low 
 
 
 
 
Medium 
 
Lycopene 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Negligible 
Low 
Negligible 
Negligible 
 
Low 
Low 
Medium 
Low 
Low 
 
Low 
Low 
Medium 
Low 
Low 
 
(1+1+2+1+1)/5 
=  1.2 
 
Negligible 
 
(1+1+2+1+1)/5 
=  1.2 
 
Low 
 
Low 
 
Melatonin 
 
Short-term 
toxicity 
Low 
Low 
Low 
High 
Medium 
High 
(2+2+3)/3 
=  2.33 
(1+3+2)/3 
=  2 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Moderate 
NA 
NA 
Medium 
NA 
NA 
 
High 
NA 
NA 
 
Low 
 
 
Medium 
 
Oxymatrine 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
 
Low 
Negligible 
Negligible 
Negligible 
Negligible 
 
Medium 
Low 
Low 
Low 
Low 
 
Medium 
Low 
Low 
Low 
Low 
 
 
 
(2+1+1+1+1)/5 
=  1.2 
 
Negligible 
 
(2+1+1+1+1)/5 
=  1.2 
 
Low 
 
 
Low 
 
 
 
Yohimbe 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
High 
High 
High 
Moderate 
Moderate 
High 
High 
High 
Medium 
Medium 
Extreme 
Extreme 
Extreme 
High 
High 
(4+4+4+3+3)/5 
=  3.6 
 
High 
 
(3+3+3+2+2)/5 
=  2.6 
 
High 
 
 
 
 
Extreme 
 
 
 
196 
 
Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Calcium 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Low 
Moderate 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
Low 
Medium 
High 
NA 
NA 
(1+2+3)/3 
=  2 
 
Low 
 
(1+1+2)/3 
=  1.33 
 
Low 
 
Medium 
 
Magnesium 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Low 
Moderate 
NA 
NA 
Low 
Low 
Medium 
NA 
NA 
Low 
Medium 
High 
NA 
NA 
(1+2+3)/3 
=  2 
 
Low 
 
(1+1+2)/3 
=  1.33 
 
Low 
 
Medium 
 
Chondroitin 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Negligible 
Low 
Low 
Moderate 
NA 
Low 
Low 
Low 
Low 
NA 
Low 
Medium 
Medium 
Medium 
NA 
(1+2+2+3)/4 
=  2 
 
Low 
 
(1+1+1+1)/4 
=  1 
 
Low 
 
Medium 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Contamination 
with heavy metals 
Pesticides residue 
Conjugated Linolenic Acid 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
Moderate 
Moderate 
Low 
NA 
Medium 
Low 
Medium 
Low 
NA 
 
 
 
Medium 
Medium 
High 
Medium 
NA 
 
(2+3+3+2)/4 
=  2.5 
 
Moderate 
 
(2+1+2+1)/4 
=  1.5 
 
Medium 
 
 
High 
 
Fish Oils 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Negligible 
Moderate 
Moderate 
Moderate 
Moderate 
 
Medium 
Low 
Medium 
Medium 
Medium 
 
 
Low 
Medium 
High 
High 
High 
 
(1+3+3+3+3)/5 
=  2.6 
 
Moderate 
 
(2+1+2+2+2)/5 
=  1.8 
 
Medium 
 
 
High 
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Name of the chemical 
hazard (Ingredient) 
Associated 
Risk(s) 
with the 
ingredient 
Severity 
(Level of 
impact on 
the Human 
Health) 
Probability (The 
chances of that risk 
happening) 
Risk Score 
(Risk score, 
found by 
combining 
impact and 
probability on 
the risk 
matrix) 
Average impact  
SUM (Risk 
Impact values)/ 
number of risks 
in same category 
Average 
probability SUM 
(Risk Probability 
values)/ number 
of risks in same 
category 
Risk Score 
(Risk score, 
found by 
combining 
average 
impact and 
average 
probability 
on the risk 
matrix) 
Iron 
 
Short-term 
toxicity 
Long-term 
toxicity 
Interactions of 
food/drugs 
Contamination 
with heavy metals 
Pesticides residue 
Low 
High 
Moderate 
Low 
Negligible 
Medium 
Low 
Medium 
Medium 
Low 
Medium 
High 
High 
Medium 
Low 
(2+4+3+2+1)/5 
=  2.4 
 
Low 
(2+1+2+2+1)/5 
=  1.6 
 
Medium 
 
 
Medium 
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Appendix C: Risk Assessment Matrix 
 Severity 
 NEGLIGIBLE 1 
small/unimportant not likely 
to have a major effect on 
Human Health 
LOW 2 
minimal 
importance has an 
effect on Human 
and impact on 
health  
MODERATE 3 
serious/important will affect the 
human health 
significantly/suffers serious 
injuries/requires immediate 
action 
HIGH 4 
maximum importance could 
result in disaster/death/serious 
injuries or toxicity 
Probability 
LOW 1 
risk has rarely been a 
problem 
LOW 
1 
MEDIUM 
2 
MEDIUM 
3 
HIGH 
4 
MEDIUM 2 
risk most likely occurs 
with this ingredient 
LOW 
2 
MEDIUM 
4 
HIGH 
6 
EXTREME 
8 
HIGH 3 
risk will occur and 
associated with the use 
of this ingredient 
MEDIUM 
3 
HIGH 
6 
HIGH 
9 
EXTREME 
12 
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Negligible coded as (1) for small/unimportant that not likely to have a major effect on 
human health, Low coded as (2) for an effect on human and impact on the health/requires 
medical treatment, Moderate coded as (3) for serious/important that will affect the human 
health significantly/suffers serious injuries requires immediate action, High coded as (4) for 
maximum importance that could result in disaster/death/serious injuries or toxicity. 
 
The probability of the risk matrix was ranging from Low coded as (1) for risk has 
rarely been a problem, Medium coded as (2) for This risk will most likely occur with this 
ingredient, and High coded as (3) for the risk will occur and associated with the use of this 
ingredient/possibly multiple times, and has occurred in the past. 
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Appendix D: Individual Ingredient Overall Risk Score 
Alfalfa scored low as an average score of severity level of impact on the human 
health, and scored medium as an average score of probability level of chances of that 
risk happening (Soto-Zarazúa et al., 2016; CPSS, 2015). The final score was medium. 
 
Bilberry/ eyebright scored negligible as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (Rouhi-Boroujeni et al., 2015; CPSS 2015). The final 
score was low.  
 
Garlic scored negligible as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (EMA, 2016; Nethathe & Russell, 2014; CPSS, 2015). The final 
score was low. 
 
Ginkgo Biloba scored low as an average score of severity level of impact on 
the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Edwards et al., 2015; Diamond & Bailey, 2013; 
Nethathe & Russell, 2014; CPSS, 2015). The final score was medium.  
 
Grape Seed Extract scored negligible as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (UMMC, 2015; Nieto-García et al, 2014; CPSS, 
2015). The final score was low. 
 
Panax Ginseng scored low as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Lee et al., 2012; Kiefer & Pantuso, 2003; Popovich et al., 2011; 
Nethathe & Russell, 2014; CPSS, 2015). The final score was medium.  
 
Siberian Ginseng scored negligible as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
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of chances of that risk happening (Cicero et al., 2004; Kiefer & Pantuso, 2003; CPSS, 
2015). The final score was low. 
 
Pygeum Africanum scored low as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Moyad, 2014; CPSS, 2015). The final score was 
medium.  
 
Saw Palmetto scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Avins et al., 2013; CPSS, 2015). The final score was medium. 
 
L-Cysteine scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (McGavigan et al., 2015; CPSS, 2015). The final score was 
medium.  
 
L-Methionine scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Tapia-Rojas et al., 2015; CPSS, 2015). The final score was 
medium. 
 
Lysine scored low as an average score of severity level of impact on the human 
health, and scored medium as an average score of probability level of chances of that 
risk happening (Huang et al., 2016; CPSS, 2015). The final score was medium.  
 
Methylsulfonyl Methane scored negligible as an average score of severity level 
of impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (Johansson et al., 1998; CPSS, 2015). The final score 
was low. 
 
Chromium (Chromium Picolinate) scored low as an average score of severity 
level of impact on the human health, and scored low as an average score of probability 
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level of chances of that risk happening (Thompson et al., 2013; Sun et al., 2015; CPSS, 
2015). The final score was medium.  
 
Tryptophan scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Oketch-Rabah et al., 2016; CPSS, 2015). The final score was 
medium. 
 
Vitamin C scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (NIH, 2016; Costa et al., 2015; Jemaa et al., 2017; Nađpal et al., 
2016; NIH, 2016; CPSS, 2015). The final score was medium.  
 
Amino Acids scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Zhenyukh et al., 2017; CPSS, 2015). The final score was medium. 
 
Caffeine scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Gurley et al., 2015; Campana, 2014; Jabbar & Hanly, 2013; 
CPSS, 2015). The final score was medium.  
 
Creatine scored negligible as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Dickinson et al., 2014; CPSS, 2015). The final score was low. 
 
Folate (Folic Acid) scored negligible as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (Manshadi et al., 2014; Zhao et al., 2014; CPSS, 
2015). The final score was low.  
 
Gentian scored moderate as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
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of that risk happening (Akileshwari et al., 2012; Huang et al., 2015; CPSS, 2015). The 
final score was high. 
 
Lecithin scored negligible as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Chen et al., 2015; CPSS, 2015). The final score was low.  
 
Lutein scored low as an average score of severity level of impact on the human 
health, and scored low as an average score of probability level of chances of that risk 
happening (Olmedilla-Alonso et al., 2014; CPSS, 2015). The final score was medium. 
 
Royal Jelly scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Karaca et al., 2010; CPSS, 2015). The final score was medium.  
 
Selenium scored moderate as an average score of severity level of impact on 
the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Yang & Jia, 2014; CPSS, 2015). The final score was 
high. 
 
Vitamin B6 scored negligible as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Zhang et al., 2013; CPSS, 2015). The final score was 
low.  
 
Vitamin D scored negligible as an average score of severity level of impact on 
the human health, and scored high as an average score of probability level of chances 
of that risk happening (Reis et al., 2009; CPSS, 2015). The final score was medium. 
 
Glucosamine scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Jacobs et al., 2013; CPSS, 2015). The final score was medium.  
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L-Carnitine scored negligible as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Serban et al., 2016; CPSS, 2015). The final score was 
low. 
 
Potassium scored negligible as an average score of severity level of impact on 
the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Chatterjee et al., 2010; CPSS, 2015). The final score 
was low.  
 
Vitamin B12 scored negligible as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Gröber et al., 2013; CPSS, 2015). The final score was 
low. 
 
Vitamin E scored negligible as an average score of severity level of impact on 
the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Ledesma et al., 2011; CPSS, 2015). The final score 
was low.  
 
Vitamins A & D scored low as an average score of severity level of impact on 
the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Ergin et al., 2013; CPSS, 2015). The final score was 
medium. 
 
Zinc scored negligible as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Plum et al., 2010; CPSS, 2015). The final score was low.  
 
Bee Pollen scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Petersen, 1977; CPSS, 2015). The final score was medium. 
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Spirulina scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Pilkington & CAM-Cancer Consortium, 2015; Karkos et al., 
2010; UMMC, 2013; CPSS, 2015). The final score was medium.  
 
Echinacea scored moderate as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Karsch‐Völk et al., 2014; Lawrenson et al., 2014; CPSS, 2015). 
The final score was medium. 
 
Glandular Extract scored high as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Hadayer & Schaal, 2016; Gangwar et al., 2015; CPSS, 
2015). The final score was extreme.  
 
Guarana scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (da Costa Krewer et al., 2014; CPSS, 2015). The final score was 
medium. 
 
Kelp scored moderate as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Barton & McLean, 2013; Rosen et al., 2014; CPSS, 2015). The 
final score was medium.  
 
Morinda Citrifolia scored negligible as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (Assi et al., 2015; CPSS, 2015). The final score was 
low. 
 
Parsley scored low as an average score of severity level of impact on the human 
health, and scored low as an average score of probability level of chances of that risk 
happening (Khosravan et al., 2017; CPSS, 2015). The final score was medium.  
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St. John’s Wort scored moderate as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Knuppel & Linde, 2004; Cui & Zheng, 2016; 
Hohmann et al., 2016; CPSS, 2015). The final score was high. 
 
Cayenne Pepper scored low as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Nantakornsuttanan et al., 2016; CPSS, 2015). The final score 
was medium.  
 
Cimicifuga Racemosa scored moderate as an average score of severity level of 
impact on the human health, and scored low as an average score of probability level 
of chances of that risk happening (Wuttke & Seidlová-Wuttke, 2015; CPSS, 2015). 
The final score was medium.  
 
Damiana Folia scored moderate as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Avelino-Flores et al., 2015; CPSS, 2015). The final 
score was high. 
 
Ephedra scored moderate as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Council for Responsible Nutrition, 2003; CPSS, 2015). The 
final score was high. 
 
Fructus Cynosbati scored low as an average score of severity level of impact 
on the human health, and scored low as an average score of probability level of chances 
of that risk happening (Andersson et al., 2012; CPSS 2015). The final score was 
medium. 
 
Ginger scored low as an average score of severity level of impact on the human 
health, and scored low as an average score of probability level of chances of that risk 
happening (Kafeshani, 2015; CPSS, 2015). The final score was medium. 
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Licorice scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Qiao et al., 2014; Hruby et al., 2013; CPSS, 2015). The final score 
was medium. 
 
Lycopene scored negligible as an average score of severity level of impact on 
the human health, and scored low as an average score of probability level of chances 
of that risk happening (Selvan et al., 2014; Viuda-Martos et al., 2014; CPSS, 2015). 
The final score was low. 
 
Melatonin scored low as an average score of severity level of impact on the 
human health, and scored medium as an average score of probability level of chances 
of that risk happening (Hartz et al., 2015; CPSS, 2015). The final score was medium. 
 
Oxymatrine scored negligible as an average score of severity level of impact 
on the human health, and scored low as an average score of probability level of chances 
of that risk happening (Lu et al., 2015; CPSS, 2015). The final score was low. 
 
Yohimbe scored high as an average score of severity level of impact on the 
human health, and scored high as an average score of probability level of chances of 
that risk happening (NIH, 2016; Wongkrajang et al., 2014; CPSS, 2015). The final 
score was extreme.  
 
Calcium scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Quinn et al., 2013; CPSS, 2015). The final score was medium. 
 
Magnesium scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (Hruby et al., 2013; CPSS, 2015). The final score was medium.  
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Chondroitin scored low as an average score of severity level of impact on the 
human health, and scored low as an average score of probability level of chances of 
that risk happening (UMMC, 2015; CPSS, 2015). The final score was medium.  
 
Conjugated Linolenic Acid scored moderate as an average score of severity 
level of impact on the human health, and scored medium as an average score of 
probability level of chances of that risk happening (Koba & Yanagita, 2014; CPSS, 
2015). The final score was high.  
 
Fish Oils Acid scored moderate as an average score of severity level of impact 
on the human health, and scored medium as an average score of probability level of 
chances of that risk happening (Mason & Sherratt, 2016; CPSS, 2015). The final score 
was high. 
 
Iron scored low as an average score of severity level of impact on the human 
health, and scored medium as an average score of probability level of chances of that 
risk happening (Aigner et al., 2015; CPSS, 2015). The final score was medium. 
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Appendix E: Information Sheet A 
Title of project: Health supplement use and related adverse events in Dubai 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide if you wish to take part. 
Several of several chemicals within the content of health supplement products 
(HS) may affect human health by inducing certain adverse events. Previous studies 
found that consumers are generally unaware regarding HS risks, its associated adverse 
events and proper reporting process to concerned authorities. This study aims to 
conduct a population based cross-sectional survey to identify the prevalence of HS 
consumption in the population of Dubai and the adverse events related to HS 
consumption. It is up to you to decide to take part or not. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. The information and 
opinions you provide will be kept strictly confidential and used only for research 
purposes. Your name and details cannot be linked to this survey and will not be 
identified in any report/publication. The completion and submission of the electronic 
questionnaire indicates the agreement for participation and acts as signature of the 
consent form. 
The study is sponsored by the College of Medicine and Health Sciences of the 
United Arab Emirates University as well as Dubai Municipality and reviewed by the 
Al Ain Medical District Human Research Ethics Committee. 
 
For any further information regarding the study, please contact: 
 
Naseem M. R. Abdulla 
Tel: +971 45035554 
E-mail: nmrafee@gmail.com 
5 March 2015 
Thank you very much for participating in the study. 
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Appendix F: Prints of the healthcare professionals questionnaire 
Section A.  Demographic Data 
Age 
Gender Male □ Female □ 
Marital status Married □ Single   □ Divorced  □ Widow □ 
Nationality Drop down list in on-line questionnaire 
Employment 
status 
Government □ Private □ Self-employed  □ 
Title 
Physician  □          Specialized physician  □             Pharmacist  □ 
Assistant pharmacist □             Other □ Specify (…………...…) 
Work 
experience 
Less than 1 year □     1-2 years  □     3-4 years □ 
5-6 years □                More than 6 years □ 
Insurance 
coverage 
Yes       □   No □ 
Education Graduate □            Post graduate □ 
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Section B. Knowledge 
1 
Do you know what health supplements are? Yes      □     No   □   
Don’t know □ 
2 Please, list as many health supplements as you can. (…………………..) 
3 
Do you agree with the statement that health 
supplements are harmless? 
Yes      □   No  □     D
on’t know  □ 
4 
Do you know about adverse events of health 
supplements? 
Yes      □   No  □     D
on’t know  □ 
5 
Please, list as many adverse events of health 
supplements as you can. 
(…………………..) 
6 Do you know what surveillance  system is? 
Yes      □   No  □      
Don’t know  □ 
7 
Do you know about any existing surveillance  system 
in the UAE? 
Yes   □ Specify 
(……)   No  □ 
8 
Do you know about any adverse event reporting system 
in your institution/organization? 
Yes   □ Specify 
(……)   No  □ 
9 
Do you know to whom you can report an adverse 
event? 
Yes    □        No   □ 
10 
Have you ever received any continuing education on 
health supplement products? 
No □  Electronic 
learning □ Product 
orientation 
(Principle) □ 
Official training 
courses □ Other □ 
Specify (…) 
11 
Have you read a scientific article related to adverse 
events of health supplements in the last 6 months? 
Yes    □        No   □ 
12 
Have you ever received training on how to report an 
adverse event? 
Yes    □        No   □ 
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Section C. Practice 
1 
Do you sell/prescribe/dispense any 
health supplements at practice site? 
(if your answer is “No”, please 
proceed to section D) 
Yes    □        No   □ 
2 Which type of health supplements do 
you usually 
prescribe/advice/dispense? (you can 
choose more than one answer) 
Dietetic □   Energy drink 
□   Food  □  Herbal □  
Mineral □    Sport 
nutrition  □   Vitamin □   Other □ 
Specify (……….) 
 
3 Which form of health supplements 
do you usually 
prescribe/advice/dispense? 
(you can choose more than one 
answer) 
Caplets 
 
□ Capsule 
 
□ Chewable 
tablets 
□ 
Chews/ 
Gummy 
□ 
 
Drink 
 
□ Drops 
 
□ 
Gel 
 
□ Gel caps 
 
□ Granule 
 
□ 
Liquid 
 
□ Lozenges □ Powder 
 
□ 
Soft gels 
 
□ Spray 
 
□ Tablet □ 
Vegicaps 
 
□ Wafers 
 
□ Don’t 
know 
□ 
 
4 
Do you have a system to record 
health supplements use? 
Yes  □ No □ 
5 
How often do you discuss health 
supplement products use with your 
patients/customers? (if your answer 
is “Never”, please proceed to 
question C9) 
Always □    Often  □   
Sometimes □   Never □ 
6 
What is the topic of discussion about 
health supplement products use with 
your patients/customers? (you can 
choose more than one answer) 
Product effect □  Product adverse 
event □ Product quality □  Product 
price □ Other □ Specify (…….…) 
7 
Which of the following health 
supplement products information 
sources are helpful in caring for your 
patients/customers? (you can choose 
more than one answer) 
Internet  □    Printed material □ 
Multimedia □  Other □  
Specify (…….…) 
8 What are the barriers that limit 
discussing health supplement 
Literacy □    Cultural ethics □ 
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products with your 
patients/customers? (you can choose 
more than one answer) 
Language □  Social level □ 
Other □        Specify (…….…) 
9 
Have you ever experienced an 
adverse event related to health 
supplement consumption in 
patients/customers during your 
practice? (if your answer is “No”, 
please proceed to question C14) 
Yes  □ 
No  □ 
10 
How frequently have you 
encountered adverse events related to 
health supplement consumption? 
Once □     Occasionally  (monthly 
or rarer)  □  Frequently (every 
week) □ 
11 What was the adverse event? 
(you can choose more than one 
answer) 
Abdominal 
pain □ 
Alopecia 
□ 
Anorexia □ 
Asthenia □ Chest 
pain □ 
Convulsion 
 □ 
Dermatitis 
□   
Diarrhea 
□ 
Dizzines
s □   
Dyspnea □      Edema □     Headach
e □       
Hypotensi
on □ 
Nausea □   Pain  □ 
Pruritus  □  Pyrexia 
□    
Sedation 
□□   
Urticaria □ Vomiting 
□ 
 
 
12 
How often have you recorded health 
supplements adverse events? (if your 
answer is “Never”, please proceed to 
question C14) 
Always □         Often  □ 
Sometimes □    Never □ 
13 
To which higher authority/ personnel 
did you report health supplement 
adverse events? (you can choose 
more than 1 answer) 
Ministry of Health □ 
Senior physician □ 
Pharmacist in-charge □ 
Other □ Specify (………) 
14 
Is adverse event reporting form 
available when you are at the job of 
prescribing/dispensing medicines to 
the patients/customers? 
Yes  □ No □ Don’t Know□ 
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Section D. Attitude 
1 
You report health supplements related 
adverse events to the higher 
authority/personnel. 
Strongly agree □   Agree □   Neutral  □ 
Disagree □     Strongly disagree □ 
2 
What is the reason if you 
don’t/wouldn’t report an adverse 
event? 
(you can choose more than one 
answer) 
It’s not important □ Don’t know where 
to report  □ Don’t know what is 
adverse event of health supplement □ 
Concerned that the report is a false 
alert □ Lack of time to investigate the 
case at work  □ Consider as extra work 
(not your concern) □ Difficulty in 
confirming/distinguishing the adverse 
event □ Other Specify (…..……)  □ 
3 
Do you think it is important to report 
all adverse events of health supplement 
products? 
Yes (all) □ Only when hospitalisation 
is needed □ Only when it is life 
threatening □ No □ 
4 
What do you think about the 
establishment of a surveillance system 
of adverse events related to health 
supplement consumption? 
Definitely beneficial □  Somewhat 
beneficial □  Not sure □  Not 
beneficial □ Definitely not beneficial □ 
5 
Are you concerned about legal 
problems of reporting an adverse 
event? 
Definitely □    Somewhat □ 
Not sure □  Not □    Definitely not □ 
6 
Do/would you feel confident when 
reporting an adverse event? 
Definitely □     Somewhat □ 
Not sure  □   Not □   Definitely not □ 
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Appendix G: Information Sheet B 
Title of project: Healthcare Professionals’ Knowledge, Attitude and Practice of 
Health Supplement Products Related Adverse Events 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide if you wish to take part. Several chemicals 
within the content of health supplement product (HS) may affect human health by 
inducing certain adverse events. Previous studies found that consumers are generally 
unaware regarding HS risks, its associated adverse events and proper reporting process 
to concerned authorities. More, many healthcare professionals have inadequate 
knowledge, attitude and practice (KAP) on the issue. This study aims to conduct a 
cross-sectional survey to identify the level of KAP among healthcare professionals in 
the Emirate of Dubai. 
It is up to you to decide if to take part. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. The information and opinions 
you provide will be kept strictly confidential and used only for research purposes. Your 
name and details cannot be linked to this survey and will not be identified in any 
report/publication. The completion and submission of the electronic questionnaire 
indicates the agreement for participation and acts as signature of the consent form. 
The study is sponsored by the College of Medicine and Health Sciences of the 
United Arab Emirates University as well as Dubai Municipality and reviewed by the 
Al Ain Medical District Human Research Ethics Committee. 
 
For any further information regarding the study, please contact: 
Naseem M. R. Abdulla 
Tel: +971 45035554 
E-mail: nmrafee@gmail.com 
March 2015 
Thank you very much for participating in this study. 
